Robert C. Bast, M.D.

Peer-Reviewed Articles

1. Grimm SL, Karki M, Blum KA, Bertocchio JP, He R, Tripathi DN, Zacharias NM, Lebenthal JM, Sheth RA, Rao P, Genovese G, Lu Z, Bast RC, Ingram DR, Lazcano R, Wani KM, Wang WL, Lazar AJ, Tannir NM, Walker CL, Coarfa C, Msaouel P. CA-125 as a Biomarker in Renal Medullary Carcinoma. Clinical Cancer Research 31(6):1057-1068, 2025. e-Pub 2025. PMID: 39836407.
2. Fahrmann, JF, Ghasemi, SM, Han, CY, Wu, R, Dennison, JB, Vykoukal, JV, Celestino, J, Lu, KH, Lu, Z, Drescher, CW, Do, K, Hanash, SM, Bast RC, Irajizad, E. A metabolite-based liquid biopsy for detection of ovarian cancer. Biomarker Research 12(1), 2024. e-Pub 2024. PMID: 39192316.
3. Guo, J, Wang, C, Luo, N, Wu, Y, Huang, W, Zhu, J, Shi, W, Ding, J, Ge, Y, Liu, C, Lu, Z, Bast RC, Ai, GH, Yang, W, Wang, R, Li, C, Chen, R, Liu, S, Jin, H, Zhao, B, Cheng, Z. IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer. BMC medicine 22(1), 2024. e-Pub 2024. PMID: 38769543.
4. Santiago-O'Farrill JM, Blessing Bollu A, Yang H, Orellana V, Pina M, Zhang X, Liu J, Bast RC, Lu Z. Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy. Mol Cancer Res 22(9):840-851, 2024. e-Pub 2024. PMID: 38780897.
5. Han CY, Lu KH, Corrigan G, Perez A, Kohring SD, Celestino J, Bedi D, Bedia E, Bevers T, Boruta D, Carlson M, Holman L, Leeds L, Mathews C, McCann G, Moore RG, Schlumbrecht M, Slomovitz B, Tobias D, Williams-Brown Y, Bevers MW, Liu J, Gornet TG, Handy BC, Lu Z, Bedia JS, Skates SJ, Bast RC. Normal Risk Ovarian Screening Study: 21-Year Update. J Clin Oncol 42(10):1102-1109, 2024. e-Pub 2024. PMID: 38194613.
6. Wang F, Yu X, Qian J, Cao Y, Dong S, Zhan S, Lu Z, Bast RC, Song Q, Chen Y, Zhang Y, Zhou J. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist Updat 74:101077, 2024. e-Pub 2024. PMID: 38518726.
7. Han YC, Bedia JS, Yang WL, Hawley SJ, Bergan L, Hopper M, Celestino J, Guo J, Gornet TG, Soosaipillai A, Yang H, Doskocil SD, Lokshin AE, Handy BC, Diamandis EP, Moore RG, Lu KH, Lu Z, Anderson KS, Drescher CW, Skates SJ, Bast RC. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. Br J Cancer 130(5):861-868, 2024. e-Pub 2024. PMID: 38195887.
8. Bildik G, Gray JP, Mao W, Yang H, Ozyurt R, Orellana VR, De Wever O, Carey MS, Bast RC, Lu Z. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas. Autophagy 20(3):675-691, 2024. e-Pub 2024. PMID: 38169324.
9. Liang X, Jung SY, Fong LW, Bildik G, Gray JP, Mao W, Zhang S, Millward SW, Gorfe AA, Zhou Y, Lu Z, Bast RC. Membrane anchoring of the DIRAS3 N-terminal extension permits tumor suppressor function. iScience 26(11):108151, 2023. e-Pub 2023. PMID: 37915607.
10. Heinzl N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, Heinze G, Yang WL, Bast RC, Sehouli J, Braicu EI, Vergote I, Van Gorp T, Mahner S, Paspalj V, Grimm C, Obermayr E, Schuster E, Holzer B, Rousseau F, Schymkowitz J, Concin N, Zeillinger R. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium. Oncogene 42(33):2473-2484, 2023. e-Pub 2023. PMID: 37402882.
11. Irajizad E, Han CY, Celestino J, Wu R, Murage E, Spencer R, Dennison JB, Vykoukal J, Long JP, Do KA, Drescher C, Lu K, Lu Z, Bast RC, Hanash S, Fahrmann JF. A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. Clin Cancer Res 28(21):4669-4676, 2022. e-Pub 2022. PMID: 36037307.
12. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
13. Brown H, Chung M, Üffing A, Batistatou N, Tsang T, Doskocil S, Mao W, Willbold D, Bast RC, Lu Z, Weiergräber OH, Kritzer JA. Structure-Based Design of Stapled Peptides That Bind GABARAP and Inhibit Autophagy. J Am Chem Soc 144(32):14687-14697, 2022. e-Pub 2022. PMID: 35917476.
14. Shi X, Yu X, Wang J, Bian S, Li Q, Fu F, Zou X, Zhang L, Bast RC, Lu Z, Guo L, Chen Y, Zhou J. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Mol Oncol 16(13):2558-2574, 2022. e-Pub 2022. PMID: 35278271.
15. Boylan KLM, Petersen A, Starr TK, Pu X, Geller MA, Bast RC, Lu KH, Cavallaro U, Connolly DC, Elias KM, Cramer DW, Pejovic T, Skubitz APN. Development of a multi-protein classifier for the detection of early stage ovarian cancer. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35804849.
16. Grindel BJ, Engel BJ, Ong JN, Srinivasamani A, Liang X, Zacharias NM, Bast RC, Curran MA, Takahashi TT, Roberts RW, Millward SW. Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. ACS Chem Biol 17(6):1543-1555, 2022. e-Pub 2022. PMID: 35611948.
17. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 13(1):3352, 2022. e-Pub 2022. PMID: 35688808.
18. Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. J Clin Invest 132(11), 2022. e-Pub 2022. PMID: 35642638.
19. Kim CS, Nevozhay D, Aburto RR, Pehere A, Pang L, Dillard R, Wang Z, Smith C, Mathieu KB, Zhang M, Hazle JD, Bast RC, Sokolov K. One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates. Bioconjug Chem 33(5):969-981, 2022. e-Pub 2022. PMID: 35522527.
20. Niu N, Yao J, Bast RC, Sood AK, Liu J. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis 10(9):65, 2021. e-Pub 2021. PMID: 34588424.
21. Han CY, Patten DA, Kim SI, Lim JJ, Chan DW, Siu MKY, Han Y, Carmona E, Parks RJ, Lee C, Di LJ, Lu Z, Chan KKL, Ku JL, Macdonald EA, Vanderhyden BC, Mes-Masson AM, Ngan HYS, Cheung ANY, Song YS, Bast RC, Harper ME, Tsang BK. Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers (Basel) 13(14), 2021. e-Pub 2021. PMID: 34298618.
22. Niu N, Shen W, Zhong Y, Bast RC, Jazaeri A, Sood AK, Liu J. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol 113:20-27, 2021. e-Pub 2021. PMID: 33887301.
23. Artibani M, Masuda K, Hu Z, Rauher PC, Mallett G, Wietek N, Morotti M, Chong K, KaramiNejadRanjbar M, Zois CE, Dhar S, El-Sahhar S, Campo L, Blagden SP, Damato S, Pathiraja PN, Nicum S, Gleeson F, Laios A, Alsaadi A, Santana Gonzalez L, Motohara T, Albukhari A, Lu Z, Bast RC, Harris AL, Ejsing CS, Klemm RW, Yau C, Sauka-Spengler T, Ahmed AA. Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. JCI Insight 6(11):e147929, 2021. e-Pub 2021. PMID: 33945502.
24. Fahrmann JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, Wu R, Long JP, Do KA, Celestino J, Lu KH, Lu Z, Bast RC, Hanash S. A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. Cancers (Basel) 13(4):1-22, 2021. e-Pub 2021. PMID: 33671595.
25. Lokshin A, Bast RC, Rodland K. Circulating Cancer Biomarkers. Cancers (Basel) 13(4):1-5, 2021. e-Pub 2021. PMID: 33671847.
26. Fan D, Yang H, Mao W, Rask PJ, Pang L, Xu C, Vankayalapat H, Ahmed AA, Bast RC, Lu Z. A novel salt inducible kinase 2 inhibitor, ARN-3261, sensitizes ovarian cancer cell lines and xenografts to carboplatin. Cancers (Basel) 13(3):1-15, 2021. e-Pub 2021. PMID: 33503955.
27. Gray JP, Uddin MN, Chaudhari R, Sutton MN, Yang H, Rask P, Locke H, Engel BJ, Batistatou N, Wang J, Grindel BJ, Bhattacharya P, Gammon ST, Zhang S, Piwnica-Worms D, Kritzer JA, Lu Z, Bast RC, Millward SW. Directed evolution of cyclic peptides for inhibition of autophagy. Chem Sci 12(10):3526-3543, 2021. e-Pub 2021. PMID: 34163626.
28. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM, Ahumada-Castro U, Aits S, Aizawa S, Akkoc Y, Akoumianaki T, Akpinar HA, Al-Abd AM, Al-Akra L, Al-Gharaibeh A, Alaoui-Jamali MA, Alberti S, Alcocer-Gómez E, Alessandri C, Ali M, Alim Al-Bari MA, Aliwaini S, Alizadeh J, Almacellas E, Almasan A, Alonso A, Alonso GD, Altan-Bonnet N, Altieri DC, ÉMC Á, Alves S, Alves da Costa C, Alzaharna MM, Amadio M, Amantini C, Amaral C, Ambrosio S, Amer AO, Ammanathan V, An Z, Andersen SU, Andrabi SA, Andrade-Silva M, Andres AM, Angelini S, Ann D, Anozie UC, Ansari MY, Antas P, Antebi A, Antón Z, Anwar T, Apetoh L, Apostolova N, Araki T, Araki Y, Arasaki K, Araújo WL, Araya J, Arden C, Arévalo MA, Arguelles S, Arias E, Arikkath J, Arimoto H, Ariosa AR, Armstrong-James D, Arnauné-Pelloquin L, Aroca A, Arroyo DS, Arsov I, Artero R, Asaro DML, Aschner M, Ashrafizadeh M, Ashur-Fabian O, Atanasov AG, Au AK, Auberger P, Auner HW, Aurelian L, Autelli R, Avagliano L, Ávalos Y, Aveic S, Aveleira CA, Avin-Wittenberg T, Aydin Y, Ayton S, Ayyadevara S, Azzopardi M, Baba M, Backer JM, Backues SK, Bae DH, Bae ON, Bae SH, Baehrecke EH, Baek A, Baek SH, Baek SH, Bagetta G, Bagniewska-Zadworna A, Bai H, Bai J, Bai X, Bai Y, Bairagi N, Baksi S, Balbi T, Baldari CT, Balduini W, Ballabio A, Ballester M, Balazadeh S, Balzan R, Bandopadhyay R, Banerjee S, Banerjee S, Á B, Bao Y, Baptista MS, Baracca A, Barbati C, Bargiela A, Barilà D, Barlow PG, Barmada SJ, Barreiro E, Barreto GE, Bartek J, Bartel B, Bartolome A, Barve GR, Basagoudanavar SH, Bassham DC, Bast RC, Basu A, Batoko H, Batten I, Baulieu EE, Baumgarner BL, Bayry J, Beale R, Beau I, Beaumatin F, Bechara LRG, Beck GR, Beers MF, Begun J, Behrends C, Behrens GMN, Bei R, Bejarano E, Bel S, B. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 17(1):1-382, 2021. e-Pub 2021. PMID: 33634751.
29. Blackman A, Mitchell J, Rowswell-Turner R, Singh R, Kim KK, Eklund E, Skates S, Bast RC, Messerlian G, Miller MC, Moore RG. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. Tumour Biol 43(1):355-365, 2021. e-Pub 2021. PMID: 34957977.
30. Bast RC, Han CY, Lu Z, Lu KH. Next steps in the early detection of ovarian cancer. Commun Med (Lond) 1(1):36, 2021. e-Pub 2021. PMID: 34676377.
31. Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernández FM, Nephew KP, Karpf AR, Widschwendter M, Sood AK, Bast RC, Godwin AK, Miller KD, Cho CH, Kim J. Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A 117(50):31993-32004, 2020. e-Pub 2020. PMID: 33262282.
32. Bast RC, Srivastava S. The National Cancer Institute Early Detection Research Network: Two Decades of Progress. Cancer Epidemiol Biomarkers Prev 29(12):2396-2400, 2020. e-Pub 2020. PMID: 33262198.
33. Bast RC, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Skates SJ. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 29(12):2504-2512, 2020. e-Pub 2020. PMID: 33051337.
34. Blessing AM, Santiago-O'Farrill JM, Mao W, Pang L, Ning J, Pak D, Bollu LR, Rask P, Iles L, Yang H, Tran S, Elmir E, Bartholomeusz G, Langley R, Lu Z, Bast RC. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. Cancer 126(15):3579-3592, 2020. e-Pub 2020. PMID: 32484926.
35. Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, Kalsi JK, Dawnay A, Marino IP, Manchanda R, Lu K, Yang WL, Timms JF, Parmar M, Skates SJ, Bast RC, Jacobs IJ, Zaikin A, Menon U. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32708856.
36. Li YC, Lytle NK, Gammon ST, Wang L, Hayes TK, Sutton MN, Bast RC, Der CJ, Piwnica-Worms D, McCormick F, Wahl GM. Analysis of RAS protein in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Proc Natl Acad Sci U S A 117(22):12121-12130, 2020. e-Pub 2020. PMID: 32424096.
37. Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, Cheon DJ, Yang-Hartwich Y, Nakshatri H, Nephew KP, Behringer RR, Fernández FM, Cho CH, Vanderhyden B, Drapkin R, Bast RC, Miller KD, Karpf AR, Kim J. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genet 16(6):e1008808, 2020. e-Pub 2020. PMID: 32497036.
38. Lyu T, Jiang Y, Jia N, Che X, Li Q, Yu Y, Hua K, Bast RC, Feng W. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. Int J Cancer 146(6):1553-1567, 2020. e-Pub 2020. PMID: 31503345.
39. Kobayashi M, Katayama H, Irajizad E, Vykoukal JV, Fahrmann JF, Kundnani DL, Yu CY, Cai Y, Hsiao FC, Yang WL, Lu Z, Celestino J, Long JP, Do KA, Lu KH, Ladd JJ, Urban N, Bast RC, Hanash SM. Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers (Basel) 12(2):485, 2020. e-Pub 2020. PMID: 32092936.
40. Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer 126(4):894-907, 2020. e-Pub 2020. PMID: 31714594.
41. Yang WL, Lu Z, Guo J, Fellman BM, Ning J, Lu KH, Menon U, Kobayashi M, Hanash SM, Celestino J, Skates SJ, Bast RC. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer 126(4):725-736, 2020. e-Pub 2020. PMID: 31714597.
42. Sutton MN, Lu Z, Li YC, Zhou Y, Huang T, Reger AS, Hurwitz AM, Palzkill T, Logsdon C, Liang X, Gray JW, Nan X, Hancock J, Wahl GM, Bast RC. DIRAS3 (ARHI) blocks RAS/MAPK signaling by binding directly to Ras and disrupting Ras clusters. Cell Rep 29(11):3448-3459.e6, 2019. e-Pub 2019. PMID: 31825828.
43. Guo J, Lu Z, Bast RC. Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers (Basel) 11(9), 2019. e-Pub 2019. PMID: 31540545.
44. Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clin Cancer Res 25(18):5702-5716, 2019. e-Pub 2019. PMID: 31391192.
45. Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. J Geriatr Oncol 10(5):pii: S1879-4068(18)30284-4, 2019. e-Pub 2019. PMID: 30795923.
46. Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results from TAILORx. J Clin Oncol 37(22):JCO1900945, 2019. e-Pub 2019. PMID: 31150316.
47. Nebgen DR, Lu KH, Bast RC. Novel approaches to ovarian cancer screening. Curr Oncol Rep 21(8):75, 2019. e-Pub 2019. PMID: 31346778.
48. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference. Cancer 125(12):1963-1972, 2019. e-Pub 2019. PMID: 30835824.
49. Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, Zheng H, Lu KH, Jacobs I, Skates S, Menon U, Bast RC. Complementary longitudinal serum biomarkers to CA125 for early detection of ovarian cancer. Cancer Prev Res (Phila) 12(6):391-400, 2019. e-Pub 2019. PMID: 30967390.
50. Sutton MN, Huang GY, Zhou J, Mao W, Langley R, Lu Z, Bast RC. Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. Cancers (Basel) 11(5):pii: E603, 2019. e-Pub 2019. PMID: 31052266.
51. Guo J, Yang WL, Pak D, Celestino J, Lu KH, Ning J, Lokshin AE, Cheng Z, Lu Z, Bast RC. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. Cancers (Basel) 11(5):pii: E596, 2019. e-Pub 2019. PMID: 31035430.
52. Sutton MN, Huang GY, Liang X, Sharma R, Reger AS, Mao W, Pang L, Rask PJ, Lee K, Gray JP, Hurwitz AM, Palzkill T, Millward SW, Kim C, Lu Z, Bast RC. DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. Cancers (Basel) 11(4):pii: E557, 2019. e-Pub 2019. PMID: 31003488.
53. Mao W, Peters HL, Sutton MN, Orozco AF, Pang L, Yang H, Lu Z, Bast RC. The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. Cancer 125(8):1267-1280, 2019. e-Pub 2019. PMID: 30620384.
54. Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multi-Protein Classifier for Ovarian Cancer Detection. Cancer Prev Res (Phila) 12(3):171-184, 2019. e-Pub 2019. PMID: 30709840.
55. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
56. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24(20):5072-5084, 2018. e-Pub 2018. PMID: 30084832.
57. Engel BJ, Gammon ST, Chaudhari R, Lu Z, Pisaneschi F, Yang H, Ornelas A, Yan V, Kelderhouse L, Najjar AM, Tong WP, Zhang S, Piwnica-Worms D, Bast RC, Millward SW. Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. Bioconjug Chem 29(9):3180-3195, 2018. e-Pub 2018. PMID: 30168713.
58. Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer 124(14):3000-3007, 2018. e-Pub 2018. PMID: 29689595.
59. Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol 51(3):293-303, 2018. e-Pub 2018. PMID: 28639753.
60. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9(1):476, 2018. e-Pub 2018. PMID: 29396402.
61. Sutton MN, Yang H, Huang GY, Fu C, Pontikos M, Wang Y, Mao W, Pang L, Yang M, Liu J, Parker-Thornburg J, Lu Z, Bast RC. RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy 14(4):637-53, 2018. e-Pub 2018. PMID: 29368982.
62. Lin CW, Yang H, Sanchez SR, Mao W, Pang L, Beckingham KM, Bast RC, Weisman RB. In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes. ACS Appl Mater Interfaces 9(48):41680-41690, 2017. e-Pub 2017. PMID: 29131572.
63. Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC, Group AS. Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clin Cancer Res 23(19):5912-5922, 2017. e-Pub 2017. PMID: 28637689.
64. Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 35(24):2838-2847, 2017. e-Pub 2017. PMID: 28692382.
65. Yang WL, Lu Z, Bast RC. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 17(6):577-591, 2017. e-Pub 2017. PMID: 28468520.
66. Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill JM, Yerramreddy Reddy VK, Alsaadi A, Ahmed AA, Yang H, Liu J, Mao W, Wang Y, Takemori H, Vankayalapati H, Lu Z, Bast RC. A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel. Clin Cancer Res 23(8):1945-1954, 2017. e-Pub 2017. PMID: 27678456.
67. Taylor C, Mannion D, Miranda F, Karaminejadranjbar M, Herrero-Gonzalez S, Hellner K, Zheng Y, Bartholomeusz G, Bast RC, Ahmed AA. Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. Oncotarget 8(11):17960-17980, 2017. e-Pub 2017. PMID: 28152500.
68. Blessing AM, Rajapakshe K, Reddy Bollu L, Shi Y, White MA, Pham AH, Lin C, Jonsson P, Cortes CJ, Cheung E, La Spada AR, Bast RC, Merchant FA, Coarfa C, Frigo DE. Transcriptional Regulation of Core Autophagy and Lysosomal Genes by the Androgen Receptor Promotes Prostate Cancer Progression. Autophagy 13(3):506-21, 2017. e-Pub 2017. PMID: 27977328.
69. Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z, Pathak S, Multani AS, Kuang J, Yao J, Bast RC, Sood AK, Hung MC, Liu J. Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis 5(12):e281, 2016. e-Pub 2016. PMID: 27991913.
70. Ornelas A, McCullough CR, Lu Z, Zacharias NM, Kelderhouse LE, Gray J, Yang H, Engel BJ, Wang Y, Mao W, Sutton MN, Bhattacharya PK, Bast RC, Millward SW. Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer 16(1):824, 2016. e-Pub 2016. PMID: 27784287.
71. Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC, Davis G, Serra S, Diamandis EP, Kulasingam V. Validation of a novel biomarker panel for the detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 25(9):1333-40, 2016. e-Pub 2016. PMID: 27448593.
72. Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell 30(2):273-289, 2016. e-Pub 2016. PMID: 27478041.
73. Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA. Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. EBioMedicine 10:137-49, 2016. e-Pub 2016. PMID: 27492892.
74. Gao M, Ma Y, Bast RC, Li Y, Wan L, Liu Y, Sun Y, Fang Z, Zhang L, Wang X, Wei Z. Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. Med Oncol 33(7):73, 2016. e-Pub 2016. PMID: 27277757.
75. Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, Lu KH, Zhang Z, Bast RC, Skates SJ. Validation of a biomarker panel and longitudinal biomarker performance for early detection of ovarian cancer. Int J Gynecol Cancer 26(6):1070-7, 2016. e-Pub 2016. PMID: 27206285.
76. Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, Xiong J, Tao X, Yan D, Xi X, Chen X, Yu Y, Bast RC, Zhang Z, Feng Y, Zheng W. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway. Oncogene 35(19):2506-17, 2016. e-Pub 2016. PMID: 26364616.
77. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF, Clinical Oncology ASO. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(10):1134-50, 2016. e-Pub 2016. PMID: 26858339.
78. Ejaz A, Mitterberger MC, Lu Z, Mattesich M, Zwierzina ME, Hörl S, Kaiser A, Viertler HP, Rostek U, Meryk A, Khalid S, Pierer G, Bast RC, Zwerschke W. Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Akt-mTOR Inhibition. EBioMedicine 6:149-61, 2016. e-Pub 2016. PMID: 27211557.
79. Morgado M, Sutton MN, Simmons M, Warren CR, Lu Z, Constantinou PE, Liu J, Francis LL, Conlan RS, Bast RC, Carson DD. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget 7(12):14871-84, 2016. e-Pub 2016. PMID: 26918940.
80. Zhang S, Mercado-Uribe I, Sood A, Bast RC, Liu J. Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes Cancer 7(3-4):60-72, 2016. e-Pub 2016. PMID: 27382431.
81. Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA. Allele-specific reprogramming of cancer metabolism by the long non-coding RNA, CCAT2. Mol Cell 61(4):520-34, 2016. e-Pub 2016. PMID: 26853146.
82. Yang H, Das P, Yu Y, Mao W, Wang Y, Baggerly K, Wang Y, Marquez RT, Bedi A, Liu J, Fishman D, Lu Z, Bast RC. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget 7(3):3018-32, 2016. e-Pub 2016. PMID: 26689988.
83. Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer 26(1):43-51, 2016. e-Pub 2016. PMID: 26588231.
84. Ma Y, Wei Z, Bast RC, Wang Z, Li Y, Gao M, Liu Y, Wang X, Guo C, Zhang L, Wang X. Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo. Lab Invest 96(1):37-48, 2016. e-Pub 2016. PMID: 26568293.
85. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
86. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15(11):668-79, 2015. e-Pub 2015. PMID: 26493647.
87. Abu Hassan SO, Nielsen DL, Tuxen MK, Bast RC, Soletormos G. Systematic review of criteria to interpret CA125 increments during monitoring of patients with advanced epithelial ovarian cancer. J Oncol Med Pract 1(1):1000101 (1-11), 2015. e-Pub 2015.
88. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women with Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 33(24):2695-704, 2015. e-Pub 2015. PMID: 26195705.
89. Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC, Lu Z. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death Dis 6:e1836, 2015. e-Pub 2015. PMID: 26247722.
90. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc 90(8):996-1000, 2015. e-Pub 2015. PMID: 26211600.
91. Pickering CR, Bast RC, Keyomarsi K. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. Cancer 121(6):806-16, 2015. e-Pub 2015. PMID: 25355050.
92. Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, Li Z, Bast RC, Le XF. Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res 13(3):393-401, 2015. e-Pub 2015. PMID: 25304686.
93. Shadfan BH, Simmons AR, Simmons GW, Ho A, Wong J, Lu KH, Bast RC, McDevitt JT. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev Res (Phila) 8(1):37-48, 2015. e-Pub 2015. PMID: 25388014.
94. Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC. CDK5 regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT activation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. PLoS One 10(7):e0131833, 2015. e-Pub 2015. PMID: 26146988.
95. Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC, Champlin RE, Cooper LJ. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 20(22):5708-19, 2014. e-Pub 2014. PMID: 24833662.
96. Bilen MA, Reyes A, Bhowmick D, Maa A, Bast RC, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. Can J Urol 21(5):7442-8, 2014. e-Pub 2014. PMID: 25347368.
97. Lu Z, Yang H, Sutton MN, Yang M, Clarke CH, Liao WS, Bast RC. ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death Differ 21(8):1275-89, 2014. e-Pub 2014. PMID: 24769729.
98. Lu Z, Baquero MT, Yang H, Yang M, Reger AS, Kim C, Levine DA, Clarke CH, Liao WS, Bast RC. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy 10(6):1071-1092, 2014. e-Pub 2014. PMID: 24879154.
99. Holman LL, Lu KH, Bast RC, Hernandez MA, Bodurka DC, Skates S, Sun CC. Risk Perception, Worry, and Test Acceptance in Average-Risk Women Undergoing Ovarian Cancer Screening. Am J Obstet Gynecol 210(3):257.e1-6, 2014. e-Pub 2014. PMID: 24246524.
100. Lyu T, Jia N, Wang J, Yan X, Yu Y, Lu Z, Bast RC, Hua K, Feng W. Expression and epigenetic regulation of angiogenesis related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics 8(12):1330-46, 2013. e-Pub 2013. PMID: 24135786.
101. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19):3454-61, 2013. e-Pub 2013. PMID: 23983047.
102. Zhang Z, Zhu Y, Lai Y, Wu X, Feng Z, Yu Y, Bast RC, Wan X, Xi X, Feng Y. Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. Int J Oncol 43(4):1194-204, 2013. e-Pub 2013. PMID: 23921511.
103. Romero I, Sun CC, Wong KK, Bast RC, Gershenson DM. Low-Grade Serous Carcinoma: New Concepts and Emerging Therapies. Gynecol Oncol 130(3):660-6, 2013. e-Pub 2013. PMID: 23707670.
104. Simmons AR, Baggerly K, Bast RC. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) 27(6):548-56, 2013. e-Pub 2013. PMID: 23909069.
105. Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J. CA125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer 23(5):815-822, 2013. e-Pub 2013. PMID: 23669443.
106. Tao X, Zhao N, Jin H, Zhang Z, Liu Y, Wu J, Bast RC, Yu Y, Feng Y. Follicle-stimulating hormone enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Endocr Relat Cancer 20(3):415-429, 2013. e-Pub 2013. PMID: 23580589.
107. Lu Z, Bast RC. The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adh Migr 7(2):232-6, 2013. e-Pub 2013. PMID: 23357870.
108. Diamandis EP, Bast RC, Gold P, Chu TM, Magnani JL. Reflection on the Discovery of Carcinoembryonic Antigen, Prostate-Specific Antigen, and Cancer Antigens CA125 and CA19-9. Clin Chem 59(1):22-31, 2013. e-Pub 2013. PMID: 23204222.
109. Diamandis EP, Bast RC, Lopez-Otín C. Conquering Cancer in Our Lifetime: New Diagnostic and Therapeutic Trends. Clin Chem 59(1):1-3, 2013. e-Pub 2013. PMID: 23204223.
110. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol 3:58, 2013. e-Pub 2013. PMID: 23519775.
111. Jia L, Zhang S, Ye Y, Li X, Mercado-Uribe I, Bast RC, Liu J. Paclitaxel Inhibits Ovarian Tumor Growth by Inducing Epithelial Cancer Cells to Benign Fibroblast-like cells. Cancer Lett 326(2):176-82, 2012. e-Pub 2012. PMID: 22902993.
112. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther 13(11):1034-41, 2012. e-Pub 2012. PMID: 22895067.
113. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47-53, 2012. e-Pub 2012. PMID: 22487539.
114. Xu J, Shetty PB, Feng W, Chenault C, Bast RC, Issa JP, Hilsenbeck SG, Yu Y. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 12(1):243, 2012. e-Pub 2012. PMID: 22695491.
115. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118(10):2603-14, 2012. e-Pub 2012. PMID: 22370716.
116. Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T, Venkitaraman AR. Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene 31(19):2450-60, 2012. e-Pub 2012. PMID: 22056875.
117. Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB, Redding SW, Lu KH, Bast RC, McDevitt JT. Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Towards Ovarian Cancer Diagnostics at the Point-of-Care. Cancer Prev Res (Phila) 5(5):706-16, 2012. e-Pub 2012. PMID: 22490510.
118. Bast RC, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: Improved algorithms and novel biomarkers. Int J Gynecol Cancer 22(10 Suppl 1):S5-8, 2012. e-Pub 2012. PMID: 22543921.
119. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Cho. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. e-Pub 2012. PMID: 22966490.
120. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol 206(4):351.e1-8, 2012. e-Pub 2012. PMID: 22284961.
121. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 206(4):349.e1-7, 2012. e-Pub 2012. PMID: 22301440.
122. Romero I, Bast RC. Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy. Endocrinology 153(4):1593-602, 2012. e-Pub 2012. PMID: 22416079.
123. Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RC. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 31(1):68-79, 2012. e-Pub 2012. PMID: 21643014.
124. Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer 118(1):91-100, 2012. e-Pub 2012. PMID: 21717433.
125. Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC. Modulation of microRNA-194 and Cell Migration by HER2-targeting Trastuzumab in Breast Cancer. PLoS One 7(7):e41170, 2012. e-Pub 2012. PMID: 22829924.
126. Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, Bast RC, Robertson FM, McMurray JS. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol 10(2):155-62, 2012. e-Pub 2012. PMID: 23350355.
127. Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC, Hortobagyi GN, Hung MC. FOXO3a dependent mechanism of E1A-Induced chemosensitization. Cancer Res 71(21):6878-87, 2011. e-Pub 2011. PMID: 21911455.
128. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2M arrest and autophagy. Cancer 117(19):4424-38, 2011. e-Pub 2011. PMID: 21491416.
129. Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC, Priebe W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol 68(4):1033-44, 2011. e-Pub 2011. PMID: 21340606.
130. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 11(10):719-725, 2011. e-Pub 2011. PMID: 21941283.
131. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC. The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. J Natl Cancer Inst 103(18):1403-22, 2011. e-Pub 2011. PMID: 21813412.
132. Ahmed AA, Wang X, Lu Z, Goldsmith J, Le XF, Grandjean G, Bartholomeusz G, Broom B, Bast RC. Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel. Cancer Res 71(17):5806-17, 2011. e-Pub 2011. PMID: 21775522.
133. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 122(3):548-53, 2011. e-Pub 2011. PMID: 21708402.
134. Le XF, Bast RC. Src Family Kinases and paclitaxel sensitivity. Cancer Biol Ther 12(4):260-9, 2011. e-Pub 2011. PMID: 21646863.
135. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC, Liao WS, McMurray JS. Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3. J Med Chem 54(10):3549-63, 2011. e-Pub 2011. PMID: 21486047.
136. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8):1661-9, 2011. e-Pub 2011. PMID: 21472713.
137. Diao L, Clarke CH, Coombes KR, Hamilton SR, Roth J, Mao L, Czerniak B, Baggerly KA, Morris JS, Fung ET, Bast RC. Reproducibility of SELDI spectra across time and laboratories. Cancer Inform 10:45-64, 2011. e-Pub 2011. PMID: 21552492.
138. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD, Team PP. A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. Cancer Prev Res (Phila) 4(3):375-383, 2011. e-Pub 2011. PMID: 21372037.
139. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4(3):365-74, 2011. e-Pub 2011. PMID: 21372036.
140. Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RC, Feng Y, Yu Y. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer 11(1):22, 2011. e-Pub 2011. PMID: 21244707.
141. Yu Y, Feng W, Lu Z, Bast RC. PEG3 (paternally expressed 3). Atlas Genet Cytogenet Oncol Haematol 15(5):422-4, 2011. e-Pub 2011.
142. Hennessey VG, Rosner GL, Bast RC, Chen MY. A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose response studies. Biometrics 66(4):1275-83, 2010. e-Pub 2010. PMID: 20337630.
143. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Mol Cancer Ther 9(12):3186-99, 2010. e-Pub 2010. PMID: 20889728.
144. Le XF, Mao W, Lu Z, Carter BZ, Bast RC. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116(21):4980-90, 2010. e-Pub 2010. PMID: 20629079.
145. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 203(3):228.e1-6, 2010. e-Pub 2010. PMID: 20471625.
146. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Study Group AOC, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2):109-121, 2010. e-Pub 2010. PMID: 20708153.
147. Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC, Yu Y. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer 10(1):378, 2010. e-Pub 2010. PMID: 20642860.
148. Yang H, Lu X, Qian J, Xu F, Hu Y, Yu Y, Bast RC, Li J. Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. Mol Med Rep 3(4):581-7, 2010. e-Pub 2010. PMID: 21472283.
149. Khleif SN, Doroshow JH, Hait WN, Bast RC. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 16(13):3299-318, 2010. e-Pub 2010. PMID: 20501613.
150. Bast RC. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 116(12):2850-3, 2010. e-Pub 2010. PMID: 20564390.
151. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. Stanniocalcin 1 and Ovarian Tumorigenesis. J Natl Cancer Inst 102(11):812-27, 2010. e-Pub 2010. PMID: 20484106.
152. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC, Lokshin A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117(3):440-5, 2010. e-Pub 2010. PMID: 20334903.
153. Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC, Chen X, Yu Y. ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep 30(3):159-68, 2010. e-Pub 2010. PMID: 19435463.
154. Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC, Zhang Z, Nicoletto MO. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol 31(3):209-15, 2010. e-Pub 2010. PMID: 20393825.
155. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28(13):2159-66, 2010. e-Pub 2010. PMID: 20368574.
156. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol 3(1):9, 2010. e-Pub 2010. PMID: 20222977.
157. Le XF, Merchant O, Bast RC, Calin GA. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron 3(1):137-47, 2010. e-Pub 2010. PMID: 21209780.
158. Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle 9(1):140-6, 2010. e-Pub 2010. PMID: 20016289.
159. Thigpen JT, Alberts D, Birrer M, Copeland L, Coleman RL, Markman M, Bast RC, Eisenhauer EL, Fleming G, Fracasso PM, Gershenson DM, Herzog T, Monk B, Ozols RF, Rustin G, Shrader M, Ranganathan A. Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer. Clinical Ovarian Cancer 3:81-97, 2010. e-Pub 2010.
160. Yu Y, Lu Z, Luo RZ, Bast RC. DIRAS3 (DIRAS family, GTP binding RAS-like 3). Atlas Genet Cytogenet Oncol Haematol 14(8):714-6, 2010. e-Pub 2010.
161. Kurzrock R, Pilat S, Bartolazzi M, Sanders D, Van Wart Hood J, Tucker SD, Webster K, Mallamaci MA, Strand S, Babcock E, Bast RC. Project zero delay: A process for accelerating the activation of cancer clinical trials. J Clin Oncol 27(26):4433-40, 2009. e-Pub 2009. PMID: 19652061.
162. Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC, Liao WS. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer 115(17):3897-908, 2009. e-Pub 2009. PMID: 19517469.
163. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther 8(8):2375-82, 2009. e-Pub 2009. PMID: 19671744.
164. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40-46, 2009. e-Pub 2009. PMID: 18851871.
165. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC, Kruk PA. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol 112(1):60-67, 2009. e-Pub 2009. PMID: 19007973.
166. Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, Bast RC, Behringer RR. CA125/MUC16 is dispensable for mouse development and reproduction. PLoS One 4(3):e4675, 2009. e-Pub 2009. PMID: 19262696.
167. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, IeM S, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, Clinical Biochemistry NAO. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54(12):e11-79, 2008. e-Pub 2008. PMID: 19042984.
168. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118(12):3917-29, 2008. e-Pub 2008. PMID: 19033662.
169. Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7(23):3747-58, 2008. e-Pub 2008. PMID: 19029832.
170. Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation 76(10):1081-1092, 2008. e-Pub 2008. PMID: 18637025.
171. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian and pancreatic cancers. Mol Carcinog 47(9):701-706, 2008. e-Pub 2008. PMID: 18176935.
172. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110(2):196-201, 2008. e-Pub 2008. PMID: 18495222.
173. Das PM, Bast RC. Early detection of ovarian cancer. Biomark Med 2(3):291-303, 2008. e-Pub 2008. PMID: 20477415.
174. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112(7):1489-502, 2008. e-Pub 2008. PMID: 18286529.
175. Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian Cancer Action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 108(3):652-657, 2008. e-Pub 2008. PMID: 18096210.
176. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108(2):402-408, 2008. e-Pub 2008. PMID: 18061248.
177. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 107(3):526-531, 2007. e-Pub 2007. PMID: 17920110.
178. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, Clinical Oncology ASO. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-312, 2007. e-Pub 2007. PMID: 17954709.
179. Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Mol Cancer Ther 6(11):2843-57, 2007. e-Pub 2007. PMID: 18025271.
180. Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R. Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 107(2):173-6, 2007. e-Pub 2007. PMID: 17950384.
181. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 106(3):490-497, 2007. e-Pub 2007. PMID: 17532030.
182. Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC, Zhou C, Liu J. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 28(1):174-82, 2007. e-Pub 2007. PMID: 16829690.
183. Brewer M, Ranger-Moore J, Satterfield W, Hao Z, Wang J, Brewer E, Wharton JT, Bast RC, Zou C. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Front Biosci 12:2260-8, 2007. e-Pub 2007. PMID: 17127462.
184. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9(4):R57, 2007. e-Pub 2007. PMID: 17764565.
185. Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107(11):2730-2740, 2006. e-Pub 2006. PMID: 17063503.
186. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313-5327, 2006. e-Pub 2006. PMID: 17060676.
187. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25(52):6986-6996, 2006. e-Pub 2006. PMID: 16715132.
188. Farley J, Bast RC, Birrer MJ. Biomarkers and clinical trial design. Gynecol Oncol 103(2 Suppl 1):S3-5, 2006. e-Pub 2006. PMID: 17027069.
189. Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103(44):16472-16477, 2006. e-Pub 2006. PMID: 17060621.
190. Brewer M, Kirkpatrick ND, Wharton JT, Wang J, Hatch K, Auersperg N, Utzinger U, Gershenson D, Bast RC, Zou C. 4-HPR modulates gene expression in ovarian cells. Int J Cancer 119(5):1005-1013, 2006. e-Pub 2006. PMID: 16570282.
191. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and Histone H4 expression via the PI3K pathway. Cell Cycle 5(15):1654-1661, 2006. e-Pub 2006. PMID: 16861913.
192. Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu Y, Bast RC. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res 12(8):2404-2413, 2006. e-Pub 2006. PMID: 16638845.
193. Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust Meeting. Cancer Res 66(6):2904-2906, 2006. e-Pub 2006. PMID: 16540635.
194. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 66(5):2740-8, 2006. e-Pub 2006. PMID: 16510595.
195. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC, Oram D, Jacobs IJ. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23(31):7919-7926, 2005. e-Pub 2005. PMID: 16258091.
196. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-277, 2005. e-Pub 2005. PMID: 16061277.
197. Young T, Mei F, Liu J, Bast RC, Kurosky A, Cheng X. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene 24(40):6174-6184, 2005. e-Pub 2005. PMID: 15940260.
198. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Lu KH. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium and colon. Clin Cancer Res 11(17):6116-6126, 2005. e-Pub 2005. PMID: 16144910.
199. Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC, Luo RZ. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res 65(15):6701-6710, 2005. e-Pub 2005. PMID: 16061651.
200. Brewer M, Wharton JT, Wang J, McWatters A, Auersperg N, Gershenson D, Bast RC, Zou C. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecol Oncol 98(2):182-192, 2005. e-Pub 2005. PMID: 15907982.
201. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11(6):2149-2155, 2005. e-Pub 2005. PMID: 15788660.
202. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280(3):2092-2104, 2005. e-Pub 2005. PMID: 15504738.
203. Rosen DG, Yang G, Cai KQ, Bast RC, Gershenson DM, Silva EG, Liu J. Subcellular localization of p27KIP1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 11(2 Pt 1):632-637, 2005. e-Pub 2005. PMID: 15701850.
204. Le XF, Pruefer F, Bast RC. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4(1):87-95, 2005. e-Pub 2005. PMID: 15611642.
205. Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 22(20):4059-4066, 2004. e-Pub 2004. PMID: 15381683.
206. Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 10(19):6559-6566, 2004. e-Pub 2004. PMID: 15475444.
207. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Res 64(16):5882-5890, 2004. e-Pub 2004. PMID: 15313933.
208. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33(12):1219-1224, 2004. e-Pub 2004. PMID: 15122311.
209. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10(10):3291-3300, 2004. e-Pub 2004. PMID: 15161682.
210. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279(10):9653-9661, 2004. e-Pub 2004. PMID: 14670967.
211. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC. A genetically defined model for human ovarian cancer. Cancer Res 64(5):1655-1663, 2004. e-Pub 2004. PMID: 14996724.
212. Samanta AK, Huang HJ, Bast RC, Liao WS. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFκB. J Biol Chem 279(9):7576-7583, 2004. e-Pub 2004. PMID: 14662759.
213. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 279(6):4339-4345, 2004. e-Pub 2004. PMID: 14625284.
214. Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest 22(2):248-256, 2004. e-Pub 2004. PMID: 15199607.
215. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 9(10 Pt 1):3660-3666, 2003. e-Pub 2003. PMID: 14506155.
216. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 9(10 Pt 1):3534-3545, 2003. e-Pub 2003. PMID: 14506139.
217. Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S, Smyth J, Ursulic S. Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer 39(13):1818-1827, 2003. e-Pub 2003. PMID: 12932658.
218. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC, Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet 12(15):1791-1800, 2003. e-Pub 2003. PMID: 12874100.
219. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 63(14):4174-4180, 2003. e-Pub 2003. PMID: 12874023.
220. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90(1):44-50, 2003. e-Pub 2003. PMID: 12821340.
221. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RC, Zhang X. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 9(7):2727-2733, 2003. e-Pub 2003. PMID: 12855653.
222. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278(26):23441-23450, 2003. e-Pub 2003. PMID: 12700233.
223. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 22(19):2897-2909, 2003. e-Pub 2003. PMID: 12771940.
224. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 21(10 Suppl):129s-132s, 2003. e-Pub 2003. PMID: 12743127.
225. Bast RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol 21(10 Suppl):200-205, 2003. e-Pub 2003. PMID: 12743135.
226. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC, Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res 9(2):845-852, 2003. e-Pub 2003. PMID: 12576458.
227. Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast RC. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22(4):484-497, 2003. e-Pub 2003. PMID: 12555062.
228. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88(1):73-79, 2003. e-Pub 2003. PMID: 12504632.
229. Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC, Gray J. Specific keynote: Molecular Therapeutics in Ovarian Cancer. Gynecol Oncol 88(1 Pt 2):S88-S92, 2003. e-Pub 2003. PMID: 12586094.
230. Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 62(24):7264-7272, 2002. e-Pub 2002. PMID: 12499268.
231. Le XF, Varela CR, Bast RC. Heregulin-induced apoptosis. Apoptosis 7(6):483-491, 2002. e-Pub 2002. PMID: 12370490.
232. Brewer M, Utzinger U, Li Y, Atkinson EN, Satterfield W, Auersperg N, Richards-Kortum R, Follen M, Bast RC. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. J Biomed Opt 7(1):20-26, 2002. e-Pub 2002. PMID: 11818008.
233. Kramer S, Yu Y, Jager W, Lang N, Bast RC, Beckmann MW. Characterization of the ARHI tumor suppressor as a target for gene therapy in ovarian cancer. Geburtsh Frauenheilk 62:870-876, 2002. e-Pub 2002.
234. Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA, Bast RC. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C α activity. Oncogene 20(57):8258-8269, 2001. e-Pub 2001. PMID: 11781840.
235. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92(11):2837-2844, 2001. e-Pub 2001. PMID: 11753957.
236. Bast RC, Mills GB, Young RC. Translational research - traffic on the bridge. Biomed Pharmacother 55(9-10):565-571, 2001. e-Pub 2001. PMID: 11769968.
237. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82(3):420-426, 2001. e-Pub 2001. PMID: 11520135.
238. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 61(15):5895-5904, 2001. e-Pub 2001. PMID: 11479231.
239. Brewer M, Utzinger U, Satterfield W, Hill L, Gershenson D, Bast RC, Wharton JT, Richards-Kortum R, Follen M. Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 10(8):889-893, 2001. e-Pub 2001. PMID: 11489756.
240. Luo RZ, Peng H, Xu F, Bao J, Pang Y, Pershad R, Issa JP, Liao WS, Bast RC, Yu Y. Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. Biochim Biophys Acta 1519(3):216-222, 2001. e-Pub 2001. PMID: 11418188.
241. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, Expert Panel ASOCOTM. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(6):1865-1878, 2001. e-Pub 2001. PMID: 11251019.
242. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Hortobagyi GN, Esteva FL. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19(6):1716-22, 2001. e-Pub 2001. PMID: 11251001.
243. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC, Stack MS. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-β. Gynecol Oncol 80(2):245-253, 2001. e-Pub 2001. PMID: 11161867.
244. Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RC. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol 80(2):145-155, 2001. e-Pub 2001. PMID: 11161852.
245. Utzinger U, Brewer M, Silva E, Gershenson D, Bast RC, Mitchell MF, Richards-Kortum R. Reflectance spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 28(1):56-66, 2001. e-Pub 2001. PMID: 11430444.
246. Brewer M, Utzinger U, Silva E, Gershenson D, Bast RC, Follen M, Richards-Kortum R. Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 29(2):128-135, 2001. e-Pub 2001. PMID: 11553899.
247. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast RC, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 19(5):459-466, 2001. e-Pub 2001. PMID: 11458813.
248. Kruzelock RP, Cuevas BD, Wiener JR, Xu FJ, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB, Bast RC. Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 19(54):6277-6285, 2000. e-Pub 2000. PMID: 11175342.
249. Mao M, Fang X, Lu Y, Lapushin R, Bast RC, Mills GB. Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J 352 Pt 2:475-482, 2000. e-Pub 2000. PMID: 11085941.
250. Einhorn N, Bast RC, Knapp R, Nilsson B, Zurawski V, Sjövall K. Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecol Oncol 79(3):466-470, 2000. e-Pub 2000. PMID: 11104621.
251. Hogdall EV, Høgdall CK, Tingulstad S, Hagen B, Nustad K, Xu FJ, Bast RC, Jacobs IJ. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 89(6):519-523, 2000. e-Pub 2000. PMID: 11102897.
252. Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 352 Pt 1:135-143, 2000. e-Pub 2000. PMID: 11062066.
253. Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97(22):11960-11965, 2000. e-Pub 2000. PMID: 11035810.
254. Xu F, Xia W, Luo RZ, Peng H, Zhao S, Dai J, Long Y, Zou L, Le W, Liu J, Parlow AF, Hung MC, Bast RC, Yu Y. The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. Cancer Res 60(17):4913-4920, 2000. e-Pub 2000. PMID: 10987306.
255. Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res 6(8):3334-3341, 2000. e-Pub 2000. PMID: 10955821.
256. Le XF, Vadlamudi R, McWatters A, Bae DS, Mills GB, Kumar R, Bast RC. Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res 60(13):3522-3531, 2000. e-Pub 2000. PMID: 10910064.
257. Peng H, Xu F, Pershad R, Hunt KK, Frazier ML, Berchuck A, Gray JW, Hogg D, Bast RC, Yu Y. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. Int J Cancer 86(5):690-694, 2000. e-Pub 2000. PMID: 10797292.
258. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25(11):1137-40, 2000. e-Pub 2000. PMID: 10849525.
259. Bast RC, Yu Y, Xu FJ, Le XF, Mills GB. Molecular approaches to management of epithelial ovarian cancer. Int J Gynecol Cancer 10(S1):2-7, 2000. e-Pub 2000. PMID: 11240724.
260. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 6(1):260-270, 2000. e-Pub 2000. PMID: 10656457.
261. Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller BE, Bast RC, Mills GB, Silva EG. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 5(12):4053-4058, 1999. e-Pub 1999. PMID: 10632339.
262. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Overexpression of Edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 5(12):4308-4318, 1999. e-Pub 1999. PMID: 10632375.
263. Fang X, Yu S, Eder A, Mao M, Bast RC, Boyd D, Mills GB. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18(48):6635-6640, 1999. e-Pub 1999. PMID: 10597268.
264. Wolf JK, Mills GB, Bazzet L, Bast RC, Roth JA, Gershenson DM. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol 75(2):261-266, 1999. e-Pub 1999. PMID: 10525383.
265. Woolas RP, Oram DH, Jeyarajah AR, Bast RC, Jacobs IJ. Ovarian cancer identified through screening with serum markers but not by pelvic imaging. Int J Gynecol Cancer 9(6):497-501, 1999. e-Pub 1999. PMID: 11240818.
266. Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5(11):3653-3660, 1999. e-Pub 1999. PMID: 10589783.
267. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC, Mills GB. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5(11):3704-3710, 1999. e-Pub 1999. PMID: 10589790.
268. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast RC, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86(7):1251-1257, 1999. e-Pub 1999. PMID: 10506711.
269. Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao XG, Slade SK, Affleck DJ, Bast RC. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol 26(7):781-790, 1999. e-Pub 1999. PMID: 10628557.
270. Baile WF, Kudelka AP, Beale EA, Glober GA, Myers EG, Greisinger AJ, Bast RC, Goldstein MG, Novack D, Lenzi R. Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer 86(5):887-897, 1999. e-Pub 1999. PMID: 10463990.
271. Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 82(4):525-531, 1999. e-Pub 1999. PMID: 10404066.
272. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC, Gallick GE. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 5(8):2164-2170, 1999. e-Pub 1999. PMID: 10473101.
273. Hogdall EV, Hogdall CK, Kjaer SK, Xu F, Yu Y, Bast RC, Blaakaer J, Jacobs IJ. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clin Chem 45(5):692-694, 1999. e-Pub 1999. PMID: 10222361.
274. Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 73(1):56-61, 1999. e-Pub 1999. PMID: 10094881.
275. Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res 5(3):655-664, 1999. e-Pub 1999. PMID: 10100719.
276. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 96(1):214-219, 1999. e-Pub 1999. PMID: 9874798.
277. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu SQ, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Przepiorka D, Burtness B, Cote R, Bast RC, Hortobagyi G, Deisseroth A. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 4(11):2717-2721, 1998. e-Pub 1998. PMID: 9829734.
278. Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res 4(10):2545-2550, 1998. e-Pub 1998. PMID: 9796989.
279. Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 70(3):404-409, 1998. e-Pub 1998. PMID: 9790795.
280. Bast RC, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM, Mendelsohn J, Berchuck A. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 17(4):313-321, 1998. e-Pub 1998. PMID: 9790065.
281. Martell RE, Xu FJ, Davis WZ, Anselmino L, Yu YH, Daly L, Bast RC. OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders. Int J Biol Markers 13(3):145-149, 1998. e-Pub 1998. PMID: 10079388.
282. Boente MP, Berchuck A, Whitaker RS, Kalén A, Xu FJ, Clarke-Pearson DL, Bell RM, Bast RC. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. Gynecol Oncol 70(1):49-55, 1998. e-Pub 1998. PMID: 9698473.
283. Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast RC, Ostrowski MC. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 58(10):2253-2259, 1998. e-Pub 1998. PMID: 9605774.
284. Bast RC, Desch CE, Hayes DF, Kemeney NE, Ravdin P, Smith TJ. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 16(2):793-5, 1998. e-Pub 1998. PMID: 9469371.
285. Fang X, Jin X, Xu HJ, Liu L, Peng HQ, Hogg D, Roth JA, Yu Y, Xu F, Bast RC, Mills GB. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 16(1):1-8, 1998. e-Pub 1998. PMID: 9467937.
286. Bast RC. Summary of the first Emil J Freireich symposium. Clin Cancer Res 3(12 Pt 2):2708-2710, 1997. e-Pub 1997. PMID: 10068278.
287. Xu HJ, Zhou Y, Ji W, Perng GS, Kruzelock R, Kong CT, Bast RC, Mills GB, Li J, Hu SX. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 15(21):2589-2596, 1997. e-Pub 1997. PMID: 9399646.
288. Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 3(9):1629-1634, 1997. e-Pub 1997. PMID: 9815853.
289. Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, Bast RC, Zalutsky MR. Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol 24(5):451-459, 1997. e-Pub 1997. PMID: 9290082.
290. Vredenburgh JJ, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, Petros WP, Peters WP, Bast RC. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 3(2):91-97, 1997. e-Pub 1997. PMID: 9267669.
291. Fang X, Gibson S, Flowers M, Furui T, Bast RC, Mills GB. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J Biol Chem 272(21):13683-13689, 1997. e-Pub 1997. PMID: 9153219.
292. Beck EP, Wagner M, Anselmino L, Xu F, Bast RC, Jaeger W. Is OVX1 a suitable marker for endometrial cancer?. Gynecol Oncol 65(2):291-296, 1997. e-Pub 1997. PMID: 9159340.
293. Bast RC, Knapp RC. CA 125: History, current status, and future prospects. McGill J Med 3:67-71, 1997. e-Pub 1997.
294. Sharp F, Blackett AD, Berek JS, Bast RC. Conclusions and recommendations of the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer. Int J Gynec Oncol, Los Angeles, California, USA 7:416-424, 1997. e-Pub 1997.
295. Woolas RP, Jacobs IJ, Xu F, Berchuck A, Soper JT, Clarke-Pearson DL, Spence-Jones C, Oram DH, Hudson CN, Shepherd JH, Bast RC. Multiple tumor marker measurements to differentiate stage I ovarian cancer from the benign ovarian cyst. J Gynecol Techniques 3:123-126, 1997. e-Pub 1997.
296. Baile WF, Lenzi R, Kudelka AP, Maguire P, Novack D, Goldstein M, Myers EG, Bast RC. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ 12(3):166-173, 1997. e-Pub 1997. PMID: 9376255.
297. Hanania EG, Giles RE, Kavanaugh J, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Hester J, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast RC, Andreeff M, Champlin R, Deisseroth AB. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A 93(26):15346-51, 1996. e-Pub 1996. PMID: 8986814.
298. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27(11):1185-1191, 1996. e-Pub 1996. PMID: 8912829.
299. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88(20):1456-1466, 1996. e-Pub 1996. PMID: 8841020.
300. Bast RC, Expert Panel TASOCOTM. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14(10):2843-77, 1996. e-Pub 1996. PMID: 8874347.
301. Young TN, Rodriguez GC, Rinehart AR, Bast RC, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62(1):89-99, 1996. e-Pub 1996. PMID: 8690299.
302. van Haaften-Day C, Russell P, Boyer CM, Kerns BJ, Wiener JR, Jensen DN, Bast RC, Hacker NF. Expression of cell regulatory proteins in ovarian borderline tumors. Cancer 77(10):2092-2098, 1996. e-Pub 1996. PMID: 8640675.
303. Skubitz AP, Bast RC, Wayner EA, Letourneau PC, Wilke MS. Expression of α6 and β4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol 148(5):1445-1461, 1996. e-Pub 1996. PMID: 8623916.
304. Wiener JR, Kassim SK, Yu Y, Mills GB, Bast RC. Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Gynecol Oncol 61(2):233-240, 1996. e-Pub 1996. PMID: 8626139.
305. Olt G, Soper J, Ramakrishnan S, Xu F, Berchuck A, Clarke-Pearson D, Dodge R, Bast RC. Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. Am J Obstet Gynecol 174(4):1316-1319, 1996. e-Pub 1996. PMID: 8623863.
306. Vredenburgh JJ, Silva O, Tyer C, DeSombre K, Abou-Ghalia A, Cook M, Layfield L, Peters WP, Bast RC. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother 5(1):57-62, 1996. e-Pub 1996. PMID: 8646482.
307. Tyer CL, Vredenburgh JJ, Heimer M, Peters WP, Bast RC. Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res 2(1):81-86, 1996. e-Pub 1996. PMID: 9816094.
308. Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Williams S, Hami L, Bitter MA, Bast RC, Jones RB. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat 41(1):1-13, 1996. e-Pub 1996. PMID: 8932871.
309. Fayed S, Wu S, Lidor Y, Super M, Berchuck A, Bast RC, Wiener JR. Detection and partial purification of a 30 kDa ovarian carcinoma-associated protein. Cancer Mol Biol 3:915-926, 1996. e-Pub 1996.
310. Nap M, Vitali A, Nustad K, Bast RC, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, Børmer OP, Saga T, de Bruijn HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarström S, Kenemans P, Hilgers J. Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol 17(6):325-331, 1996. e-Pub 1996. PMID: 8938947.
311. Woolas R, Xu FJ, Jacobs I, Oram D, Bast RC. Case Report: Elevated serum levels of macrophage colony stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer. Int J Gynecol Cancer 6:156-158, 1996. e-Pub 1996.
312. Nustad K, Bast RC, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Børmer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarström S, Kenemans P, Hilgers J. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 17(4):196-219, 1996. e-Pub 1996. PMID: 8685601.
313. Vredenburgh JJ, Peters WP, Rosner G, DeSombre K, Johnston WW, Kamel A, Wu K, Bast RC. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy. Bone Marrow Transplant 16(6):815-821, 1995. e-Pub 1995. PMID: 8750275.
314. Skates SJ, Xu FJ, Yu YH, Sjövall K, Einhorn N, Chang Y, Bast RC, Knapp RC. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76(10 Suppl):2004-2010, 1995. e-Pub 1995. PMID: 8634992.
315. Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC, Mills GB. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 76(9):1615-1620, 1995. e-Pub 1995. PMID: 8635066.
316. Xu F, Yu Y, Bast RC, Cornelissen G, Fujii S, Takagi M, O'Brien T, Halberg F. Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130. In Vivo 9(4):407-12, 1995. e-Pub 1995. PMID: 8555442.
317. Portela A, Cornélissen G, Halberg F, Bast RC, Fujii S, Xu F, Yu Y, Takagi M, Halberg J, Halberg F. Spectral differences between epitopes in the cronomes of salivary CA130 and CA125. In Vivo 9(4):341-346, 1995. e-Pub 1995. PMID: 8555433.
318. Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast RC, Berchuck A. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β. Cancer Res 55(4):944-948, 1995. e-Pub 1995. PMID: 7531618.
319. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT, Clarke-Pearson DL, Rodriguez G, Oram DH, Bast RC. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59:111-116, 1995. e-Pub 1995. PMID: 7557595.
320. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC, Iglehart JD, Marks JR. Transforming growth factor β 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5(12):1301-1307, 1994. e-Pub 1994. PMID: 7696178.
321. Xu FJ, Boyer CM, Bae DS, Wu S, Greenwald M, O'Briant K, Yu YH, Mills GB, Bast RC. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. Int J Cancer 59(2):242-247, 1994. e-Pub 1994. PMID: 7927925.
322. McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370(6490):558-561, 1994. e-Pub 1994. PMID: 8052311.
323. Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC, Berchuck A. Transforming growth factor-ß inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74(1):93-99, 1994. e-Pub 1994. PMID: 8004589.
324. Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast RC, McCulloch W. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83(11):3132-3137, 1994. e-Pub 1994. PMID: 8193351.
325. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Berchuck A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73(9):2380-2385, 1994. e-Pub 1994. PMID: 7909491.
326. Young TN, Rodriguez GC, Moser TL, Bast RC, Pizzo SV, Stack MS. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 170(5 Pt 1):1285-1296, 1994. e-Pub 1994. PMID: 8178854.
327. Campbell IG, Nicolai HM, Foulkes WD, Senger G, Stamp GW, Allan G, Boyer C, Jones K, Bast RC, Solomon E. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet 3(4):589-594, 1994. e-Pub 1994. PMID: 8069304.
328. Wiener JR, Hurteau JA, Kerns BJ, Whitaker RS, Conaway MR, Berchuck A, Bast RC. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. Am J Obstet Gynecol 170(4):1177-1183, 1994. e-Pub 1994. PMID: 8166206.
329. Wu S, Meeker WA, Wiener JR, Berchuck A, Bast RC, Boyer CM. Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-α) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-α. Gynecol Oncol 53(1):59-63, 1994. e-Pub 1994. PMID: 8175024.
330. Xu FJ, Yu YH, Daly L, Anselmino L, Hass GM, Berchuck A, Rodriguez GC, Soper JT, Clarke-Pearson DL, Hollis D, Boyer C, Bast RC. OVX1 as a marker for early stage endometrial carcinoma. Cancer 73(7):1855-1858, 1994. e-Pub 1994. PMID: 8137210.
331. Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, Bast RC. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst 86(5):372-378, 1994. e-Pub 1994. PMID: 7905928.
332. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, Stack MS. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 56(4):552-559, 1994. e-Pub 1994. PMID: 8112891.
333. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 52(2):232-236, 1994. e-Pub 1994. PMID: 7508877.
334. Kerns BJ, Jordan PA, Faerman LL, Berchuck A, Bast RC, Layfield LJ. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 101(2):192-197, 1994. e-Pub 1994. PMID: 8116574.
335. Liu FS, Kohler MF, Marks JR, Bast RC, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 83(1):118-124, 1994. e-Pub 1994. PMID: 8272291.
336. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170(1 Pt 1):246-252, 1994. e-Pub 1994. PMID: 8296829.
337. Kassim SK, Wiener JR, Berchuck A, Bast RC. Protein tyrosine phosphatases: Biology and role in human cancers. Cancer Mol Biol 1:133-144, 1994. e-Pub 1994.
338. van den Brûle FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, Castronovo V. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 30A(8):1096-1099, 1994. e-Pub 1994. PMID: 7654437.
339. Abou-Ghalia A, Silva O, Vredenburgh JJ, Bast RC. Advances in the detection of marrow micrometastases in breast cancer. Cancer Res Ther Control 4:43-47, 1994. e-Pub 1994.
340. Jacobs IJ, Rivera H, Oram DH, Bast RC. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol 100(12):1120-1124, 1993. e-Pub 1993. PMID: 8297846.
341. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85(21):1748-1751, 1993. e-Pub 1993. PMID: 8411259.
342. Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J Clin Invest 92(5):2440-2447, 1993. e-Pub 1993. PMID: 8227359.
343. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85(18):1513-1519, 1993. e-Pub 1993. PMID: 8360934.
344. Kohler MF, Nishii H, Humphrey PA, Saski H, Marks J, Bast RC, Clarke-Pearson DL, Boyd J, Berchuck A. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. Am J Obstet Gynecol 169(3):690-694, 1993. e-Pub 1993. PMID: 8372881.
345. Gallion HH, Bast RC. National Cancer Institute Conference on Investigational Strategies for Detection and Intervention in Early Ovarian Cancer. Cancer Res 53(16):3839-3842, 1993. e-Pub 1993. PMID: 8339296.
346. Lidor YJ, Xu FJ, Martínez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res 207(2):332-339, 1993. e-Pub 1993. PMID: 8344385.
347. F-J X, Y-A Y, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper J, Clarke-Pearson D, Boyer C, Layfield LJ, Bast RC. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J Clin Oncol 11(8):1506-1510, 1993. e-Pub 1993. PMID: 8336189.
348. McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 71(12):3942-3946, 1993. e-Pub 1993. PMID: 8099528.
349. Jordan PA, Kerns BJ, Pence JC, Kohler MF, Bast RC, Kinney RB, Berchuck A. Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 99(6):736-740, 1993. e-Pub 1993. PMID: 8322710.
350. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11(6):1132-1143, 1993. e-Pub 1993. PMID: 8501500.
351. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81(5 Pt 1):643-650, 1993. e-Pub 1993. PMID: 8469448.
352. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RC. Tumor necrosis factor alpha (TNF-α) as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and TNF-α expression. Cancer Res 53(8):1939-1944, 1993. e-Pub 1993. PMID: 8385577.
353. Jacobs IJ, Smith SA, Wiseman RW, Futreal PA, Harrington T, Osborne RJ, Leach V, Molyneaux A, Berchuck A, Ponder BAJ, Bast RC. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 53(6):1218-1221, 1993. e-Pub 1993. PMID: 8095178.
354. Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 53(3):401-408, 1993. e-Pub 1993. PMID: 7679090.
355. Rodríguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu F, Bast RC. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am J Obstet Gynecol 168(1 Pt 1):228-232, 1993. e-Pub 1993. PMID: 8420332.
356. Woolas R, Xu FJ, Daly L, Soper JT, Berchuck A, Rodriguez G, Clarke-Pearson DL, Boyer CM, Bast RC. Screening strategies for ovarian cancer. Diagn Oncol 3:287-293, 1993. e-Pub 1993.
357. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84(23):1793-1798, 1992. e-Pub 1992. PMID: 1433368.
358. Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker R, Xu FJ, Marks J, Clarke-Pearson DL, Bast RC. The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. Am J Obstet Gynecol 167(6):1877-1882, 1992. e-Pub 1992. PMID: 1361720.
359. Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer 70(8):2137-2142, 1992. e-Pub 1992. PMID: 1394043.
360. Pence JC, Deutsch MA, Kerns BJM, Huper G, Jordan LK III, Wolfe WG, Samuelson WM, Jr FW, Dodge RK, Plate CA, Bast RC, Iglehart JD. Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. Cancer 70(5):1115-1123, 1992. e-Pub 1992. PMID: 1515986.
361. Jacobs IJ, Oram DH, Bast RC. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 80(3 Pt 1):396-399, 1992. e-Pub 1992. PMID: 1495694.
362. Einhorn N, Sjövall K, Knapp RC, Hall P, Scully RE, Bast RC, Zurawski VR. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80(1):14-18, 1992. e-Pub 1992. PMID: 1603484.
363. Daly L, Ferguson J, Cram GP, Hars V, George SL, McCarty KS, Bast RC. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. J Clin Oncol 10(7):1057-1065, 1992. e-Pub 1992. PMID: 1607912.
364. Cornelissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RC Jr, Fujii S, Long HJ 3rd, Halberg F, Tamura K. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy. Chronobiologia 19(3-4):131-49, 1992. e-Pub 1992. PMID: 1362146.
365. Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 40(7):1047-1051, 1992. e-Pub 1992. PMID: 1607637.
366. Deutsch MA, Pence JC, Kerns BJ, Plate CA, Kinney R, Gooch G, Iglehart JD, Bast RC. Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. Cancer 69(12):2894-2904, 1992. e-Pub 1992. PMID: 1375528.
367. O'Briant K, Chrysson N, Hunter V, Tyson F, Tanner M, Daly L, George S, Berchuck A, Soper J, Fowler W, Clarke-Pearson D, Bast RC. Ha-ras polymorphisms in epithelial ovarian cancer. Gynecol Oncol 45(3):229-302, 1992. e-Pub 1992. PMID: 1351862.
368. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC, Marks JR. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52(6):1622-1627, 1992. e-Pub 1992. PMID: 1540970.
369. Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-α. Am J Obstet Gynecol 166(3):997-1007, 1992. e-Pub 1992. PMID: 1550178.
370. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, Clarke-Pearson DL, Bast RC. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-ß. Am J Obstet Gynecol 166(2):676-684, 1992. e-Pub 1992. PMID: 1536252.
371. Berchuck A, Boente MP, Kerns BJ, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC, Bacus SS. Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecol Oncol 44(1):61-65, 1992. e-Pub 1992. PMID: 1370427.
372. Johnston CS, Shpall EJ, Williams S, Hami L, Jones RB, Bast RC, Ceriani RL, Franklin W. Detection of minimal residual breast cancer in bone marrow. Prog Clin Biol Res 377:637-642, 1992. e-Pub 1992. PMID: 1438446.
373. Lidor YJ, Shpall EJ, Peters WP, Bast RC. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 49(5):704-710, 1991. e-Pub 1991. PMID: 1937956.
374. Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 165(5 Pt 1):1356-1362, 1991. e-Pub 1991. PMID: 1957862.
375. Bast RC, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S, Knapp RC. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 68(8):1758-1763, 1991. e-Pub 1991. PMID: 1913520.
376. Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast RC. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 51(19):5361-5369, 1991. e-Pub 1991. PMID: 1680547.
377. Bast RC, Capizzi RL, Pagano JS, Wiley AL. Insurance coverage of screening mammography and Pap smears. The directors of North Carolina's University-based cancer centers speak out. N C Med J 52(10):496-498, 1991. e-Pub 1991. PMID: 1944619.
378. O'Briant KC, Shpall EJ, Houston LL, Peters WP, Bast RC. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer 68(6):1272-1278, 1991. e-Pub 1991. PMID: 1873781.
379. Tyson FL, Boyer CM, Kaufman R, O'Briant K, Cram G, Crews JR, Soper JT, Daly L, Jr FW, Haskill JS, Bast RC. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 165(3):640-646, 1991. e-Pub 1991. PMID: 1679963.
380. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC, Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51(11):2908-2916, 1991. e-Pub 1991. PMID: 1709586.
381. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51(11):2979-2984, 1991. e-Pub 1991. PMID: 2032235.
382. Ozols RF, Hamilton TC, Hoskins WJ, Bast RC, Young RC. Summary of symposium: Biology and therapy of ovarian cancer. Semin Oncol 18(3):297-306, 1991. e-Pub 1991. PMID: 2042066.
383. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 164(3):745-750, 1991. e-Pub 1991. PMID: 2003535.
384. Shpall EJ, Bast RC, Joines WT, Jones RB, Anderson I, Johnston C, Eggleston S, Tepperberg M, Edwards S, Peters WP. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 7(2):145-151, 1991. e-Pub 1991. PMID: 2049558.
385. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164(2):669-674, 1991. e-Pub 1991. PMID: 1992720.
386. Yu YH, Schlossman DM, Harrison CL, Rhinehardt-Clark A, Soper JT, Klug TL, Zurawski VR, Bast RC. Coexpression of different antigenic markers on moieties that bear CA 125 determinants. Cancer Res 51(2):468-475, 1991. e-Pub 1991. PMID: 1702359.
387. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164(1 Pt 1):15-21, 1991. e-Pub 1991. PMID: 1670908.
388. Shpall EJ, Jones RB, Bast RC, Rosner GL, Vandermark R, Ross M, Affronti ML, Johnston C, Eggleston S, Tepperburg M. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 9(1):85-93, 1991. e-Pub 1991. PMID: 1985173.
389. Harlozinska A, Bar JK, Rabczynski J, Bast RC, Richter R, Cislo M. Reactivity of polyclonal and two monoclonal antibodies with cell subsets isolated from cystic fluids of ovarian serous neoplasms. Tumori 76(5):505-510, 1990. e-Pub 1990. PMID: 1701581.
390. Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 163(4 Pt 1):1164-1167, 1990. e-Pub 1990. PMID: 2171337.
391. Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol 163(4 Pt 1):1204-1209, 1990. e-Pub 1990. PMID: 2220931.
392. Westhoff C, Gollub E, Patel J, Rivera H, Bast RC. CA 125 levels in menopausal women. Obstet Gynecol 76(3 Pt 1):428-431, 1990. e-Pub 1990. PMID: 2381621.
393. Shpall EJ, Clarke-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC, Ross M, Lidor Y, Vanacek K, Tyler T. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38(3):386-391, 1990. e-Pub 1990. PMID: 2121627.
394. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 76(3 Pt 1):381-387, 1990. e-Pub 1990. PMID: 1974342.
395. Jones RB, Shpall EJ, Shogan J, Affronti ML, Coniglio D, Hart L, Halperin E, Iglehart JD, Moore J, Gockerman J, Bast RC, Peters WP. The Duke AFM program. Intensive induction chemotherapy for metastatic breast cancer. Cancer 66(3):431-436, 1990. e-Pub 1990. PMID: 2364358.
396. Leslie DS, Johnston WW, Daly L, Ring DB, Shpall EJ, Peters WP, Bast RC. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol 94(1):8-13, 1990. e-Pub 1990. PMID: 2193508.
397. Welch WR, Niloff JM, Anderson D, Battaile A, Emery S, Knapp RC, Bast RC. Antigenic heterogeneity in human ovarian cancer. Gynecol Oncol 38(1):12-16, 1990. e-Pub 1990. PMID: 2162315.
398. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50(13):4087-4091, 1990. e-Pub 1990. PMID: 1972347.
399. Yu YH, Crews JR, Ramakrishnan S, Houston LL, Leslie DS, George SL, Lidor Y, Boyer CM, Ring DB, Bast RC. Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. Cancer Res 50(11):3231-3238, 1990. e-Pub 1990. PMID: 2334918.
400. Montgomery RB, Kurtzberg J, Rhinehardt-Clark A, Haleem A, Ramakrishnan S, Olsen GA, Peters WP, Smith CA, Haynes BF, Houston LL, Bast RC. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'- deoxycoformycin, deoxyadenosine and an immunotoxin. Bone Marrow Transplant 5(6):395-402, 1990. e-Pub 1990. PMID: 2369680.
401. Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT, Boyer CM, Clarke-Pearson DL, Leslie DS, Bast RC. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol 162(4):883-888, 1990. e-Pub 1990. PMID: 2327461.
402. Zurawski VR, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC, Eklund G, Mattsson B, Connor RJ, Prorok PC. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 36(3):299-305, 1990. e-Pub 1990. PMID: 2318438.
403. Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol 36(2):161-165, 1990. e-Pub 1990. PMID: 2404835.
404. Soper JT, Hunter VJ, Daly L, Tanner M, Creasman WT, Bast RC. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 75(2):249-254, 1990. e-Pub 1990. PMID: 2300353.
405. Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast RC, Boyer CM. The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol 75(2):255-262, 1990. e-Pub 1990. PMID: 2300354.
406. Shpall EJ, Anderson IC, Bast RC, Joines WT, Jones RB, Ross M, Edwards S, Eggleston S, Johnston C, Tepperberg M. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. Prog Clin Biol Res 333:321-335; discussion 336, 1990. e-Pub 1990. PMID: 2308989.
407. Soisson AP, Berchuck A, Lessey BA, Soper JT, Clarke-Pearson DL, McCarty KS, Bast RC. Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. Am J Obstet Gynecol 161(5):1258-1263, 1989. e-Pub 1989. PMID: 2589448.
408. Berchuck A, Soisson AP, Olt GJ, Soper JT, Clarke-Pearson DL, Bast RC, McCarty KS. Epidermal growth factor receptor expression in normal and malignant endometrium. Am J Obstet Gynecol 161(5):1247-1252, 1989. e-Pub 1989. PMID: 2480065.
409. Sallan SE, Niemeyer CM, Billett AL, Lipton JM, Tarbell NJ, Gelber RD, Murray C, Pittinger TP, Wolfe LC, Bast RC. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol 7(11):1594-1601, 1989. e-Pub 1989. PMID: 2809677.
410. Berchuck A, Soisson AP, Soper JT, Clarke-Pearson DL, Bast RC, McCarty KS. Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues. Arch Pathol Lab Med 113(10):1155-1158, 1989. e-Pub 1989. PMID: 2802945.
411. Anderson IC, Shpall EJ, Leslie DS, Nustad K, Ugelstad J, Peters WP, Bast RC. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 49(16):4659-4664, 1989. e-Pub 1989. PMID: 2663144.
412. Boyer CM, Dawson DV, Neal SE, Winchell LF, Leslie DS, Ring D, Bast RC. Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res 49(11):2928-2934, 1989. e-Pub 1989. PMID: 2497969.
413. Berchuck A, Soisson AP, Clarke-Pearson DL, Soper JT, Boyer CM, Kinney RB, McCarty KS, Bast RC. Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res 49(8):2091-2095, 1989. e-Pub 1989. PMID: 2702650.
414. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC, Brown EL. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83(3):921-926, 1989. e-Pub 1989. PMID: 2646321.
415. Ciobanu N, Runowicz CD, Wiernik PH, Strauman T, Sheridan C, Bast RC. CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. Am J Obstet Gynecol 160(2):354-355, 1989. e-Pub 1989. PMID: 2644834.
416. Boyer CM, Borowitz MJ, McCarty KS, Kinney RB, Everitt L, Dawson DV, Ring D, Bast RC. Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. Int J Cancer 43(1):55-60, 1989. e-Pub 1989. PMID: 2463226.
417. Peters WP, Stuart A, Klotman M, Gilbert C, Jones RB, Shpall EJ, Gockerman J, Bast RC, Moore JO. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol 23(6):377-383, 1989. e-Pub 1989. PMID: 2653660.
418. Zalutsky MR, Bast RC, Knapp RC. Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. Int J Rad Appl Instrum B 16(4):405-411, 1989. e-Pub 1989. PMID: 2777582.
419. Einhorn N, Knapp RC, Bast RC, Zurawski VR. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol 28(5):655-657, 1989. e-Pub 1989. PMID: 2590540.
420. Conkling PR, Chua CC, Nadler P, Greenberg CS, Doty E, Misukonis MA, Haney AF, Bast RC, Weinberg JB. Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. Cancer Res 48(19):5604-5609, 1988. e-Pub 1988. PMID: 3046744.
421. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6(9):1368-1376, 1988. e-Pub 1988. PMID: 3047332.
422. Malkasian GD, Knapp RC, Lavin PT, Zurawski VR, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC, Ritts RE. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 159(2):341-346, 1988. e-Pub 1988. PMID: 2457318.
423. Olsen GA, Gockerman JP, Bast RC, Borowitz M, Peters WP. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. Transplantation 46(1):57-60, 1988. e-Pub 1988. PMID: 3293287.
424. Zurawski VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC, Ritts RE, Malkasian G. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 30(1):7-14, 1988. e-Pub 1988. PMID: 2452773.
425. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Gilbert CJ, Oette DH. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318(14):869-876, 1988. e-Pub 1988. PMID: 3281007.
426. Knauf S, Bast RC. Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination. Int J Biol Markers 3(2):75-81, 1988. e-Pub 1988. PMID: 3243980.
427. Zalutsky MR, Knapp RC, Bast RC. Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. Int J Rad Appl Instrum B 15(4):431-437, 1988. e-Pub 1988. PMID: 3255739.
428. Kenemans P, Bast RC, Yedema CA, Price MR, Hilgers J. CA 125 and polymorphic epithelial mucin as serum tumor markers. Cancer Rev 11-12:119-144, 1988. e-Pub 1988.
429. Endo K, Matsuoka Y, Nakashima T, Fujii S, Kunimatsu M, Saga T, Watanabe Y, Kawamura Y, Koizumi M, Konishi J, Torizuka K, Bast RC. Development of a new sensitive immunoradiometric assay for CA125: Mixed use of two monoclonal antibodies reactive with separate epitopes. J Tumor Marker Oncol 3:65-71, 1988. e-Pub 1988.
430. Koerner TJ, Hamilton TA, Introna M, Tannenbaum CS, Bast RC, Adams DO. The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. Biochem Biophys Res Commun 149(3):969-974, 1987. e-Pub 1987. PMID: 3426621.
431. Peters WP, Henner WD, Grochow LB, Olsen G, Edwards S, Stanbuck H, Stuart A, Gockerman J, Moore J, Bast RC. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47(23):6402-6406, 1987. e-Pub 1987. PMID: 2824032.
432. Leoni F, Bast RC, Canevari S, Menard S, Soper JT, Colnaghi MI. Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer. Int J Cancer 40(5):592-597, 1987. e-Pub 1987. PMID: 2445699.
433. Haleem A, Kurtzberg J, Olsen GA, Rhinehardt-Clark A, Leslie DS, Ray L, Smith CA, Peters WP, Haynes BF, Bast RC. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. Cancer Res 47(17):4608-4612, 1987. e-Pub 1987. PMID: 3113721.
434. Introna M, Bast RC, Tannenbaum CS, Hamilton TA, Adams DO. The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages. J Immunol 138(11):3891-3896, 1987. e-Pub 1987. PMID: 3108379.
435. Introna M, Bast RC, Johnston PA, Adams DO, Hamilton TA. Homologous and heterologous desensitization of proto-oncogene cfos expression in murine peritoneal macrophages. J Cell Physiol 131(1):36-42, 1987. e-Pub 1987. PMID: 3571335.
436. Zurawski VR, Broderick SF, Pickens P, Knapp RC, Bast RC. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol 69(4):606-611, 1987. e-Pub 1987. PMID: 2434895.
437. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69(2):223-227, 1987. e-Pub 1987. PMID: 2433652.
438. Lan MS, Bast RC, Colnaghi MI, Knapp RC, Colcher D, Schlom J, Metzgar RS. Co-expression of human cancer-associated epitopes on mucin molecules. Int J Cancer 39(1):68-72, 1987. e-Pub 1987. PMID: 2432019.
439. Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Bast RC, Schnipper L, Frei E III. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 71:119-125, 1987. e-Pub 1987. PMID: 3542208.
440. Davis HM, Zurawski VR, Bast RC, Klug TL. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 46(12 Pt 1):6143-6148, 1986. e-Pub 1986. PMID: 2430690.
441. Introna M, Hamilton TA, Kaufman RE, Adams DO, Bast RC. Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. J Immunol 137(8):2711-2715, 1986. e-Pub 1986. PMID: 3760571.
442. Eder JP, Bast RC, Peters WP, Henner D, Sanchez E, Schryber S, Frei E, Schnipper LE. Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Res 46(9):4496-4499, 1986. e-Pub 1986. PMID: 3524814.
443. Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR, Bast RC. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 155(1):56-60, 1986. e-Pub 1986. PMID: 3460341.
444. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 67(5):685-689, 1986. e-Pub 1986. PMID: 3457330.
445. Barbieri RL, Niloff JM, Bast RC, Scaetzl E, Kistner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril 45(5):630-634, 1986. e-Pub 1986. PMID: 3457709.
446. Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast RC, Gargone B, Antman K. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol 4(5):646-654, 1986. e-Pub 1986. PMID: 3517240.
447. Bregni M, De Fabritiis P, Raso V, Greenberger J, Lipton J, Nadler L, Rothstein L, Ritz J, Bast RC. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody: Ricin A chain conjugates. Cancer Res 46(3):1208-1213, 1986. e-Pub 1986. PMID: 3510720.
448. Einhorn N, Bast RC, Knapp RC, Tjernberg B, Zurawski VR. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 67(3):414-416, 1986. e-Pub 1986. PMID: 2418395.
449. De Fabritiis P, Bregni M, Lipton J, Reynolds C, Nadler L, Ritz J, Bast RC. Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leuk Res 10(1):35-42, 1986. e-Pub 1986. PMID: 2935682.
450. Sekine H, Hayes DF, Ohno T, Keefe KA, Schaetzl E, Bast RC, Knapp R, Kufe DW. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol 3(10):1355-1363, 1985. e-Pub 1985. PMID: 2413181.
451. Mahvi DM, Meyers WC, Bast RC, Seigler HF, Metzgar RS. Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. Ann Surg 202(4):440-445, 1985. e-Pub 1985. PMID: 4051597.
452. Bast RC Jr, Siegal FP, Runowicz C, Klug TL, Zurawski VR Jr, Schonholz D, Cohen CJ, Knapp RC. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 22(1):115-20, 1985. e-Pub 1985. PMID: 2410329.
453. Knauf S, Anderson DJ, Knapp RC, Bast RC. A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. Am J Obstet Gynecol 152(7 Pt 1):911-913, 1985. e-Pub 1985. PMID: 2411137.
454. Niloff JM, Knapp RC, Jones G, Schaetzl EM, Bast RC. Recombinant leukocyte α interferon in advanced ovarian carcinoma. Cancer Treat Rep 69(7-8):895-896, 1985. e-Pub 1985. PMID: 4016797.
455. Bast RC, Knapp RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 19(6):354-356, 1985. e-Pub 1985. PMID: 4018373.
456. De Fabritiis P, Bregni M, Lipton J, Greenberger J, Nadler L, Rothstein L, Korbling M, Ritz J, Bast RC. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 65(5):1064-1070, 1985. e-Pub 1985. PMID: 3995166.
457. Niloff JM, Bast RC, Schaetzl EM, Knapp RC. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 151(7):981-986, 1985. e-Pub 1985. PMID: 3157319.
458. Greenberger JS, Rothstein L, DeFabritiis P, Bregni M, Bast RC, Ritz J, Nadler LM, Lipton JM, Sakakeeny MA. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. Cancer Res 45(2):758-767, 1985. e-Pub 1985. PMID: 3967246.
459. Bast RC, De Fabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 45(2):499-503, 1985. e-Pub 1985. PMID: 3967224.
460. Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz RS, Parker L, Zighelboim J, Bast RC. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obstet Gynecol 152:1003-1010, 1985. e-Pub 1985. PMID: 2992276.
461. Obrist R, Obrecht JP, Bast RC, Sandberg AL. Chemotactic anti-tumor antibodies - in vitro results with four different antibody preparations. Adv Exp Med Biol 186:827-832, 1985. e-Pub 1985. PMID: 4050600.
462. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 64(5):703-707, 1984. e-Pub 1984. PMID: 6208522.
463. Berek JS, Bast RC, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, Knapp RC, Zighelboim J. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol 64(5):708-714, 1984. e-Pub 1984. PMID: 6493663.
464. Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossman SF. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 2(8400):427-431, 1984. e-Pub 1984. PMID: 6147502.
465. Lichtenstein A, Berek J, Bast RC, Spina C, Hacker N, Knapp RC, Zighelboim J. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum. J Biol Response Mod 3(4):371-378, 1984. e-Pub 1984. PMID: 6541243.
466. Bast RC, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, Zurawski VR, Knapp RC. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol 149(5):553-559, 1984. e-Pub 1984. PMID: 6204531.
467. Masuho Y, Zalutsky M, Knapp RC, Bast RC. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res 44(7):2813-2819, 1984. e-Pub 1984. PMID: 6202400.
468. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148(8):1057-1058, 1984. e-Pub 1984. PMID: 6201072.
469. Klug TL, Bast RC, Niloff JM, Knapp RC, Zurawski VR. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 44(3):1048-1053, 1984. e-Pub 1984. PMID: 6198078.
470. Feig LA, Bast RC, Knapp RC, Cooper GM. Somatic activation of rasK gene in a human ovarian carcinoma. Science 223(4637):698-701, 1984. e-Pub 1984. PMID: 6695178.
471. Kabawat SE, Bast RC, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer 32(5):547-554, 1983. e-Pub 1983. PMID: 6358053.
472. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309(15):883-887, 1983. e-Pub 1983. PMID: 6310399.
473. Berkowitz R, Kabawat S, Lazarus H, Colvin R, Knapp R, Bast RC. Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. Am J Obstet Gynecol 146(6):607-612, 1983. e-Pub 1983. PMID: 6346879.
474. Bast RC, Reinherz EL, Maver C, Lavin P, Schlossman SF. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 28(1):101-114, 1983. e-Pub 1983. PMID: 6409485.
475. Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res 43(3):1395-1401, 1983. e-Pub 1983. PMID: 6825108.
476. Bast RC, Ritz J, Lipton JM, Feeney M, Sallan SE, Nathan DG, Schlossman SF. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 43(3):1389-1394, 1983. e-Pub 1983. PMID: 6337707.
477. Valone FH, Obrist R, Tarlin N, Bast RC. Enhanced arachidonic acid lipoxygenation by K562 cells stimulated with 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 43(1):197-201, 1983. e-Pub 1983. PMID: 6401164.
478. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 79(1):98-104, 1983. e-Pub 1983. PMID: 6336888.
479. Sang DN, Duncan J, Rodrick M, Steele G, Schepens CL, Bast RC. Circulating immune complex levels in peripheral uveitis: Discriminant analysis. Proceedings of the XXIV International Congress of Ophthalmology:453-459, 1983. e-Pub 1983.
480. Ritz J, Sallan SE, Bast RC, Lipton JM, Nathan DG, Schlossman SF. In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. Haematol Blood Transfus 28:117-123, 1983. e-Pub 1983. PMID: 6345287.
481. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2(3):275-285, 1983. e-Pub 1983. PMID: 6196309.
482. Obrist R, Reilly R, Leavitt T, Knapp RC, Bast RC. Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. Int J Immunopharmacol 5(4):307-314, 1983. e-Pub 1983. PMID: 6629591.
483. Galli SJ, Bast RC, Bast BS, Isomura T, Zbar B, Rapp HJ, Dvorak HF. Bystander suppression of tumor growth: evidence that specific targets and bystanders are damaged by injury to a common microvasculature. J Immunol 129(2):890-899, 1982. e-Pub 1982. PMID: 6282973.
484. Ritz J, Sallan SE, Bast RC Jr, Lipton JM, Clavell LA, Feeney M, Hercend T, Nathan DG, Schlossman SF. Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet 2(8289):60-3, 1982. e-Pub 1982. PMID: 6177990.
485. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331-1337, 1981. e-Pub 1981. PMID: 7028788.
486. Feeney M, Knapp RC, Greenberger JS, Bast RC. Elimination of leukemic cells from rat bone marrow using antibody and complement. Cancer Res 41(9 Pt 1):3331-3335, 1981. e-Pub 1981. PMID: 6942913.
487. Clavell LA, Lipton JM, Bast RC, Kudisch M, Pesando J, Scholssman SF, Ritz J. Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood 58(2):333-336, 1981. e-Pub 1981. PMID: 6941821.
488. Bast RC, Miller H, Rapp HJ, Gelboin HV. Aryl hydrocarbon (benzo[a]pyrene) hydroxylase in guinea pig lymphoid tissue. J Natl Cancer Inst 67(2):359-364, 1981. e-Pub 1981. PMID: 6943374.
489. Berkowitz RS, Hornig-Rohan J, Martin-Alosco S, Klein S, Goldstein DP, Bast RC, DeWolf WC. HL-A antigen frequency distribution in patients with gestational choriocarcinoma and their husbands. Placenta Suppl 3:263-267, 1981. e-Pub 1981. PMID: 6963960.
490. Zbar B, Canti G, Rapp HJ, Ashley MP, Sukumar S, Bast RC. Immunoprophylaxis of syngeneic methycholanthrene-induced murine sarcomas with Bacillus Calmette-Guerin and tumor cells. Cancer Res 40(4):1036-1042, 1980. e-Pub 1980. PMID: 7357533.
491. Frei E, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 68(3):370-376, 1980. e-Pub 1980. PMID: 6965819.
492. Bast RC, Knapp RC, Donahue VC, Thurston JG, Mitchell AK, Feeney M, Schlossman SF. Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. J Natl Cancer Inst 64(2):365-372, 1980. e-Pub 1980. PMID: 6986493.
493. Bast RC, Knapp RC, Mitchell AK, Thurston JG, Tucker RW, Schlossman SF. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity. J Immunol 123(5):1945-1951, 1979. e-Pub 1979. PMID: 489967.
494. Okuda T, Vesell ES, Plotkin E, Tarone R, Bast RC, Gelboin HV. Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. Cancer Res 37(11):3904-3911, 1977. e-Pub 1977. PMID: 561657.
495. Okuda T, Bast RC, Miller H, Rapp HJ, Gelboin HV. The half-life of aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human blood monocytes. Chem Biol Interact 14(3-4):379-382, 1976. e-Pub 1976. PMID: 954153.
496. Bast RC, Okuda T, Plotkin E, Tarone R, Rapp HJ, Gelboin HV. Development of an assay for aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Cancer Res 36(6):1967-1974, 1976. e-Pub 1976. PMID: 1268850.
497. Detrick-Hooks B, Smith HG, Bast RC, Dunkel VC, Borsos T. Naturally soluble tumor antigens from guinea pig hepatomas: isolation and partial characterization. J Immunol 116(5):1324-1331, 1976. e-Pub 1976. PMID: 178795.
498. Bast RC, Segerling M, Ohanian SH, Greene SL, Zbar B, Rapp HJ, Borsos T. Regression of established tumors and induction of tumor immunity by intratumor chemotherapy. J Natl Cancer Inst 56(4):829-832, 1976. e-Pub 1976. PMID: 176411.
499. Borsos T, Bast RC, Ohanian SH, Segerling M, Zbar B, Rapp HJ. Induction of tumor immunity by intratumoral chemotherapy. Ann N Y Acad Sci 276:565-572, 1976. e-Pub 1976. PMID: 194520.
500. Smith HG, Bast RC, Zbar B, Rapp HJ. Eradication of microscopic lymph nodes metastases after injection of living BCG adjacent to the primary tumor. J Natl Cancer Inst 55(6):1345-1352, 1975. e-Pub 1975. PMID: 1107574.
501. Bast RC, Zbar B, Rapp HJ. Local antitumor activity of a primary and an anamnestic response to a syngeneic guinea pig hepatoma. J Natl Cancer Inst 55(4):989-994, 1975. e-Pub 1975. PMID: 171435.
502. Bast RC, Zbar B, Miller TE, Mackaness GB, Rapp HJ. Antitumor activity of bacterial infection. II. effect of Listeria monocytogenes on growth of a guinea pig hepatoma. J Natl Cancer Inst 54(3):757-761, 1975. e-Pub 1975. PMID: 164568.
503. Bast RC, Zbar B, Mackaness GB, Rapp HJ. Antitumor activity of bacterial infection. I. Effect of Listeria monocytogenes on growth of a murine fibrosarcoma. J Natl Cancer Inst 54(3):749-756, 1975. e-Pub 1975. PMID: 804566.
504. Zbar B, Smith H, Bast RC, Rapp HJ. Immunotherapy with BCG: Approaches to human malignant melanoma based on a guinea pig model. Behring Inst Mitt 56:35-40, 1975. e-Pub 1975.
505. Bast RC, Doos WG, Zbar B, Harmel RP, Dalgard DW, Steward AM. Intracolonic injection of BCG in the rhesus monkey. J Natl Cancer Inst 53(5):1423-1426, 1974. e-Pub 1974. PMID: 4431061.
506. Bast RC, Whitlock JP, Miller H, Rapp HJ, Gelboin HV. Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Nature 250(5468):664-665, 1974. e-Pub 1974. PMID: 4850643.
507. Zwilling BS, Leonard EJ, Bast RC, Zbar B. Destruction of syngeneic tumors by tuberculin-stimulated peritoneal exudate cells from guinea pigs immunized to Mycobacterium bovis (strain BCG). J Natl Cancer Inst 53(2):541-546, 1974. e-Pub 1974. PMID: 4367248.
508. Dunkel VC, Bast RC, Gerwin BI, Heine U, Cottler-Fox M, Borsos T. Presence of A-type and absence of C-type virus particles in a chemically induced guinea pig hepatoma. J Natl Cancer Inst 53(2):591-593, 1974. e-Pub 1974. PMID: 4135601.
509. Bast RC, Zbar B, Borsos T, Rapp HJ. BCG and cancer (first of two parts). N Engl J Med 290(25):1413-20, 1974. e-Pub 1974. PMID: 4364286.
510. Bast RC, Zbar B, Borsos T, Rapp HJ. BCG and cancer (second of two parts). N Engl J Med 290(26):1458-1469, 1974. e-Pub 1974. PMID: 4598691.
511. Bast RC, Cleveland RP, Littman BH, Zbar B, Rapp HJ. Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol 10(2):248-259, 1974. e-Pub 1974. PMID: 4218128.
512. Bast RC, Shears BW, Rapp HJ, Gelboin HV. Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in guinea pig peritoneal macrophages: benz(a)anthracene-induced increase of enzyme activity in vivo and in cell culture. J Natl Cancer Inst 51(2):675-678, 1973. e-Pub 1973. PMID: 4765380.
513. Dvorak AM, Bast RC, Dvorak HF. Morphologic changes in draining lymph nodes and in lymphocyte cultures after sensitization with complete or incomplete Freund's adjuvant. Correlation with immunologic events in vivo and in culture. J Immunol 107(2):422-435, 1971. e-Pub 1971. PMID: 5568772.
514. Dvorak HF, Simpson BA, Bast RC, Leskowitz S. Cutaneous basophil hypersensitivity. III. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. J Immunol 107(1):138-148, 1971. e-Pub 1971. PMID: 5091955.
515. Bast RC, Simpson BA, Dvorak HF. Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity. J Exp Med 133(2):202-215, 1971. e-Pub 1971. PMID: 5316262.
516. Bast RC, Manseau EJ, Dvorak HF. Heterogeneity of the cellular immune response. I. Kinetics of lymphocyte stimulation during sensitization and recovery from tolerance. J Exp Med 133(2):187-201, 1971. e-Pub 1971. PMID: 5316261.
517. Dvorak HF, Bast RC. Nature of the immunogen in crystalline serum albumins. Immunochemistry 7(1):118-124, 1970. e-Pub 1970. PMID: 5416390.
518. Dvorak HF, Simpson BA, Bast RC. Immunologic unresponsiveness in the adult guinea pig. IV. Induction of unresponsiveness with aggregated serum proteins. J Immunol 102(5):1163-1171, 1969. e-Pub 1969. PMID: 4181547.
519. Heilman DH, Bast RC. In vitro assay of endotoxin by the inhibition of macrophage migration. J Bacteriol 93(1):15-20, 1967. e-Pub 1967. PMID: 5335889.
520. Heilman DH, Bast RC. Effect of Endotoxin on Macrophages of the Adult Chicken. Proc Soc Exp Biol Med 116:1019-1022, 1964. e-Pub 1964. PMID: 14230331.
521. Serie D, Moser K, Wong M, Desai K, Pickering C, Xu G, Smith C, Quach E, Grech M, Bast RC, Ciccone M, Vocal Consortium. GlycoKnow Ovarian: a Glycoprotein-based, Serum Diagnostic to Distinguish Ovarian Cancers from Benign Pelvic Masses.
522. Fahrmann JF, Mahmood MS, Han CY, Wu R, Dennison JB, Vykoukal J, Celestino J, Lu K, Lu Z, Drescher C, Do KA, Hanash S, Bast RC, Irajizad E. Validation of a blood based metabolite biomarker panel for early detection of ovarian cancer. Biomarker Research.
523. Gray JP, Bildik G, Kim HN, Sutton MN, Wang J, Osuji AO, Batistatou N, Yang H, Mao W, Tan Z, Gasmi-Seabrook GMC, Liu J, Hancock JF, Marshall CB, Kritzer JA, Ikura M, Bast RC, Millward SW, Lu Z. Cyclic peptides derived from DIRAS3 disrupt KRAS-RAF interaction and KRAS nanoclustering to inhibit pancreatic cancer cell growth.

Invited Articles

1. Finkler NJ, Bast RC, Knapp RC. Tumor markers in gynecologic cancer. Contemporary OB/GYN 30:29-42, 1987. e-Pub 1987.
2. Knapp RC, StJohn E, Bast RC. A review of intraperitoneal therapy of human ovarian carcinoma. Peritoneal Dialysis Bull 3:59-62, 1983. e-Pub 1983.
3. Bast RC, Rapp HJ. Immunotherapy of cancer - the skin is deep enough. Mod Med 43:45-51, 1975. e-Pub 1975.

Other Articles

1. Bildik G, Liang X, Sutton MN, Bast RC, Lu Z DIRAS3: An Imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy and tumor dormancy. Mol Cancer Ther 21(1):25-37, 2022. PMID: 34667114.
2. Elias KM, Guo J, Bast RC Early Detection of Ovarian Cancer. Hematol Oncol Clin North Am 32(6):903-914, 2018. PMID: 30390764.
3. Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel) 10(11), 2018. PMID: 30424539.
4. Santiago, J, Bast RC, Lu Z Commentary: Autophagy and Cancer Chemotherapy – Inhibition or Enhancement?. Single Cell Biol 5(3):1000145, 2016.
5. Bast RC Molecular approaches to personalizing management of ovarian cancer. Ann Oncol 22 Suppl 8:viii5-viii15, 2011. PMID: 22180401.
6. Moore RG, MacLaughlan S, Bast RC Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 116(2):240-5, 2010. PMID: 19879639.
7. Bast RC Biomarkers for ovarian cancer: New technologies and targets to address persistently unmet needs. Cancer Biomark 8(4-5):161-166, 2010. PMID: 22045350.
8. Bast RC, Hennessy B, Mills GB The Biology of Ovarian Cancer: New Opportunities for Translation. Nat Rev Cancer 9(6):415-28, 2009. PMID: 19461667.
9. Badgwell D, Bast RC Early detection of ovarian cancer. Dis Markers 23(5-6):397-410, 2007. PMID: 18057523.
10. Bast RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y Prevention and early detection of ovarian cancer: Mission impossible?. Recent Results Cancer Res 174:91-100, 2007. PMID: 17302189.
11. Fu S, Kavanagh JJ, Hu W, Bast RC Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer 16(5):1717-1732, 2006. PMID: 17009963.
12. Fu S, Hu W, Kavanagh JJ, Bast RC Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets 10(1):77-85, 2006. PMID: 16441230.
13. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K New tumor markers: CA 125 and beyond. Int J Gynecol Cancer 15 Suppl 3:274-281, 2005. PMID: 16343244.
14. Bast RC, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A Translational crossroads for biomarkers. Clin Cancer Res 11(17):6103-8, 2005. PMID: 16144908.
15. Rustin GJ, Bast RC, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW Use of CA 125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10(11):3919-3926, 2004. PMID: 15173101.
16. Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF Biomarkers, surrogate endpoints, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res 10(11):3881-3884, 2004. PMID: 15173097.
17. Bast RC Early detection of ovarian cancer: New technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc 115:233-248, 2004. PMID: 17060970.
18. See HT, Kavanagh JJ, Hu W, Bast RC Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 13(6):701-734, 2003. PMID: 14675307.
19. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30(5 Suppl 16):93-104, 2003. PMID: 14613030.
20. Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci 983:268-277, 2003. PMID: 12724231.
21. Bast RC, Mills GB General keynote: molecular therapeutics and pharmacogenomics. Gynecol Oncol 88(1 Pt 2):S84-7; discussion S93-6, 2003. PMID: 12586093.
22. Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC, Brewer MA Specific keynote: chemoprevention of ovarian cancer: the journey begins. Gynecol Oncol 88(1 Pt 2):S59-66; discussion S67-70, 2003. PMID: 12586088.
23. Brewer MA, Johnson K, Follen M, Gershenson D, Bast RC Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 9(1):20-30, 2003. PMID: 12538447.
24. Bösze P, Bast RC, Berchuck A, Burke HB, Buller RE, Creasman WT, Dubeau L, Fox H, Geisler HE, Geisler JP, Henson DE, Rustin GJ, Vermorken JB, Wells M, Wilbanks GD Consensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO. Eur J Gynaecol Oncol 21(5):513-526, 2000. PMID: 11198047.
25. Brewer MA, Mitchell MF, Bast RC Prevention of ovarian cancer. In Vivo 13(1):99-106, 1999. PMID: 10218141.
26. Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB CA 125: The past and the future. Int J Biol Markers 13(4):179-187, 1998. PMID: 10228898.
27. Pusztai L, Siddik ZH, Mills GB, Bast RC Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncol 37(7-8):629-40, 1998. PMID: 10050979.
28. Bast RC SCC antigen. Summary remarks. Tumour Biol 19(6):527-8, 1998. PMID: 9817982.
29. Berek JS, Bast RC Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 76(10 Suppl):2092-2096, 1995. PMID: 8635006.
30. Berchuck A, Bast RC p53-based gene therapy of ovarian cancer: Magic bullet?. Gynecol Oncol 59(2):169-170, 1995. PMID: 7590466.
31. Bast RC, Boyer CM, Xu FJ, Wiener J, Dabel R, Woolas R, Jacobs I, Berchuck A Molecular approaches to prevention and detection of epithelial ovarian cancer. J Cell Biochem Suppl. 23:219-222, 1995. PMID: 8747399.
32. Bast RC Clinical and laboratory directions for ovarian cancer research. Gynecol Oncol 55(3 Pt 2):S164-167, 1994. PMID: 7835802.
33. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1(3):181-190, 1994. PMID: 9419769.
34. Bast RC, Boyer CM, Xu FJ, Wu S, Wiener JR, Kassim SK, Kohler MF, O'Briant K, DeSombre K, Bast RC, Dean S, Daly L, Berchuck A Selected molecular targets for diagnosis and therapy of epithelial ovarian cancer. Cancer Mol Biol 1:87-93, 1994.
35. Bast RC Perspectives on the future of cancer markers. Clin Chem 39(11 Pt 2):2444-2451, 1993. PMID: 8222257.
36. Boente MP, Hurteau J, Rodriguez GC, Bast RC, Berchuck A The biology of ovarian cancer. Curr Opin Oncol 5(5):900-907, 1993. PMID: 8218503.
37. Bast RC, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A Cell growth regulation in epithelial ovarian cancer. Cancer 71(4 Suppl):1597-1601, 1993. PMID: 8431895.
38. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC Growth regulation and transformation of ovarian epithelium. Cancer 71(2 Suppl):545-551, 1993. PMID: 8420675.
39. Wiener JR, Berchuck A, Bast RC Biology and therapy with biologic agents in gynecologic cancer. Curr Opin Oncol 4(5):946-954, 1992. PMID: 1457511.
40. Berchuck A, Kohler MF, Bast RC Oncogenes in ovarian cancer. Hematol Oncol Clin North Am 6(4):813-827, 1992. PMID: 1500387.
41. Berchuck A, Boente MP, Bast RC The use of tumor markers in the management of patients with gynecologic carcinomas. Clin Obstet Gynecol 35(1):45-54, 1992. PMID: 1544249.
42. Berchuck A, Bast RC Overexpression of HER-2/neu in gyn cancer. Contemp Obstet Gynecol 37:25-38, 1992.
43. Bookman MA, Bast RC The immunobiology and immunotherapy of ovarian cancer. Semin Oncol 18(3):270-291, 1991. PMID: 1710393.
44. Olt G, Berchuck A, Bast RC The role of tumor markers in gynecologic oncology. Obstet Gynecol Surv 45(9):570-577, 1990. PMID: 1697940.
45. Olt GJ, Berchuck A, Bast RC Gynecologic tumor markers. Semin Surg Oncol 6(6):305-313, 1990. PMID: 2263805.
46. Berchuck A, Bast RC New directions in diagnosing, monitoring and detecting epithelial ovarian cancer. Adv Oncol 6:18-22, 1990.
47. Jacobs I, Bast RC The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4(1):1-12, 1989. PMID: 2651469.
48. Lidor Y, Bast RC Serotherapy of ovarian cancer. Nat Immun Cell Growth Regul 7(4):193-215, 1988. PMID: 3070370.
49. Boyer CM, Lidor Y, Lottich SC, Bast RC Antigenic cell surfacemarkers in human solid tumors. Antibody Immunocon Radiopharm 1:105-162, 1988.
50. Berchuck A, Boyer CM, Bast RC The role of CA 125 in ovarian cancer. Postgrad Obstet Gynecol 8:1-7, 1988.
51. Bast RC, Hunter V, Knapp RC Pros and cons of gynecologic tumor markers. Cancer 60(8 Suppl):1984-1992, 1987. PMID: 2443235.
52. Greenberger JS, FitzGerald TJ, Rothstein L, Pierce J, Sakakeeny MA, Weichselbaum RR, Naparstek E, Newburger P, Griffin J, Bast RC Long-term culture of human granulocytes and granulocyte progenitor cells. Prog Clin Biol Res 211:159-185, 1986. PMID: 3008194.
53. Bast RC, Ritts RE Antigens shed by tumor cells. Hybridoma 5:171-172, 1986.
54. Bast RC, Klug T, Niloff JM, Knapp RC Clinical usefulness of CA 125. Cancer Bulletin 37:80-81, 1985.
55. Bast RC, Knapp RC Monitoring epithelial ovarian cancer. Lab Med 16:315-318, 1985.
56. Bast RC, Knapp RC Immunologic approaches to the management of ovarian carcinoma. Semin Oncol 11(3):264-274, 1984. PMID: 6207593.
57. Ritz J, Bast RC, Takvorian T, Sallan SE Clinical applications of monoclonal antibodies in acute leukemia. Ann N Y Acad Sci 428:308-317, 1984. PMID: 6234835.
58. Bast RC, Bast BS Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. Ann N Y Acad Sci 277(00):60-93, 1976. PMID: 826208.

Editorials

1. Bast RC, Mills GB. Dissecting PI3Kness: The complexity of personalized therapy for ovarian cancer. Cancer Discov 2(1):16-8, 2012. PMID: 22585163.
2. Ahmed AA, Becker CM, Bast RC. The origin of ovarian cancer. BJOG 119(2):134-6, 2012. PMID: 22168761.
3. Bast RC, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol 121(3):429-30, 2011. PMID: 21601106.
4. Bast RC, Markman M. Chemotherapy: A new standard combination for recurrent ovarian cancer?. Nat Rev Clin Oncol 7(10):559-60, 2010. PMID: 20877420.
5. Bast RC, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28(22):3545-8, 2010. PMID: 20547987.
6. Moore RG, Bast RC. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol 25(27):4159-61, 2007. PMID: 17698803.
7. Bast RC, Hortobagyi GN. Individualized care for patients with cancer: A work in progress. N Engl J Med 351(27):2865-2867, 2004. PMID: 15591336.
8. Mills GB, Bast RC, Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 93(19):1437-1439, 2001. PMID: 11584052.
9. Mills GB, Schmandt R, Gershenson D, Bast RC. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects?. Clin Cancer Res 5(9):2286-2288, 1999. PMID: 10499594.
10. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem 44(7):1379-1380, 1998. PMID: 9665412.
11. Bast RC. Progress in radioimmunotherapy. N Engl J Med 329(17):1266-1268, 1993. PMID: 8413396.
12. Bast RC, Jacobs I, Berchuck A. Malignant transformation of ovarian epithelium. J Natl Cancer Inst 84(8):556-558, 1992. PMID: 1556762.
13. McVie JG, Bast RC. Therapeutic modalities: Editorial overview. Curr Opin Oncol 1:171-173, 1989.

Abstracts

1. Bast RC. Accelerating Translational Research in Precision Cancer Medicine, 2021. e-Pub 2021.
2. Han CY, W-L Y, Guo J, Liu Y, Yang H, Celestino J, Lu KH, Lu Z, Anderson KS, Drescher CW, Skates SJ, Bast RC. Multi-biomarker panel assessment of serological assays in early detection of ovarian cancer, 2021. e-Pub 2021.
3. Bast RC. Keynote: Lifetime experience with biomarkers, 2021. e-Pub 2021.
4. Bildik-Elcik G, Gray JP, Mao W, Bast RC, Lu Z. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in Ras-driven pancreatic and ovarian carcinomas, 2021. e-Pub 2021.
5. Handley KF, Sims TT, Glassman D, Fleming ND, Lee S, Yao H, Yao J, Liu J, Bast RC, Lu Z, Westin SN, Celestino J, Bateman N, Rangel KM, Conrads TP, Maxwell GL, Ram PT, Sood AK. If looks could kill: Morphologic subtypes of high grade serous ovarian cancer, 2021. e-Pub 2021.
6. Liang X, Lee K, Jung SY, Bildik G, Mao W, Gray JP, Milward S, Lu Z, Bast RC. Structural and biochemical properties of DIRAS3 N terminal extension that permit its function as a tumor suppressor of oncogenic Ras, 2021. e-Pub 2021.
7. Fahrmann JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, Wu R, Long JP, Do KA, Celestino J, Lu KH, Lu Z, Bast RC, Hanash S. Screening for polyamines in plasma identifies a MYC-related signature in early stage ovarian cancer pathogenesis, 2020. e-Pub 2020.
8. Skubitz APN, Boylan KLM, Starr TK, Pu X, Cao Q, Geschwind K, Bast RC, Lu KH, Celestino J, Petersen AJ. Improving the detection of ovarian cancer by a blood test, 2019. e-Pub 2019.
9. Petersen A, Pu X, Boylan KLM, Bast RC, Skubitz APN. Constructing multi-protein classifiers for early-stage ovarian cancer screening, 2019. e-Pub 2019.
10. Heinzl N, Maritschnegg E, Koziel K, Wilson S, Wallisch C, Heinze G, Horvat R, Yang WL, Bast RC, Sehouli J, Braicu J, Vergote I, Vanderstichele A, Mahner S, Obermayr E, Schuste E, Holzer E, Concin N, Zeillinger R. The prognostic impact of p53 aggregates in high-grade serous ovarian cancer, 2019. e-Pub 2019.
11. Blessing AM, Mao W, Pang L, Rask P, Lu Z, Bast RC. Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to ALK inhibition, 2019. e-Pub 2019.
12. Luan B, Zhao H, Bast RC, Lu Z, Yu Y. Corilagin could help to overcome PARP inhibitor resistance by inhibiting ERK signaling pathways, 2019. e-Pub 2019.
13. Guo J, W-L Y, Celestino J, Lu K, Lu Z, Bast RC. Macrophage Inhibitory Factor (MIF), Osteopontin (OPN) and anti- Interleukin-8 (IL-8) autoantibodies (AAb) complement CA125 for detection of early stage ovarian cancer, 2019. e-Pub 2019.
14. Santiago-O’Farrill JM, Werhoa SJ, Hou X, Pang L, Rask P, Lu Z, Bast RC. PARP Inhibitor-induced Autophagy provides an Adaptive Mechanism of Drug Resistance in preclinical models of ovarian cancer, 2019. e-Pub 2019.
15. Bischoff F, Mathieu K, Kulp A, Pang L, Bast RC, Hazle J, Zhang M. Detection of HER2 positive tumor cells using functionalized iron oxide nanoparticles. Cancer Res 79(4 Suppl):10.1158/1538-7445.SABCS18-P6-01-05, 2019. e-Pub 2019.
16. Zhang M, Dewing A, Liu X, Vargas J, Pang L, Kulp A, Mathieu K, Bast RC, Hazle J, Bischoff F. Detection of HER2 positive tumor cells using functionalized iron oxide nanoparticles, 2018. e-Pub 2018.
17. Bischoff FZ, Mathieu KB, Pang L, Kulp A, Lu Z, Huber D, Hazle JD, Bast RC, Paciotti G. Detection and measurement of HER2+ breast cancer cells using tumor targeted iron oxide particles and magnetic relaxometry. Proc Amer Soc Clin Oncol, J Clin Oncol 36(15 suppl):e13019, 2018. e-Pub 2018.
18. Bischoff F, Mathieu K, Kulp A, Pang L, Bast RC, Hazle J, Zhang M. Detection of HER2 positive tumor cells using functionalized iron oxide nanoparticles. J Clin Oncol 36(15 suppl):e13019, 2018. e-Pub 2018.
19. Yang WL, Lu Z, Lu K, Menon U, Hanash S, Skates S, Bast RC. HE4 antigen-autoantibody complexes complement CA125 for detecting early stage ovarian cancer and can be elevated with CA125 in pre-clinical disease 59, 2018. e-Pub 2018.
20. Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS. Development of a blood test to screen women with ovarian cancer, 2018. e-Pub 2018.
21. Skubitz A, Boylan KLM, Geschwind K, Cao Q, Star TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS. Development of a multi-protein classifier for ovarian cancer detection by simultaneous measurement of 92 proteins on Proseek Multiplex Oncology II plates, 2018. e-Pub 2018.
22. Bischoff FZ, Zhang M, Mathieu KB, Bast RC, Hazle JD, Paciotti G. Precision MRX®: A versatile iron oxide nanoparticle platform for targeted in vivo detection of cancer, 2018. e-Pub 2018.
23. Skubitz A, Boylan KLM, Geschwind K, Cao Q, Star TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS. Development of a multi-protein classifier for ovarian cancer detection by simultaneous measurement of 92 proteins on Proseek Multiplex Oncology II plates, 2018. e-Pub 2018.
24. Romero Aburto R, Mathieu K, Vreeland E, Lu Z, Bast RC, Hazle J, Sokolov K. Molecularly targeted micellar magnetic probes for in vivo early cancer detection using superparamagnetic relaxometry, 2017. e-Pub 2017.
25. Romero Aburto R, Mathieu K, Vreeland E, Lu Z, Bast RC, Hazle J, Sokolov K. Contrast agent development and validation for in-vivo early cancer detection using magnetic relaxometry, 2017. e-Pub 2017.
26. Aburto RR, Mathieu KB, Vreeland EC, Lu Z, Bast RC, Hazle JD Sokolov K. Contrast agent development and validation for in-vivo early cancer detection through Magnetic Relaxometry, 2017. e-Pub 2017.
27. Aburto RR, Mathieu KB, Vreeland EC, Lu Z, Bast RC, Hazle JD Sokolov K. Magnetic relaxometry detection of stealth, antibody-targeted micellar iron oxide nanoparticles in vivo, 2017. e-Pub 2017.
28. Romero Aburto R, Mathieu K, Kulp A, Vreeland E, Lu Z, Bast RC, Sokolov K, Hazle J. Magnetic relaxometry detection of stealth, antibody-targeted micellar iron oxide nanoparticles in-vivo, 2017. e-Pub 2017.
29. Yang H, Zhang S, Mao W, Ahmed AA, Jennings N, Rodriquez-Aguayo C, Lopez-Berestein G, Sood AK, F-X L, Liu X, Bast RC. Silencing PFKFB2 enhances paclitaxel sensitivity by modulating metabolism of p53 wild type ovarian and breast cancer xenografts, 2017. e-Pub 2017.
30. Weisman RB, Lin CW, Bachilo SM, Beckingham KM, Yang H, Bast RC. Noninvasive detection and spectral triangulation of single-walled carbon nanotubes in vivo, 2017. e-Pub 2017.
31. Sutton MN, Lu Z, Li YC, Nan X, Reger AS, Hurwitz A, Palzkill T, Gray JW, Wahl G, Bast RC. DIRAS3 (ARHI) blocks RAS/MAPK signaling by binding directly to Ras and disrupting Ras clusters, 2017. e-Pub 2017.
32. Bast RC. Early detection of ovarian cancer: An update:21, 2017. e-Pub 2017.
33. Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Bast RC, Lu K, Koopmeiners JS. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multi-Protein Classifier for Ovarian Cancer Detection:91, 2017. e-Pub 2017.
34. Mathieu KB, Lu Z, Yang H, Pang L, Kulp A, Hazle JD, Bast RC. Feasibility for magnetic relaxometry for ovarian cancer detection: Preliminary evaluation in cell culture and in mice, 2017. e-Pub 2017.
35. Thrower SL, Mathieu K, Stefan W, Lu Z, Bast RC, Sovizi J, Fuentes D, Hazle JD. Volumetric reconstruction of targeted nanoparticles for superparamagnetic relaxometry, 2017. e-Pub 2017.
36. Blessing A, Wang Y, Mao W, Pang L, Bartholomeusz G, Lu Z, Bast RC. Autophagic ovarian cancer cells exhibit substantially enhanced response to crizotinib, 2017. e-Pub 2017.
37. Santiago-O’Farrill JM, Essien S, Figueroa M, Pang L, Lu Z, Bast RC. Autophagy protects ovarian cancer cells from olaparib-induced toxicity, 2017. e-Pub 2017.
38. Sutton MN, Lu Z, Yang H, Huang G, Wang Y, Mao W, Bast RC. DIRAS1 and DIRAS 2 are novel ovarian cancer tumor suppressors that regulate cell growth, motility and autophagy, 2016. e-Pub 2016.
39. Zhou J, Alfredi A, Zhang S, Santiago-O’Farrill J, Yerramreddy KR, Ahmed AA, Yang H, Mao W, Wang Y, Takmori H, H* V, Z* L, Bast RC. A novel compound ARN-3236 inhibits SIK2 and sensitizes ovarian cancer cells to paclitaxel, 2016. e-Pub 2016.
40. Kobayashi M, Boldt CR, Yang WL, Aguilar-Bonavides C, Wang H, Lu Z, Bast RC, Hanash SM. Development of an autoantibody panel that reflects disease pathogenesis in ovarian cancer, 2016. e-Pub 2016.
41. Simmons AR, Gentry-Maharaj A, Skates S, Baggerly K, Fourkala O, Ryan A, Zhang Z, Jacobs J, Menon U, Bast RC. Validation of a multi-marker panel for early detection of ovarian cancer, 2016. e-Pub 2016.
42. Sutton MN, Lu Z, Li Y, Reger A, Hurwitz A, Palzkill T, Wahl G, Bast RC. DIRAS3 (ARHI) downregulates Ras/MAPK signaling via interaction and inhibition of Ras dimers. Journal of Clinical and Translational Science, 2016. e-Pub 2016.
43. Liang L, Mercado-Uribe I, Yang Y, Cheng W, Broaddus R, Bast RC, Mills G, Sood A, Liu J. Establishment of patient-derived xenograft (PDX) models of ovarian cancer, 2016. e-Pub 2016.
44. Lu Z, Orozco AF, Mao W, Wang Y, Sutton MN, Yang H, Levine DA, Bast RC. IL-8, VEGF and IGF-1 play an important role in ARHI mediated tumor dormancy in ovarian cancer, 2016. e-Pub 2016.
45. Yang H, Wang X, Ahmed A, Iles L, Bartholomeusz G, Lu Z, Bast RC. Combinations of kinase siRNAs potentiates paclitaxel sensitivity in ovarian cancer, 2016. e-Pub 2016.
46. Morgado M, Sutton MN, Simmons M, Liu J, Lu Z, Papadopoulos PE, Bast RC, Carson DD. MUC16/CA125, TNF-alpha, and IFN gamma are co-expressed in malignant gynecologic neoplasms 56, 2015. e-Pub 2015.
47. Lu Z, Mao W, Wang Y, Levine DA, Bast RC. ARHI plays a critical role in tumor dormancy by inhibition of the angiogenic switch 56, 2015. e-Pub 2015.
48. Lu Z, Orozco A, Sutton M, Wang J, Mao W, Bast RC. IL-8, VEGF and IGF-1 rescue ovarian cancer cells undergoing ARHI-mediated autophagic cell death 56, 2015. e-Pub 2015.
49. Yang H, Das P, Mao W, Marquez R, Lu Z, Bast RC. The imprinted tumor suppressor gene NDN inhibits cell motility in ovarian cancer by re-activating FAK and Rho A 56, 2015. e-Pub 2015.
50. Livingston JA, Santiago-O’Farrill JM, Tsai JW, Lu Z, Bast RC, Wang WL, Gordon M, Kleinerman E. Heat shock protein 27 as a predictor of autophagic fate in chemotherapy-induced autophagy in osteosarcoma, 2015. e-Pub 2015.
51. Huang GY, Lu Z, Sutton MN, Reger AS, Hurwitz A, Palzkill T, Kim C, Bast RC. ARHI Induces autophagy in part by binding to the coiled-coiled domain of Beclin-1, monomerizing Beclin-1 dimers, and displacing Bcl-2, 2015. e-Pub 2015.
52. Wang H, Wang X, Ahmed A, Iles L, Bartholomeusz G, Lu Z, Bast RC. Combinations of kinase siRNAs enhance sensitivity to paclitaxel, 2015. e-Pub 2015.
53. Shadfan B, Simmons A, Simmons G, Wong J, Lu K, McDevitt J, Bast RC. A multiplexable, microfluidic platform for the rapid quantification of a biomarker panel for early detection of ovarian cancer at point of care, 2015. e-Pub 2015.
54. Sutton MN, Lu Z, Bast RC. DIRAS1 and DIRAS2 are tumor suppressor candidates that inhibit cell growth, motility and proliferation while regulating autophagy in ovarian cancer, 2015. e-Pub 2015.
55. Lu Z, Orozco A, Wang Y, Mao W, Levine DA, Bast RC. Survival of ARHI mediated dormant autophagic cells in vivo requires permissive levels of VEGF, IL-8 and IGF-1 in the tumor microenvironment, 2015. e-Pub 2015.
56. Beckenham KM, Vu M, Lin CW, Bast RC, Weisman RB. Developing short-wave infrared fluorescent immunoprobes based on single walled carbon nanotubes, 2015. e-Pub 2015.
57. Yang WL, Simmons A, Lu Z, Baggerly K, Lu K, Gentry-Maharaj A, Jacobs I, Menon U, Bast RC. TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer 56, 2015. e-Pub 2015.
58. Lyu TJ, Jia N, Wang J, Bast RC, Baak JP, Hua K, Feng W. Histone methyltransferase SMYD3 promotes invasion in ovarian cancer spheroids 56, 2015. e-Pub 2015.
59. Mathieu KB, Flynn ER, Adolphi NL, Lovato DM, Larson RS, De Haro LP, Lu Z, Bast RC, Hazle JD. Early detection of ovarian cancer through nanomagnetic relaxometry, 2014. e-Pub 2014.
60. Beckingham KM, Vu M, Lin CW, Williams A, Bast RC, Weisman RB. Immunoprobes for spectrally multiplexed detection and imaging in biomedical applications, 2014. e-Pub 2014.
61. Bast RC, Sutton MN, Mao W, Wang Y, Lu Z. Elimination of dormant ovarian cancer cells by targeting autophagy, 2014. e-Pub 2014.
62. Bast RC, Sutton MN, Gomez S, Fu C, Pontikos M, Lu Z. The role of the imprinted tumor suppressor gene DIRAS3 (ARHI) in regulating ovarian cancer cell growth, motility, autophagy and tumor dormancy, 2014. e-Pub 2014.
63. Boldt C, Simmons A, Wang H, Baggerly K, Bast RC, Hanash S. Integrating Genomics, Transcriptomics, and Proteomics for the Discovery of Novel Biomarkers to Complement CA125 in Ovarian Cancer Early Detection, 2014. e-Pub 2014.
64. Alfredi A, Zhang S, Mao W, Wang Y, Takemori H, Bast RC, Lu Z, Vankayalapati H. Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts 55, 2014. e-Pub 2014.
65. Tao X, Jin H, Zhang Z, Bast RC, Feng Y, Yu Y. Downregulation of TRPC3 enhances sensitivity to cisplatin and inhibits motility in epithelial ovarian cancer 55, 2014. e-Pub 2014.
66. Sutton M, Lu Z, Gomez S, Fu C, Bast RC. ARHI (DIRAS3) downregulates Ras-MAPK signaling and inhibits transformation of NIH3T3 cells through direct interaction with GTP-bound Ras 55, 2014. e-Pub 2014.
67. Liu Y, Tao X, Zhang Z, Jin H, Lu Y, Lu Z, Bast RC, Feng Y, Yu Y. Follicle-stimulating hormone inhibits apoptosis and autophagy in ovarian cancer cells by activating multiple signaling pathways, 2014. e-Pub 2014.
68. H* Y, P* D, Yu Y, Baggerly K, Wang Y, Mao W, Marquez RT, Lu Z, Liu J, Bast RC. NDN, an imprinted tumor suppressor gene, inhibits ovarian cancer cell growth and motility and is downregulated by genetic and epigenetic mechanisms 55, 2014. e-Pub 2014.
69. Zhang Z, Zhu Y, Xu X, Xi X, Bast RC, Yu YH, Feng Y. Follicle stimulating hormone (FSH) inhibits apoptosis in ovarian cancer cells through regulating the OCT4 stem cell signaling pathway 54, 2013. e-Pub 2013.
70. Sutton MN, Fu C, Pontikos M, Lu Z, Bast RC. DIRAS family members inhibit cell growth and proliferation while inducing autophagy in human ovarian cancer cells 54, 2013. e-Pub 2013.
71. MN* W, Suh G, AF* O, Yang M, Wang W, Gao F, Atkinson EN, Liao W, Lu Z, Bast RC. ARHI-induced autophagy enhances chemosensitivity to cisplatin in human ovarian cancer cell lines and xenografts 54, 2013. e-Pub 2013.
72. Yang H, Wang X, Ahmed AA, Lu Z, Bast RC. Knockdown of kinases that regulate microtubule stability and centrosome function enhance paclitaxel sensitivity in multiple ovarian cancer cell lines 54, 2013. e-Pub 2013.
73. Zhang S, Sood AK, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Bast RC, Le XF. Knockdown of the glycolytic enzyme PFKFB2 induces growth inhibition and enhances sensitivity to paclitaxel in ovarian cancer cells and xenografts 54, 2013. e-Pub 2013.
74. Morgado M, Sutton M, Simmons M, Lu Z, Bast RC, Carson D. Cytokine stimulation of MUC16 expression in human endometrial and ovarian epithelial cell lines, 2013. e-Pub 2013.
75. Raamanathan A, Holman LL, Baggerly K, Shen Y, Urbauer D, Bast RC, Lu KH. Clinical factors affecting HE4 and CA125 in women at high risk of developing ovarian cancer, 2013. e-Pub 2013.
76. Le XF, Ling H, Mao M, Zhang H, Calin GA, Wu Y, Bast RC. miR-495 functions as a novel regulator of the estrogen and progesterone receptors in human breast cancers 54, 2013. e-Pub 2013.
77. Shadfan B, Raamanathan A, Simmons G, Bast RC, McDevitt JT. Multiplexed detection of early stage ovarian cancer biomarkers using a microfluidic bead-based biosensor 54, 2013. e-Pub 2013.
78. Raamanathan A, Lu Z, Bast RC, Skates S. Intra-person and Inter-person biomarker variation for modeling longitudinal values of ovarian cancer early detection biomarkers 54, 2013. e-Pub 2013.
79. Bast RC. Biomarkers for ovarian cancer: Three decades of progress, 2013. e-Pub 2013.
80. Bast RC. Use of Biomarkers to Personalize Care for Ovarian Cancer, 2012. e-Pub 2012.
81. Yang H, Das P, Lu Z, Yu Y, Marquez RT, Liao WSL, Bast RC. Epigenetic regulation and growth suppression by NDN, an imprinted tumor suppressor gene whose expression is decreased in epithelial ovarian cancers 53, 2012. e-Pub 2012.
82. Lu Z, Liao WSL, Yang M, Gao F, Bast RC. ARHI downregulates PI3K and Ras-MAP signaling and induces autophagy by promoting integrin and EGFR membrane protein degradation 53, 2012. e-Pub 2012.
83. Holman LL, Lu KH, Hernandez MA, Bast RC, Bodurka, D, Skates S, Gershenson DM, Sun CC. Perception of Risk, Cancer Worry, Anxiety, and Acceptability of Screening Among Low-Risk Women Undergoing Ovarian Cancer Screening with the Risk of Ovarian Cancer Algorithm. Soc Gynecol Oncol 125:s116-7, 2012. e-Pub 2012.
84. Zhang S, Mao M, Ahmed AA, Li Z, Le FX, Bast RC. CDK5 modulates the cell cycle, apoptosis and paclitaxel sensitivity in human ovarian cancer cells with wild-type p53 function 53, 2012. e-Pub 2012.
85. Raamanathan A, Shadfan B, Ho A, Bast RC, McDevitt JT. Integrated microfluidic bead-based immunosensor for multiplexed determinations of ovarian cancer biomarkers at point of care 53, 2012. e-Pub 2012.
86. Bast RC, Lokshin A, Skates S, Zhang Z, Lu Z, Baggerly K, Atkinson JN, Diao L, He WW, Bedi DG, Bevers T, Adeyinka O, Newland W, Moore R, Leeds L, Harris S, Fritsche H, Lu KH. Early detection of ovarian cancer: The MDACC Ovarian SPORE Trial and development of strategies to detect preclinical disease, 2011. e-Pub 2011.
87. Le XF, Wu Y, Spizzo R, Yoo SY, Mao M, Wang J, Calin GA, Bast RC. Trastuzumab targeting of HER2 upregulates miRNA-194 and downregulates profilin 2 and DNMT3A in HER2-positive breast cancer cells 52, 2011. e-Pub 2011.
88. Liao W, Lu Z, Gao F, Yang M, Bast RC. ARHI-induced autophagy is mediated through activation of FoxO3a and induction of its target genes to promote the formation of autophagic complexes 52, 2011. e-Pub 2011.
89. Lu Z, Liao WS, Yang M, Gao F, Bast RC. ARHI (DiRAS3): A novel component in the formation of the autophagy initiation complex 52, 2011. e-Pub 2011.
90. Tao X, Jin H, Bast RC, Yu Y, Feng Y. Follicle-stimulating hormone (FSH) enhances the proliferation of epithelial ovarian cancer cells by activating transient receptor potential channel C3 (TRPC3) 52, 2011. e-Pub 2011.
91. Ahmed AA, Bast RC, Bowtell D, Goldsmith J. Nonsense mediated decay defines deleterious TP53 mutations and tumor aggressiveness in ovarian cancer 52, 2011. e-Pub 2011.
92. Zhang Z, Skates SJ, Sokoll LJ, Lu Z, Clarke CH, Hernandez MA, Lu KH, Bast RC. A multivariate longitudinal algorithm for early detection of ovarian cancer using multiple biomarkers 29:339s, 2011. e-Pub 2011.
93. Bast RC. Recent Advances in Integrating Molecular Diagnostics for Personalized Care of Cancer Patients, 2011. e-Pub 2011.
94. Yu Y, Lu Z, Das P, Yang H, Feng W, Chen M, Bast RC. Multiple imprinted tumor suppressor genes in ovarian cancer. ICC Course: Genomic imprinting and beyond – Monoallelic expression in health and disease, 2011. e-Pub 2011.
95. Bast RC. Use of Biomarkers to Personalize Care for Epithelial Ovarian Cancer, 2011. e-Pub 2011.
96. Bast RC, MacLaughlan S, Moore RG. Differential diagnosis of a pelvic mass: Improved algorithms for triage to specially trained surgeons, 2010. e-Pub 2010.
97. Bast RC. Biomarkers for epithelial ovarian cancer: An update, 2010. e-Pub 2010.
98. Le XF, Spizzo R, Mao W, Wu Y, Calin GA, Bast RC. DNA (cytosine-5-)-methyltransferases 3A (DNMT3A) is a direct target of miR-194 in breast cancer 51, 2010. e-Pub 2010.
99. Lu Z, Liao WSL, Bast RC. ARHI is required for induction of Beclin-1/PI(3)K Class III-mediated autophagy 51, 2010. e-Pub 2010.
100. Nolen B, Lomakin A, Bast RC, Lu K, Grizzle WE, Jhala NC, Eloubeidi MA, Christein JD, Arnoletti JP, Oleschlager DK, Vickers SM, Marrangoni A, Lokshin A. Urine biomarkers outperform serum biomarkers in the diagnosis of different cancers 51, 2010. e-Pub 2010.
101. Mandal PK, Liao W, Gao F, Robertson F, Thudi N, Ekmekcioglu S, Chattopadhyay C, Ren Z, Chen X, Lu Z, Bast RC, McMurray JS. Potent, highly specific peptidomimetic targeting the SH2 domain of Stat3 decreases vasculogenic mimicry, invasion and anchorage independent growth of cancer cells 51, 2010. e-Pub 2010.
102. Ahmed AA, Le XF, Lu Z, Mao M, Aiken A, Bast RC. Loss of CDK5 sensitizes cells to paclitaxel by enhancing intracellular retention 51, 2010. e-Pub 2010.
103. Jackson AL, Miller CM, Bast RC, Lu KH, Lambert-Messerlian G, Moore RG. Descriptive analysis of HE4 in healthy women, pregnancy and women with benign gynecologic disorders, 2010. e-Pub 2010.
104. Bast RC. Update on biomarkers for management of epithelial ovarian cancer, 2010. e-Pub 2010.
105. Lu KH, Skates S, Bevers T, Adeyinka O, Newland W, Moore R, Leeds L, Harris L Harris S, Fritsche H, Bast RC. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA) 28, 2010. e-Pub 2010.
106. Lu Z, Liao WSL, Suh GL, Bast RC. Integrin and FAK signaling regulate ARHI-induced autophagy 51, 2010. e-Pub 2010.
107. Le SF, Mao W, Zhang Q, Tian L, Ahmed A, Slingerland J, Claret FX, Bast RC. P27Kip1 protein levels predict dasatinib-induced potentiation of paclitaxel activity in human ovarian cancer cells 50, 2009. e-Pub 2009.
108. Lu Z, Badgwell DB, Le K, Suh GK, Das P, Andreeff M, Ahmed A, Liao WS, Bast RC. Re-expression of the tumor suppressor gene ARHI suppresses ovarian cancer cell motility through inhibition of Stat3 and the Rho/ROCK signaling 50, 2009. e-Pub 2009.
109. Le XF, Mao W, Lu Z, Bast RC. Dasatinib induces autophagy as well as growth arrest in human ovarian cancer cells 50, 2009. e-Pub 2009.
110. Moore RG, Jabrey-Raughley M, Brown AK, Robison KM, Miller CM, Allard JW, Nilsson O, Kurman RJ, Bast RC, Skates SJ. Comparison of a novel multimarker assay versus the risk of malignancy index for prediction of epithelial ovarian cancer in patients with a pelvic mass. Proc Soc Gynecol Oncol 112:S25, 2009. e-Pub 2009.
111. Landen CN, Goodman B, Nick AM, Amaiz-Pena G, Danes C, Stone RL, Shahzad M, Jennings N, Gershenson DM, Bast RC, Coleman R, Sood AK. Markers for discovering stemness in ovarian cancer. Proc Soc Gynecol Oncol 112:S140-41, 2009. e-Pub 2009.
112. Landen CN, Goodman B, Nick AM, Armaiz-Pena G, Stone RL, Danes C, Shahzad M, Jennings N, Gershenson DM, Bast RC, Coleman R, Sood A. Isolation of potential ovarian cancer stem cells by aldehyde dehydration expression 50, 2009. e-Pub 2009.
113. Ahmed A, Jacomo RO, Lu Z, Das P, Zheng JF, Liao W, Andreeff M, Bast RC. The salt inducible kinase 2 (SIK2) is required for centrosome separation at the onset of mitosis 50, 2009. e-Pub 2009.
114. Ahmed A, Le XF, Lu Z, Bast RC. Kinase regulated microtubule stabilization correlates with paclitaxel response in a target specific siRNA kinome screen 50, 2009. e-Pub 2009.
115. Bast RC. Molecular diagnostics and molecular therapeutics in the individualized management of human cancer:16-17, 2009. e-Pub 2009.
116. Bast RC, Skates S, Zhang Z, Coombes K, Atkinson EN, Lokshin A, Clarke C, Lu Z, Zheng JF, Das P, Badgwell D, Celestino J, Hernandez MA, Moore R, Granai C, Newland W, Shadur C, Adeyinka O, Harris SA, Fung E, Allard J, Somers E, Fritsche H, Menon U, Jacobs I, Lu KH. Early detection of ovarian cancer: An update, 2009. e-Pub 2009.
117. Arun B, Murray J, Walters R, Brewster A, Rivera E, Valero V, Bast RC, Theriault RL, Green M, Hortobagyi GN. The combination of letrozole and imatinib mesylate for breast cancer, 2009. e-Pub 2009.
118. Zou CF, Yao M, Jin H, Zhao N, Bast RC, Feng Y, Yu Y. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel, 2009. e-Pub 2009.
119. Liao W, Lu Z, Elizondo S, Suh GK, Bast RC. ARHI-induced autophagy is mediated through transcription factor FoxO3a and can be rescued by growth factors 50, 2009. e-Pub 2009.
120. Das PM, Lu Z, Bedi A, Marquez R, Atashroo D, Yu Y, Bast RC. The imprinted tumor suppressor gene Necdin (NDN) is a potent growth suppressor and is downregulated in ovarian cancer 50, 2009. e-Pub 2009.
121. Ahmed A, Fokt I, Bast RC, Priebe W. A soluble genistein unsaturated glycoside induces severe microtubule depolymerization and mitotic arrest in ovarian cancer cells 50, 2009. e-Pub 2009.
122. Cramer DW, Bast RC, Clarke C, Coombes K, Diamandis E, Fung E, Godwin AK, Lokshin A, Lu K, McIntosh M, Mor G, Skates S, Sluss P, Thornquist M, Zhang Z, Urban N. Phase III validation of ovarian cancer biomarkers in pre-diagnostic specimens from the PLCO screening trial 50, 2009. e-Pub 2009.
123. Clarke CH, Yip C, Joy C, Lu K, Badgwell D, Fung ET, Coombes K, Bast RC. Proteomic markers added to CA125 increases sensitivity for detection of epithelial ovarian cancer, 2008. e-Pub 2008.
124. Das P, Lu Z, Marquez R, Atashroo D, Yu Y, Bast RC. Downregulation of multiple imprinted genes in ovarian cancer 49, 2008. e-Pub 2008.
125. Yu Y, Hu X, Huang S, Lu Z, Luo R, Liao W, X-F Q, Bast RC. Knockdown of ARHI promotes the proliferation of normal breast and ovarian epithelial cells and enhances breast cancer growth 49, 2008. e-Pub 2008.
126. Bast RC. Early detection of ovarian cancer, 2008. e-Pub 2008.
127. Moore RG, McMeeken S, Brown AK, DiSilvestro P, Miller C, Allard J, Gajewski W, Kurman R, Bast RC, Skates S. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass, 2008. e-Pub 2008.
128. Brown A, Miller C, Robison K, Somers E, Allard J, Granai CO, Skates S, Bast RC, Moore RG. Differential expression of CA125 and a novel serum tumor marker HE4 in epithelial ovarian cancer 26:301s, 2008. e-Pub 2008.
129. Bast RC, Skates S, Zhang Z, Coombes K, Baggerly K, Atkinson EN, Lokshin A, Clarke C, Lu Z, Zheng JF, Das P, Badgwell D, Celestino J, Hernandez MA, Moore R, Granai C, Newland N, Shadur C, Adeyinka O, Harris SA, Fung E, Allard J, Somers E, Fritsche H, Menon U, Jacobs I, Lu K. Optimizing a two-stage strategy for early detection of ovarian cancer:300, 2008. e-Pub 2008.
130. Cramer D, Bast RC, Godwin AK, Lokshin AE, McIntosh MW, Skates S, Sluss P, Thornquist MD, Berg CD, Urban ND. Validation of ovarian cancer biomarkers in pre-diagnostic specimens from the PLCO Trial:465, 2008. e-Pub 2008.
131. Clarke CH, Fung ET, Yip C, Joy C, Badgwell D, Coombes K, Zhang Z, Lu K, Bast RC. A panel of proteomic markers improves the sensitivity of CA125 for detecting Stage I epithelial ovarian cancer 26:303s, 2008. e-Pub 2008.
132. Bast RC, Iyer R, Hu W, Kavanagh J, Coleman R, Levenback C, Sood A, Wolf J, Gershenson D, Markman M, Fu S. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer 26:153s, 2008. e-Pub 2008.
133. X-F L, Mao W, Bast RC. SiRNA library screening identifies Src family kinases as regulators of the anti-tumor activity of paclitaxel in human ovarian cancer cells 49, 2008. e-Pub 2008.
134. Feng W, Orlandi R, Xu J, Bast RC, Yu Y. Methylation profiles in lymph node metastases from breast cancers 49, 2008. e-Pub 2008.
135. Bermudez Y, Anderson NS, Badgwell D, Chen R, Nicosia SV, Bast RC, Kruk PA. Urinary levels of Bcl-2 are elevated in ovarian cancer 49, 2008. e-Pub 2008.
136. Lu Z, S-L LW, Yu Y, Le K, Elizondo S, Cheng KW, Lu Y, Luo R, Kondo S, Mills GB, Bast RC. Tumor suppressor gene ARHI (DIRAS3) is required for spontaneous and rapamycin-induced autophagy in normal and ovarian cancer cells 49, 2008. e-Pub 2008.
137. Donach M, Donach M, Artioli G, Artioli G, Banna G, Banna G, Feng W, Feng W, Jr BR, Bast RC, Zhang Z, Zhang Z, Yu Y, Yu Y, Nicoletto MO, Nicoletto MO. Biomarkers for screening patients with high risk of ovarian and breast cancers 48, 2007. e-Pub 2007.
138. Cheon DJ, Wang Y, Chen CM, Lu Z, Luo RZ, Cunningham SL, Xing D, Orsulic S, Bast RC, Behringer RR. Knockout of the Ovarian Cancer Antigen CA125 Gene (Mucin 16) in the Mouse 48, 2007. e-Pub 2007.
139. M-Y C, Yu Y, Lu Z, Rosner GL, Atkinson EN, Fu S, Kavanagh J, Bast RC. Synergistic inhibition of ovarian cancer cell growth with demethylating agents and histone deacetylase inhibitors 48, 2007. e-Pub 2007.
140. Badgwell D, Lu J, Luo R, Yu Y, J-J B, Liao W, Bast RC. Re-expression of the tumor suppressor gene ARHI decreases ovarian cancer cell motility by inhibiting STAT3 signaling 48, 2007. e-Pub 2007.
141. X-F L, Horne MC, Mao W, Arachchige-Don AS, Bast RC. Roles of HER2, JNK, PI3K, and p70S6K signaling in the regulation of cyclin G2 expression in human breast cancer cells 48, 2007. e-Pub 2007.
142. Lu Z, Luo RZ, Zhang X, Yu Y, Bast RC. A novel tumor suppressor gene ARHI (DIRAS3) enhances polymerization of microtubules and increases the anti-tumor activity of paclitaxel 48, 2007. e-Pub 2007.
143. Luo RZ, Lu Z, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Liao W, Mills GB, Bast RC. A novel tumor suppressor gene ARHI induces autophagy and tumor dormancy in ovarian cancer xenografts 48, 2007. e-Pub 2007.
144. Clarke CH, Yip C, Joy C, Badgwell D, Fung ET, Coombes K, Bast RC. Addition of a Panel of Seven Proteomic Markers to CA 125 Increases Sensitivity for Detection of Patients with Stage I Epithelial Ovarian Cancer:135, 2007. e-Pub 2007.
145. Clarke CH, Yip C, Joy C, Badgwell D, Fung ET, Coombes K, Bast RC. Proteomic markers enhance the sensitivity of CA125 for detection of Stage I epithelial ovarian cancer, 2007. e-Pub 2007.
146. Huang S, Chang IS, Luo RZ, Lu Z, Bast RC, Chen X, Yu Y. The ARHI tumor suppressor gene may prevent nuclear translocation of p-STAT3 by antagonizing the interaction of Ran with importin proteins 48, 2007. e-Pub 2007.
147. Bast RC. Biomarkers For Ovarian Cancer. Chemotherapy Foundation Symposium XXV, Cancer Investigation 25:24 Suppl. 1, 2007. e-Pub 2007.
148. X-F L, Mao W, Lu C, Sood AK, Bast RC. Potentiation of the anti-tumor effects of trastuzumab in breast cancer xenografts that overexpress HER2 using the angiogenic antagonist VEGF-Trap:152, 2007. e-Pub 2007.
149. Clarke CH, Dang T, Badgwell D, Fung ET, Bast RC. Proteomics discovery of urinary biomarkers for early stage ovarian cancer 48, 2007. e-Pub 2007.
150. Le XF, Lu C, Mao W, Li Y, Sood AK, Bast RC. Implication of platelet-derived growth factors (PDGFs) and their receptors in the angiogenesis of breast cancer cells that overexpress HER2 47, 2006. e-Pub 2006.
151. Bast RC. Early detection for ovarian cancer:83, 2006. e-Pub 2006.
152. Bast RC. Translational research in gynecologic oncology:6, 2006. e-Pub 2006.
153. Feng W, Shen L, Rosen DG, Hu X, Liu J, Shen Y, Hunt KK, Orlandi R, Bast RC, J-P I, Yu Y. CpG island methylator phenotype (CIMP): a novel biomarker to predict new therapy for breast cancer, 2006. e-Pub 2006.
154. Bast RC. New tumor markers for ovarian cancer: CA125 and beyond, 2006. e-Pub 2006.
155. Zhang Z, Bast RC, Vergote I, Hogdall C, Ueland FR, van der Zee A, Wang Z, Yip C, Chan DW, Fung ET. A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer 24(18):269S, 2006. e-Pub 2006.
156. Badgwell D, Lu Z, Fritsche H, Atkinson EN, Sommers E, Allard J, Moore R, Lu K, Bast RC. Soluble mesothelin-related protein (SMRP) is elevated in the serum and urine of patients with early stage ovarian cancer, 2006. e-Pub 2006.
157. Bast RC. Imprinted tumor suppressor genes in the pathogenesis of ovarian cancer, 2006. e-Pub 2006.
158. Bast RC. Novel markers for early detection of ovarian cancer, 2006. e-Pub 2006.
159. Moore RG, Brown AK, Miller MC, Lu Z, Badgwell D, Verch T, Allard WJ, Lu K, Granai CO, Bast RC. A novel multiple biomarker assay for the detection of ovarian cancer 24:261s, 2006. e-Pub 2006.
160. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Verch T, Allard WJ, Granai CO, Bast RC, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer 24:264s, 2006. e-Pub 2006.
161. Fu S, Kavanagh J, Perry G, Hu W, Moore C, Wolf J, Coleman R, Gershenson D, Yu Y, Bast RC. A phase I study of a hypomethylating agent azacytidine in combination with carboplatin in patients with platinum resistant epithelial ovarian cancer 24:269s, 2006. e-Pub 2006.
162. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Yu Y, Bast RC. Genetic and epigenetic regulation of two imprinted tumor suppressor genes - ARHI and PEG3 - in ovarian cancer 47, 2006. e-Pub 2006.
163. Feng W, Shen L, Rosen DG, Hu X, Liu J, Hunt KK, Bast RC, Issa JP, Yu Y. Methylation profile of multiple tumor suppressor genes in breast cancer 47, 2006. e-Pub 2006.
164. Luo R, Lu Z, Lu Y, Khare S, Kondo S, Kondo Y, Yu Y, Liao WS, Mills GB, Bast RC. A novel tumor suppressor gene ARHI induces autophagy in ovarian cancer 47, 2006. e-Pub 2006.
165. Le XF, Mao W, Lu Y, Mills GB, Bast RC. HER2 antibodies pertuzumab and trastuzumab differ in their effect on cell signaling and growth inhibition in breast cancer cells 47, 2006. e-Pub 2006.
166. Yang G, Rosen D, Bast RC, Mills G, Mercado-Uribe I, Liu J. Chemokine growth regulated oncogene 1 (Gro-1) mediates RAS-induced transformation of human ovarian surface epithelial cells through induction of senescence of stromal fibroblasts 47, 2006. e-Pub 2006.
167. Bast RC. Prevention and Detection of Ovarian Cancer: The Impossible Dream?, 2006. e-Pub 2006.
168. Lu Z, Luo R, Khare S, Wang Y, Cheon DJ, Chen CM, Behringer RR, Bast RC. Distribution of murine MUC16, a homolog of human ovarian cancer marker CA125, in adult murine reproductive tissues 47, 2006. e-Pub 2006.
169. Wen X, Liu J, Bast RC, X-F L. HER2 signaling regulates different angiogenic factors through different pathways in breast cancer cells 46:2035, 2005. e-Pub 2005.
170. Lu Z, Luo RZ, Khare S, Yu Y, Bast RC. Inducible expression of tumor suppressor gene ARHI in ovarian cancer cells triggers G2M arrest and inhibits cancer cell growth in vitro and in vivo 46:2895, 2005. e-Pub 2005.
171. Rosen DG, Amin HM, Bast RC, Lai R, Liu J. Clinical significance STAT3 activation in human ovarian cancer 85:935A (A#104), 2005. e-Pub 2005.
172. Yang G, Rosen D, Mercado-Uribe I, Zhou C, Mills GB, Bast RC, Liu J. Immortalization of human ovarian surface epithelial cells using a combination of retrovirus-mediated small interfering RNA against p53 or pRb and ectopic expression of the catalytic subunit of telomerase 46:6109, 2005. e-Pub 2005.
173. Bast RC, Marquez R, Lu Z, Luo R, J-J B, Feng W, Rosen D, Liu J, Lu K, Mills G, Gershenson D, Liao W, Yu Y. Imprinted tumor suppressor genes in epithelial ovarian cancer, 2005. e-Pub 2005.
174. X-F L, Mao W, Bedrosian I, Wen X, Murray M, Keyomarsi K, M-H L, Bast RC. Growth arrest by anti-HER2 antibody blocks breast cancer cells in the late G1 phase of the cell cycle 46:2275, 2005. e-Pub 2005.
175. Bast RC. Ovarian tumor markers: CA125 and beyond, 2005. e-Pub 2005.
176. Luo R, Lu Z, Khare S, Yu Y, Bast RC. Expression of the tumor suppressor gene ARHI induces autophagic cell death in ovarian cancer cells 46:844, 2005. e-Pub 2005.
177. Yu Y, Luo RZ, Lu Z, Feng W, Hawke DH, Kobayashi R, Lu Y, Chen X, Liao WSL, Bast RC. Interactions between a small GTP-binding protein ARHI and importins 7 and 9 may play an important role in ARHI tumor suppressor function 272:332, 2005. e-Pub 2005.
178. Bast RC. Molecular Approaches to Management of Ovarian Cancer, 2005. e-Pub 2005.
179. Feng W, Lu Z, Luo R, Zhang X, Seto E, Bast RC, Yu Y. The ARHI tumor suppressor gene is repressed by multiple histone deacetylases (HDACs) in breast cancer 46:2732, 2005. e-Pub 2005.
180. Nishimoto A, Yu Y, Lu Z, Ren Z, Mao X, Watowich SS, Mills GB, Liao W, Chen X, Bast RC. ARHI directly inhibits STAT3 translocation and activity in human breast and ovarian cancer cells 45:412, 2004. e-Pub 2004.
181. Yu Y, Lu Z, Luo RZ, Peng H, Nishmoto A, Huang M, WS-L L, Bast RC. Transcriptional regulation of the tumor suppressor gene ARHI by E2F-HDAC complexes in breast and ovarian cancers. Chromatin structure and gene expression mechanisms as therapeutic targets, 2004. e-Pub 2004.
182. Yang G, Cai K, Lanza J, Bast RC, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated siRNA silencing against HER-2/neu gene expression 45:273, 2004. e-Pub 2004.
183. Lu Z, Luo RZ, Peng H, Nishimoto A, Huang M, WS-L L, Bast RC, Yu Y. E2F-HDAC complexes downregulate expression of the tumor suppressor gene ARHI in breast cancer cell lines 45:809, 2004. e-Pub 2004.
184. Lee Z, Swaby R, Liang Y, Yu S, Liu S, Bast RC, Mills GB, Fang F. Identification of lysophosphatidic acid as a major regulator of growth-regulated oncogene α (GROα) in ovarian cancer, 2004. e-Pub 2004.
185. X-F L, Lammayot A, Gold D, Chang T, Bast RC. Genes affecting cell cycle and cell growth/maintenance are preferentially regulated by anti-HER2 antibody: Implications for antibody-enhanced docetaxel effect 45:520, 2004. e-Pub 2004.
186. Nishimoto A, Yu Y, Lu Z, S-L LW, Bast RC, Luo RZ. A novel tumor suppressor gene interacts with and inhibits STAT3 activity in breast and ovarian cancer 3:80:5.45, 2004. e-Pub 2004.
187. Marquez R, Patterson A, Yu U, Wang L, Rosen D, Liu J, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson D, Mills G, Bast RC. Frequent dysregulation of imprinted genes in ovarian cancer, 2004. e-Pub 2004.
188. X-F L, Lammayot A, Lu Y, Mills GB, Bast RC. Inhibition of the Phosphatidylinositol 3'-kinase (PI3k) signaling pathway selectively enhances paclitaxel-induced apoptosis by modulating akt and bad phosphorylation in ovarian cancer cells 45:888, 2004. e-Pub 2004.
189. Luo R, Lipska B, Nishimoto A, Lu Y, Mills GB, Wang L, Yu Y, Bast RC. Inhibition of tumor cell growth with ARHI correlates with disorganization of microtubular structure 45:412, 2004. e-Pub 2004.
190. Brewer MA, Hao Z, Wang J, Wharton JT, Gershenson D, Bast RC, Zou C. Combination of 4-HPR and oral contraceptive induced apoptosis and retinoid receptor expression in monkey ovaries 45:1131, 2004. e-Pub 2004.
191. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, J-P I, Bast RC, Yu Y. The role of histone modification in the imprinted tumor suppressor gene ARHI, 2004. e-Pub 2004.
192. Yu Y, J-J B, Fang B, Lu Z, Luo RZ, Bast RC. ARHI gene therapy and paclitaxel exert additive cytotoxicity for breast cancer cells through caspase-independent and caspase-dependent apoptotic mechanisms, 2004. e-Pub 2004.
193. Lu Z, Luo RZ, Peng H, Huang M, Nishmoto A, Liao W, Yu Y, Bast RC. The imprinted tumor suppressor gene ARHI is downregulated both transcriptionally and post-transcriptionally in ovarian cancer 45:809 (A#3508), 2004. e-Pub 2004.
194. J-J B, R-Y W, X-F L, Bray E, Andreeff M, Jr PC, Fang B, Yu Y, Bast RC. Tumor suppressor gene ARHI induces cytoskeletal reorganization in ovarian cancer cells 45:30, 2004. e-Pub 2004.
195. Bast RC. Early detection of ovarian cancer: New technologies in pursuit of a disease that is neither common nor rare. Proceedings American Clinical and Climatological Association, 2003. e-Pub 2003.
196. Lu Z, Luo RZ, Peng HX, Yu Y, Bast RC. Transcriptional and post-transcriptional regulation of the imprinted tumor suppressor gene ARHI in breast and ovarian cancers 44:1138, 2003. e-Pub 2003.
197. Nishimoto A, Yu Y, WS-L L, Bast RC, Luo RZ. Expression of the tumor suppressor gene ARHI inhibits Stat3 activity in breast and ovarian cancers 44:1137, 2003. e-Pub 2003.
198. X-F L, Deshpande D, Lammoyat A, Bast RC. Blockade of HER2 signaling decreases expression of proliferating cell nuclear antigen (PCNA) 44:1254, 2003. e-Pub 2003.
199. Brewer M, Zhou J, Wharton JT, Ye J, Bast RC, Zou C. Biomarkers of 4-HPR response of ovarian carcinoma OV-CA 433 cells 44:661, 2003. e-Pub 2003.
200. Luo RZ, Fang X, Marquez R, S-Y L, Mills GB, WS-L L, Yu Y, Bast RC. ARHI is an unusual Ras family member that inhibits growth and constitutively binds GTP in resting cells 44:685, 2003. e-Pub 2003.
201. Liu J, Patterson A, Thompson JA, Mills G, Gray J, Bast RC. Transformation targets of human ovarian surface epithelial cells by oncogenic H-rasV12 or K-rasV12 revealed by gene expression array 44:270, 2003. e-Pub 2003.
202. Lu KH, Patterson A, Atkinson EN, Baggerly K, Marquez R, Liu J, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC. Selection of potential markers for epithelial ovarian cancer with gene expression array and recursive descent partition analysis 44:573, 2003. e-Pub 2003.
203. X-F L, Lammayot A, Tian L, Deshpande D, F-X C, Tari A, Bast RC. Role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER-2 antibody-induced cell cycle arrest and tumor growth inhibition 44:232, 2003. e-Pub 2003.
204. Yang G, Thompson JA, Mills GB, Liu J, Bast RC. Retention of wild-type BRCA2 allele during malignant transformation of human ovarian surface epithelial cells carrying an inherited BRCA2 germline mutation 44:1133, 2003. e-Pub 2003.
205. Bao JJ, Bao JJ, R-Y W, Wang RY, Brey E, Brey E, Andreeff M, Andreeff M, Patrick CW, Patrick CW, Yu Y, Yu Y, Jr BR, Bast RC. Re-expression of the ARHI gene suppresses motility of ovarian cancer cells 44:1003, 2003. e-Pub 2003.
206. Sun CC, Bodurka DD, Lu KH, Efron B, Anderson R, Bevers TB, Gershenson DB, Bast RC. Perceptions of OVCA risk and screening: Differences between women with a history of breast cancer and women with no history of breast cancer, 2003. e-Pub 2003.
207. Zhang Z, Bast RC, Fung E, Yu Y, Li J, Rosenzweig J, Cameron B, Berchuck A, deBrujn HWA, van der Zee A, Van Haaften-Day C, Hacker N, Chan DW. A panel of three potential biomarkers discovered from serum proteomic profiling improves sensitivity of CA125 in detection of early stage ovarian cancer - a multi-institutional study 44:1316, 2003. e-Pub 2003.
208. Liu J, Mills G, Bast RC. Modeling human ovarian cancer through genetic modification of human ovarian surface epithelial cells, 2003. e-Pub 2003.
209. W-L K, Lapuk A, Konczal D, Vincent R, Merchant S, Glenn P, Zaloudek C, Smith-McCune K, Berchuck A, Bast RC, Mills G, Chin K, de Jong P, Jain A, Gray J. Genomic analyses of ovarian cancer using array CGH, recurrent aberrations and clinical associations 44:742, 2003. e-Pub 2003.
210. Marquez R, Baggerly K, Patterson A, Frumovitz M, Atkinson EN, Liu J, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson D, Mills GB, Bast RC, Lu KH. Gene expression array analysis distinguishes different histotypes of epithelial ovarian cancer and suggests a distinct transcriptional program for mucinous cancers 44:575, 2003. e-Pub 2003.
211. Wang L, Liu J, Jain A, Luo RZ, Rosen D, Lu K, Yu Y, Bast RC. Expression of the tumor suppressor gene ARHI is maintained in well differentiated ovarian cancers and is associated with increased expression of p21WAF1/CIP1 44:1133, 2003. e-Pub 2003.
212. Bast RC, Marquez R, Patterson A, Baggerly K, Atkinson EN, Frumovitz M, Liu J, Ramoth L, Shridhar V, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Hellstrom I, Gershenson DM, Mills GB, Lu K. Gene expression array analysis of epithelial ovarian cancers, 2003. e-Pub 2003.
213. X-F L, Hittelman W, Arlinghaus RB, Lu J, McWatters A, Mills GB, Bast RC. Paclitaxel reduces activity of p70S6K associated with phosphorylation of threonine 421 and serine 424 via multiple signaling pathways 43:791, 2002. e-Pub 2002.
214. Bast RC, Yu Y, Bao J, Luo R, Liu J, Mills G, Zou C, Brewer M, Gershenson D, Smith D, Shridhar V, Berchuck A, Fishman D, Lu K, Zhang Z, Skates S. Prevention and detection of ovarian cancer: A challenge for the 21st Century, 2002. e-Pub 2002.
215. Brewer M, Wang J, Wharton JT, Bast RC, Xou C. Response of normal and immortalized human ovarian epithelial cells and ovarian carcinoma cells to 4-HPR with growth inhibition and apoptosis induction 43:644, 2002. e-Pub 2002.
216. Oh J, Ramondetta LM, Fritsche HA, Bast RC, Mills GB, Wolf JK. Serum IGF-1, IGFBP-2 and IGFBP3 in advanced ovarian cancer 43:189, 2002. e-Pub 2002.
217. Skates SJ, Zhang Z, Bast RC. High sensitivity and specificity for detection of ovarian cancer using mixtures of multivariate normal distributions to combine information from CA125, CA15.3, CA72.4 & MCSF 21:205a, 2002. e-Pub 2002.
218. Luo R, Marquez R, Fang X, Mills GB, Yu Y, Bast RC. Characterization of ARHI, a novel Ras superfamily member that inhibits growth of ovarian and breast cancers 43:986, 2002. e-Pub 2002.
219. J-J B, X-F L, R-Y W, Andreeff M, Yu Y, Bast RC. ARHI induces apoptosis through a caspase-independent pathway 43:620, 2002. e-Pub 2002.
220. Tu SM, Reyes AO, Fanning T, Troncoso P, Bast RC, Logothetis CJ. Advanced prostate carcinoma and elevated serum CA-125 level 21:158b, 2002. e-Pub 2002.
221. Yu YH, Yuan JH, Fujii S, Luo RZ, Bast RC. Methylation and histone acetylation regulate expression of the imprinted ARHI tumor suppressor gene, 2002. e-Pub 2002.
222. Fujjii S, Yuan J, Luo RZ, Hu W, Andreeff M, Kadota M, Oshimura M, J-P I, Bast RC, Yu Y. Transcriptional reactivation of the imprinted tumor suppressor gene ARHI in human breast cancer by inhibition of histone deacetylase 43:1116, 2002. e-Pub 2002.
223. Wang L, Luo R, Liu J, Sahin AA, McWatters A, Bast RC, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with the progression of breast cancer 43:43, 2002. e-Pub 2002.
224. Yuan J, Luo RZ, Fujii S, Hu W, Andreeff M, Kadota M, Oshimura M, J-P I, Bast RC, Yu Y. Aberrant methylation inhibits expression of the imprinted tumor suppressor gene ARHI in human breast cancer 43:1114, 2002. e-Pub 2002.
225. Hartmann L, Couch F, Kaufmann SH, Cliby WA, Iturria S, Kalli K, Lu K, Bast RC, Lillie J, Stec J, Shridhar V, Smith DI, Clark E. Chemoprediction in ovarian cancer - Genomic approaches 33:74, 2002. e-Pub 2002.
226. X-F L, McWatters A, Ramoth LR, F-X C, Lee MH, Mills GB, Bast RC. Decreased phosphorylation and proteasome mediated degradation of p27Kip1 during growth inhibition by anti-HER2 monoclonal antibodies in HER2-overexpressing breast cancer cells 43:87, 2002. e-Pub 2002.
227. Liu J, Yang Z, Thompson JA, Mills GB, Hahn WC, Bast RC. Malignant transformation of human ovarian surface epithelial cells through genetic modifications 43:5, 2002. e-Pub 2002.
228. Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Dent S, Issa JP, Bast RC. Modulation of ARHI and its Role in Carcinogenesis:10, 2002. e-Pub 2002.
229. Bao JJ, Luo RZ, F-J X, Fang X, LaPushin R, Mills GB, Fang B, Yu YH, Bast RC. ARHI gene expression mediated by a binary adenoviral vector system induces apoptosis and inhibits growth of ovarian cancer cells, 2001. e-Pub 2001.
230. Cristofanilli M, Fratarcangeli T, Frye D, Esteva F, Rosales M, Booser DJ, Pusztai L, Bast RC, Rivera E, Sneige N, Singletary SE, McNeese M, Strom E, Buchholz T, Whitman G, Hortobagyi G, Ibrahim NK. Weekly high dose paclitaxel (HD-P) has significant antitumor activity in inflammatory breast cancer (IBC) 20:15b, 2001. e-Pub 2001.
231. Yu YH, Luo RZ, Bao J, Xu FJ, Pan Y, Bast RC. ARHI, an imprinted tumor suppressor gene, plays an important role in the oncogenesis, 2001. e-Pub 2001.
232. Zhang Z, Xu F, Yu Y, Berchuck A, Havrilesky LJ, deBrujn HWA, van der Zee A, Woolas RP, Jacobs I, Bast RC. Use of multiple markers to detect stage I epithelial ovarian cancers: Neural network analysis 20:219a, 2001. e-Pub 2001.
233. Donato ML, Aleman AS, Gershenson DM, Wharton JT, Bast RC, Burke TW, Bodurka-Bevers D, Bevers M, Levenback CF, Wolf JK, Freedman RS, Cooke S, Ippoliti C, Brewer M, Gajewski J, Champlin RE. Long term results of 102 patients with advanced ovarian cancer treated with high dose chemotherapy 20:204a, 2001. e-Pub 2001.
234. X-F L, McWatters A, Bast RC. Impairment of a Protein Kinase C-dependent pathway potentiates heregulin-induced apoptosis 42:594, 2001. e-Pub 2001.
235. Pusztai L, Krishnamurthi S, Perez-Cardona J, Sneige N, Esteva FJ, Hortobagyi GN, Bast RC, Takayama S, Krajewski S, Reed JC. Expression of BAG-1 and Bcl-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer 20:428a, 2001. e-Pub 2001.
236. Xu F, Chen JI, Yu Y, Peng H, Bast RC. Expression of ARHI, an imprinted tumor suppressor gene, is lost in pancreatic cancer 42:479, 2001. e-Pub 2001.
237. Schmandt R, Clifford S, Lee J, Lillie J, Deavers M, Shaw P, Jung M, Levenback C, Bast RC, Mills GB, Gershenson D, Lu K. Differential expression of the secreted protease inhibitor, HE4, in epithelial ovarian cancer 32:103, 2001. e-Pub 2001.
238. Brewer M, Utzinger U, Satterfield W, Gershenson D, Bast RC, Richards-Kortum R, Follen M. Biomarker modulation in a non-human primate model for ovarian cancer chemoprevention 32:101, 2001. e-Pub 2001.
239. Shvartsman HS, Lu K, Lee J, Lillie J, Deavers M, Clifford S, Wolf J, Mills G, Bast RC, Gershenson D, Schmandt R. Over-expression of NES-1 in epithelial ovarian cancer 32:103, 2001. e-Pub 2001.
240. Yu Y, Luo R, Bao J, Xu F, Pan Y, Bast RC. ARHI (NOEY2), an imprinted tumor suppressor gene, is downregulated in cancers at multiple sites, 2001. e-Pub 2001.
241. Pan Y, Luo RZ, Peng H, Bao J, Hu W, Andreeff M, J-P I, Bast RC, Yu Y. Aberrant methylation of an imprinted tumor suppressor gene ARHI in human breast cancer cells 42:475, 2001. e-Pub 2001.
242. Pusztai L, Lillie J, Brown J, Van Huffel C, Voltchenok M, Breitenfelder P, Hortobagyi GN, Bast RC. Transcriptional profiling of breast cancer cells before and after exposure to paclitaxel (TAXOL ®):122, 2000. e-Pub 2000.
243. Y-H Y, Xu FJ, Xia W, Zhao S, Peng HQ, Luo RZ, Long Y, Parlow AF, Hung MC, Bast RC. ARHI inhibits the production of prolactin and progesterone, and induces defects of ovary and mammary gland development in transgenic mice 41:227, 2000. e-Pub 2000.
244. Donato M, Gershenson DM, Ippoliti C, Wharton JT, Bevers MW, Bodurka-Bevers D, Levenback C, Wolf JK, Freedman RS, Bast RC, Burke TW, Champlin RE. Topotecan in combination with cyclophosphamide and melphalan for stem cell transplantation: Results of a large Phase I trial in advanced ovarian cancer 19:50a, 2000. e-Pub 2000.
245. Luo RZ, Peng HQ, Xu FJ, Long Y, Yu YH, Bast RC. Purification and characterization of ARHI, a new member of the ras family and a putative tumor suppressor gene 41:441, 2000. e-Pub 2000.
246. Pusztai L, Brown J, MacBeth KJ, Lillie J, Hess K, Voltchenok M, Breitenfelder P, Bast RC, Hortobagyi GN. Expression profiles in normal breast epithelial cells and breast cancer 19:646a, 2000. e-Pub 2000.
247. Bast RC, Yu Y, F-J X, Fang X, Luo R, Bao JJ, Mills GB. Molecular Approaches to the Management of Epithelial Ovarian Cancer, 2000. e-Pub 2000.
248. Lenzi R, Buckman R, Glober GA, Beale EA, Bast RC, Kudelka AP, Baile WF. The difficult task of breaking bad news: Oncologists attitudes, practices and challenges 19:598a, 2000. e-Pub 2000.
249. Schmidt M, McWatters A, White A, Groner B, Wels W, Fan Z, Bast RC. In vitro and in vivo growth inhibition of HER-2 overexpressing ovarian cancer cells by combinations of a HER-2 specific antibody-toxin fusion protein and ionizing radiation 41:286, 2000. e-Pub 2000.
250. X-F L, Vadlamudi R, McWatters A, Bae DS, Kumar R, Mills GB, Bast RC. Differential signaling through p185HER2 with a monoclonal antibody and with heregulin β1 in SKBR3 cells 41:67, 2000. e-Pub 2000.
251. Bast RC. New approaches to the diagnosis, prevention and treatment of epithelial ovarian cancer, 2000. e-Pub 2000.
252. Bast RC, Luo RZ, F-J X, Fang XJ, Peng HQ, Bao JJ, Long Y, Yu YH. ARHI (NOEY2): An imprinted putative tumor suppressor gene whose expression is lost in ovarian and breast cancers:71, 2000. e-Pub 2000.
253. Gaweski J, Donato M, Anderlini P, Korbling M, Ueno N, Saliba R, Rondon G, Ippoliti C, Bast RC, Buzdar A, Hortobagyi GN, Champlin R. Intensive chemotherapy with G-CSF with mobilization yields improved peripheral blood progenitor (PBPC) collection, quicker recovery after high dose chemotherapy and reduces progression risk compared to G-CSF alone for mobilization 19:123a, 2000. e-Pub 2000.
254. Bast RC. Molecular biology of ovarian cancer:2, 1999. e-Pub 1999.
255. Fang X, Yu S, La Pushin R, Lu Y, Furui T, Bast RC, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts 40:168, 1999. e-Pub 1999.
256. Bozorgi K, Pusztai L, Dalrymple J, McWatter A, Mills GB, Bast RC. Anti-P185c-erbB-2-Ricin-A-chain immunotoxin induces p53 independent apoptosis by preferentially inhibiting antiapoptotic protein expression 72:509, 1999. e-Pub 1999.
257. Gershenson D, Devers M, Tortelero-Luna G, Diaz S, Miller B, Silva E, Bast RC, Wolf JK, Mills G, Wharton JT. The prognostic significance of p53 expression in Stage II and III ovarian serous borderline tumors 72:506, 1999. e-Pub 1999.
258. Le L, Vadlamudi R, McWatters A, Kumar R, Bast RC. Contrasting effects of heregulin and a tumor-inhibitory monoclonal antibody to HER-2 receptor on mitogen-activated protein kinases and phosphoinositide-3-kinase pathways 40:425, 1999. e-Pub 1999.
259. Bast RC. Molecular approaches to management of epithelial ovarian cancer. Second International Symposium, 1999. e-Pub 1999.
260. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, W-L K, Gray J, Siciliano M, Mills GB, Bast RC. NOEY2 (ARHI) an imprinted tumor suppressor gene in ovarian and breast cancers, 1999. e-Pub 1999.
261. Pusztai L, Van Huffel C, Lillie J, Voltchenok M, Breitenfelder P, Hortobagyi GN, Bast RC. Transcriptional profiling of normal and neoplastic breast epithelial cells before and after exposure to paclitaxel, 1999. e-Pub 1999.
262. Yu YH, Peng HQ, Luo RZ, Xu FJ, Fang XJ, Long Y, Zhao SL, Xia WY, Gray JW, Bast RC. ARHI (NOEY2), an imprinted putative tumor suppressor gene in breast carcinoma, 1999. e-Pub 1999.
263. Bast RC, Richards-Kortum R. Biology/physiology: oncology overview, 1999. e-Pub 1999.
264. Peng HQ, Xu FJ, Pershad R, Gray JW, Bast RC, Yu YH. The functional allele of ARHI (NOEY2), an imprinted tumor suppressor gene, is deleted in ovarian and breast cancers 40:896, 1999. e-Pub 1999.
265. Yu YH, Pen HQ, RZ-T L, Xu, FJ, Fang XJ, Zhao S, Xia W, Gray JW, Bast RC. The mechanism leading to silencing of ARHI, an imprinted putative tumor suppressor gene, in ovarian and breast cancers, 1999. e-Pub 1999.
266. Bast RC. Molecular approaches to management of epithelial ovarian cancer 40:762, 1999. e-Pub 1999.
267. Brewer M, Utzinger U, Gershenson D, Silva E, Bast RC, Richards-Kortum R, Mitchell MF. Optical characterization of ovarian tissue in vivo with reflectance spectroscopy 72:474, 1999. e-Pub 1999.
268. Donato M, Gershenson D, Wharton JT, Aleman A, Ippoliti C, Bodurka D, Levenback C, Bevers M, Wolf J, Freedman R, Gajewski J, Bast RC, Champlin RE. Phase I study of high-dose topotecan and alkylating agents for advanced ovarian cancer 18:44a, 1999. e-Pub 1999.
269. Gajewski J, Donato M, Anderlini P, Korbling M, Khouri I, Rondon G, Giralt S, Buzdar A, Ueno N, Andersson B, Durrett A, Saliba R, Bruton J, Molldrem J, Ippoliti C, Raber M, Bast RC, Hortobagyi G, Champlin R. Preliminary results of a randomized trial comparing intensive chemotherapy with growth factor (GF) for peripheral blood progenitor cell (PBPC) mobilization to growth factor alone for hematopoietic rescue after high dose chemotherapy (HDC) 18:50a, 1999. e-Pub 1999.
270. Yu YH, Peng HQ, Xu FJ, Zhao SL, Huang Z, Thornton A, Devers M, Kuo WL, Gray JW, Mills GB, Bast RC. ARHI (NOEY2) is an imprinted suppressor gene on 1p31 40:546, 1999. e-Pub 1999.
271. Kruzelock RP, Xu F, Yu Y, Mills GB, Bast RC. Microcell fusion of human chromosome 22 into malignant ovarian cancer cells reduces proliferation, abrogates anchorage independent growth, and diminishes tumorigenicity 39:625, 1998. e-Pub 1998.
272. Kudelka A, Baile WF, Lenzi R, Beale E, Glober G, Bast RC. The physician-patient relationship in oncology: Outcome of workshops for faculty, 1998. e-Pub 1998.
273. Ueno NT, Hung MC, Weiden P, Wolf JK, Xia W, Zhang S, Daifuku R, Kilbourn RG, Willey JS, Warner DL, Payne JY, Nandagiri R, Aldridge R, Carey M, Lincoln ST, Aboulafia D, De Jaeger RL, Tucker S, Putnam JB, Sneige N, Katz RL, Spohn WH, Bast RC, Holmes FA, Ibrahim NK, Murray JL, Theriault RL, Rahman ZU, Valero V, Kudelka AP, Kavanaugh JJ, Freedman RS, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hortobagyi G. Phase I trial of E1A gene therapy in patients with advanced breast cancer, 1998. e-Pub 1998.
274. Ueno NT, Hung MC, Zhang S, Xia W, Willey JS, Warner DL, Payne JY, Nandagiri R, Aldridge R, De Jager RL, Tucker S, Putnam JB, Sneige N, Katz RL, Spohn WH, Bast RC, Holmes FA, Ibrahim NK, Theriault RL, Rahman ZU, Valero V, Kudelka AP, Kavanaugh JJ, Freedman RS, Wolf JK, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hortobagyi GN. Phase I E1A gene therapy in patients with advanced breast and ovarian cancers 39:360, 1998. e-Pub 1998.
275. Ueno NT, Hung MC, Zhang S, Xia W, Willey JS, Warner DL, Payne JY, Nandagiri R, Aldridge R, De Jager RL, Tucker S, Putman JB, Sneige N, Katz RL, Spohn WH, Bast RC, Holmes FA, Ibrahim NK, Theriault RL, Rahman ZU, Valero V, Kudelka A, Kavanagh JJ, Freedman R, Wolf JK, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hortobagyi GN. Phase I E1A gene therapy in patients with advanced breast and ovarian cancers 17:432a, 1998. e-Pub 1998.
276. Pusztai L, Bozorgi K, Xu FJ, Bast RC. Ricin-A/anti-HER-2-immunoconjugate-induced p53-independent programmed cell death is associated with selective depletion of intracellular bcl-2 protein in ovarian cancer cells 39:439, 1998. e-Pub 1998.
277. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu SQ, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Vershraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Dayne A, Holzmayer T, Hamer J, Bachier C, Ostrove J, Przepiorka D, Burtners B, Cote R, Bast RC, Hortobagyi G, Deisseroth A. 12 cycles of paclitaxel immediately following high dose chemotherapy with autologous stem cell transplantation can induce complete remissions in patients with breast and ovarian carcinoma 17:75a, 1998. e-Pub 1998.
278. Xu FJ, Yu YH, Zhao SL, Xia WY, Dai JY, Peng HQ, Zou LL, Le WD, Hung MC, Bast RC. Expression of NOEY2, a novel tumor suppressor gene, in transgenic mice 39:467, 1998. e-Pub 1998.
279. Peng H, Yu Y, F-J X, Frazier M, Li Q, J-P I, Bast RC. NOEY2, a putative tumor suppressor gene in 1p31, is maternally imprinted, 1998. e-Pub 1998.
280. Kudelka AP, Vershraegen CF, Edwards CL, Freedman RS, Plunkett W, Ruiz van Haperin VWT, Fossella F, Lifschitz S, Steger M, Bast RC, Kavanagh JJ. A preliminary report of a phase 2 study of gemcitabine in women with platinum refractory mullerian (ovarian, fallopian tube and primary peritoneal) carcinomas 17:367a, 1998. e-Pub 1998.
281. Lu YL, Wu JY, Xu FJ, LaPushin R, Mills GB, Bast RC, Yu YH. Ras-related NOEY2 is a novel negative regulator of T cell signaling 39:535, 1998. e-Pub 1998.
282. Yu YH, Xu FJ, Fang XJ, Dai JY, Peng HQ, Bast RC. Characterization of the NOEY2 genomic structure 39:132, 1998. e-Pub 1998.
283. Wiener JR, Kruzelock RP, Nakano K, Estrella VC, Mills GB, Bast RC, Gallick GE. Abrogation of anchorage-independent growth of a HER-2-overexpressing human ovarian cancer cell line transfected with an antisense expression vector specific for c-SRC, 1998. e-Pub 1998.
284. Lenzi R, Baile WF, Beale E, Glober G, Kudelka A, Myers E, Bast RC. Communicating bad news: Outcome of a workshop for oncologists, 1998. e-Pub 1998.
285. Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH. Cytotoxicity and G1-arrest by 1R,2R-diaminocyclohexane-diacetato-dichloro-platinum(IV) (DACH-Pt) in cisplatin-resistant ovarian tumor cells is dependent on p53 status 39:161, 1998. e-Pub 1998.
286. Freedman RS, Kudelka AP, Vershraegen CF, Edwards CL, Tomasovic B, Kaplan A, Bast RC, Longnecker M, Steger M, Kavanagh JJ. Therapeutic anti-cancer vaccine: A randomized double blind dose comparison study of sialyl TN-KLH for active specific immunotherapy of ovarian cancer 17:365a, 1998. e-Pub 1998.
287. Diaz S, Gershenson D, Bast RC, Nicolson G. Protease expression in human breast and ovarian carcinoma: Relation to behavior, 1998. e-Pub 1998.
288. Gajewski J, Rondon G, Mirza N, Mehra R, Donato M, Anderlini P, Korbling M, Therialt R, Khouri I, Giralt S, Buzdar A, Ueno N, Przepiorka D, Andersson B, Durrett A, Saliba R, Burton J, Rahman Z, Ippoliti C, Hortobagyi G, Raber M, Bast RC, Champlin R. Preliminary results of a randomized trial comparing intensive chemotherapy with growth factor (GF) for peripheral blood progenitor cell (PBPC) mobilization to GF alone for hematopoietic rescue after high dose chemotherapy (HDC) 17:80a, 1998. e-Pub 1998.
289. Wu JY, Xu FJ, Yu YH, Lu YL, Bast RC. Differential signaling induced by heregulin and antibodies to p185c-erbB-2 (p185HER-2) in SKBr3 breast cancer cells that overexpress the receptor 39:205, 1998. e-Pub 1998.
290. Diaz SR, Gershenson D, Van Haaften Day C, Nicolson GL, Atkinson N, Bast RC. Expression of 92 kD type IV collagenase, 72 kD type IV collagenase, and heparanase in borderline ovarian tumors. Relation to clinical behavior 39:295, 1998. e-Pub 1998.
291. Rahman Z, Kavanagh J, Giles R, Hanania E, Holmes F, Booser D, Fu SQ, Zu Z, Ellerson D, Calvert L, Claxton D, Bachier C, Berenson R, Holzmayer T, Dayn A, Heimfield S, Hortobagyi G, Bast RC, Andreeff M, Champlin R, Deisseroth A. Post autologous transplant taxol chemotherapy results in responses above and beyond that achievable with pre-transplantation intensive therapy, 1997. e-Pub 1997.
292. Wolf JK, Hahn H, Mills GB, Bast RC, Roth JA, Gershenson DM. Growth inhibition of human ovarian cancer cells by combination treatment with cisplatin and transfection with adenovirus-mediated P53 Basic Science Section:A#5, 1997. e-Pub 1997.
293. Xu FJ, Yu YH, Boyer CM, Desonbre K, Foulon CS, Affleck D, Zhao XG, Zalutsky MR, Bast RC. N-succinimidyl-5-Iodo-3-pyridinecarboxylate (SIPC) and tyramine cellobiose (TCB) compared to iodogen for radiolabeling HER-2 antibodies 38:249, 1997. e-Pub 1997.
294. Woolas RP, Oram DH, Skates S, Prys Davies A, Bast RC, Jacobs IJ. Increasing the sensitivity of a multimodal screening strategy for ovarian cancer: role of sequential tumour marker assay 7:76, 1997. e-Pub 1997.
295. Dalrymple JL, Ward K, Mills GB, Bast RC. Induction of apoptosis by TGF-β and all-trans retinoic acid (ATRA) in ovarian cancer cell lines is regulated by bcl-x 38:90, 1997. e-Pub 1997.
296. Pustilnik T, Bast RC, Mills G. Lysophosphatidic acid induces urokinase secretion in ovarian cancer cells 38:410, 1997. e-Pub 1997.
297. Bast RC, F-J X, Yu YH, Wiener J, Wolf J, Gershenson D, Mills GB. Molecular approaches to the diagnosis and management of ovarian cancer:83, 1997. e-Pub 1997.
298. Bast RC, F-J X, Yu YA, Wiener J, Wolf J, Gershenson D, Mills GB. Molecular approaches to the diagnosis and management of ovarian cancer, 1997. e-Pub 1997.
299. Bast RC, Xu FJ, Yu YA, Weiner J, Wolf J, Barnhill S, Zhang Z, Gershenson D, Mills GB. Molecular approaches to the diagnosis and management of ovarian cancer, 1997. e-Pub 1997.
300. Dalrymple J, Bozorgi K, Xu FJ, Mills GB, Bast RC. Immunotoxin-induced apoptosis by a p53-independent pathway in ovarian cancer 38:28, 1997. e-Pub 1997.
301. Yu YH, Xu FJ, Fang XJ, Zhao SL, Li Y, Siciliano MJ, Gray JW, Mills GB, Bast RC. Identification of a novel ras-related, tumor suppressor gene in ovarian carcinomas 38:81-82, 1997. e-Pub 1997.
302. Rahman Z, Kavanaugh J, Giles R, Hanania E, Holmes F, Booser D, Fu SQ, Zu Z, Ellerson D, Calvert L, Claxton D, Bachier C, Berenson R, Holzmayer T, Dayn A, Heimfield S, Hortobagyi G, Bast RC, Andreeff M, Champlin R, Deisseroth A. Paclitaxel immediately following autologous bone marrow transplantation further reduces residual disease in patients with metastatic breast cancer (MBC) 38:25, 1997. e-Pub 1997.
303. Rahman Z, Kavanagh J, Giles R, Hanania E, Holmes F, Booser D, Fu SQ, Au Z, Ellerson D, Calvert L, Claxton D, Bachier C, Berenson R, Heimfeld S, Hortobagyi G, Bast RC, Andreeff M, Champlin R, Deisseroth A. Toxicity/response analysis of 12 cycles of post-transplant chemotherapy for breast and ovarian cancer shows safety and efficacy 16:187a, 1997. e-Pub 1997.
304. Newman, RA, Yu YH, Xu FJ, Thomton A, Bast RC, Von Hoff DD, Vidal JC, Etcheverry MA. Cellular pharmacology and cytotoxicity of crotoxin, a phospholipase A2 toxin, against human breast, colon and ovarian cancer cell lines 37:393, 1996. e-Pub 1996.
305. Yu YH, Xu FJ, Fang XJ, Walch E, Thornton A, Bast RC. Differential display of genes expressed in normal ovarian surface epithelium, but not in ovarian cancer 37:592, 1996. e-Pub 1996.
306. Termrungruanglert W, Kudelka AP, Verschraegen CF, Freedman RS, Edwards CL, Tomascovic B, Piamsomboon S, Balat O, Levy T, Bast RC, Longnecker M, Steger M, Kavanaugh JJ. Therapeutic anti-cancer vaccine: a randomized double blind dose comparison study of sialyl TN-KLH with detox-β SE adjuvant for active specific immunotherapy of ovarian cancer (OC) 15:558, 1996. e-Pub 1996.
307. Xu FJ, Leadon SA, Yu YH, Boyer CM, O'Briant K, Zhao XG, Slade S, Bae DS, DeSombre K, Zalutsky M, Bast RC. Super-additive interaction between anti-p185c-erbB-2 immunotoxins and radionuclide conjugates in vivo 37:371, 1996. e-Pub 1996.
308. Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH. Studies of cisplatin (CDDP) resistance with 1R,2R-diaminocyclohexane (DACH)-diacetato-dichloro-Pt(IV) (acetato-Pt) in ovarian cancer cell lines 37:402, 1996. e-Pub 1996.
309. Xu FJ, Yu YH, Boyer CM, Walch E, Khan H, Mills G, Bast RC. Stimulation or inhibition of ovarian cancer cell proliferation by heregulin is dependent on the ratio of HER2 to HER3 or HER4 expression 37:191, 1996. e-Pub 1996.
310. Gershenson DM, Burke TW, Levenback C, Morris M, Bast RC, Guaspari A, Warner D, Wharton JT. A phase I study of a daily x3 schedule of intravenous navelbine for refractory epithelial ovarian cancer 15:294, 1996. e-Pub 1996.
311. Martell RE, Xu FJ, Anselmino L, Yu YH, Davis WB, Daly L, Bast RC. OVX1 and CEA in patients with colon carcinoma and benign colon disorders 15:92, 1996. e-Pub 1996.
312. Baile WF, Lenzi R, Kudelka A, Novack D, Goldstein M, Maguire P, Myers E, Bast RC. Improving the physician-patient relationship in cancer care: Report of a workshop 5, 1996. e-Pub 1996.
313. Wolf JK, Bazelle L, Mills GB, Bast RC, Roth JA, Gershenson DL. Growth inhibition of human ovarian cancer cells by transfection with adenovirus-mediated p53 is independent of endogenous p53 status 37:205, 1996. e-Pub 1996.
314. F-J X, Leadon SA, O'Briant K, Yu YH, Zhao XG, Slade S, Bae DS, Boyer CM, Zalutsky M, Bast RC. Synergistic cytotoxicity is produced with ionizing radiation and anti-p185c-erbB-2 immunotoxins in cells that overexpress p185c-erbB-2 36:484, 1995. e-Pub 1995.
315. Xu FJ, Hsieh JT, Yu YH, Logothetis C, Bast RC. OVX1, a potential prognostic marker for prostate cancer 14:23, 1995. e-Pub 1995.
316. Berek J, Martinez-Maza O, Bast RC. Ovarian Cancer Screening: The use of complementary tumor markers to improve specificity for early detection, 1995. e-Pub 1995.
317. Mills GB, Fang XJ, Wiener JR, Xu F, Yu Y, Wolf J, Gershenson J, Wharton JT, Bast RC. Molecular mechanisms regulating the growth of ovarian cancer cells: potential diagnostics and targets for therapy:61-62, 1995. e-Pub 1995.
318. Beck E, Anselmino L, Xu FJ, Bast RC, Jäger W. Is OVX1 a suitable marker for endometrial cancer?, 1995. e-Pub 1995.
319. Bae DS, F-J X, Mills G, Bast RC. Heregulin and antibodies against p185c-erbB-2 (p185) activate distinct signaling pathways 36:55, 1995. e-Pub 1995.
320. Skubitz APN, Grossman PE, Bast RC, Wayner EA, Wilke MS. Expression of laminin and type IV collagen correlated with the expression of α6 and β4 integrins in serous epithelial ovarian carcinoma 6S:166A, 1995. e-Pub 1995.
321. Skubitz APN, Bast RC, Wayner EA, Wilke MS. Expression of α6 and β4 integrins in serous epithelial ovarian carcinoma correlates with expression of basement membrane proteins, laminin and type IV collagen, 1995. e-Pub 1995.
322. Heimer M, Tyer C, Vredenburgh JJ, Peters WP, Bast RC. The effect of immunomagnetically purged peripheral blood progenitor cells on bone marrow reconstitution, 1995. e-Pub 1995.
323. Allard WJ, Neaman IE, Very DL, Boyer C, Daly L, O'Briant KS, Yeung KK, Bast RC. Nonspecific cross-reacting antigen 50/90 as a member of a cancer biomarker panel detects breast cancer recurrence with a lead time of 5-6 months 36:211, 1995. e-Pub 1995.
324. Halberg F, Cornélissen G, Fine RL, Bast RC. Chronopharmacology awaiting implementation by pharmacists, 1995. e-Pub 1995.
325. DeSombre K, Tyer CL, Silva O, Cook M, Vredenburgh JJ, Peters WP, Bast RC. A comparison of immunohistochemistry, two-color immunofluorescence and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow, 1995. e-Pub 1995.
326. Fine RL, Cornélissen G, Halberg F, Bast RC, Haus E, Walker R, Jatoi A, F-J X, Y-H Y, Takagi M, Fujii S, Dahl J, Hunter D, Halberg J, Halberg F, Von Hoff DD. Chronochemo- sensitivity assays by marker rhythmometry target cancer treatment in time, kind and dose 15:A520, 1995. e-Pub 1995.
327. Einhorn N, Sjovall S, Bast RC, Skates S, Xu FJ, Ha W, Knapp R. A nine-year follow-up of 6632 women screened for ovarian cancer, 1995. e-Pub 1995.
328. Tyer CL, DeSombre K, Vredenburgh JJ, Peters WP, Bast RC. Two-color immunofluorescence tumor cell detection in immunomagnetically purged stage IV breast samples, 1995. e-Pub 1995.
329. Boyer CM, Wu S, F-J X, Desombre K, Whitaker R, Bast B, Stack MS, Conaway M, Bast RC. Stimulation of human ovarian cancer cell growth in vivo with TNFa or IL-1 in immunodeficient scid mice 36:71, 1995. e-Pub 1995.
330. Vredenburgh J, Silva O, deSombre K, Franklin W, Cirrincione C, Berry D, Peters WP, Bast RC. The significance of bone marrow micrometastases for patients (pts) with breast cancer and $10+ lymph nodes treated with high-dose chemotherapy and hematopoietic support 14:317, 1995. e-Pub 1995.
331. Dabal R, Boyer CM, Berchuck A, Roberts A, Roche N, Sporn M, Bast RC. Synergistic inhibition of ovarian cancer cell proliferation by TGFb and retinoic acid (RA) derivatives 36:635, 1995. e-Pub 1995.
332. Rodriguez GC, Berchuck A, Whitaker R, Stack MS, Soper JT, Clarke-Pearson DL, Pizzo S, Bast RC. Regulation of invasion in ovarian cancer cell lines by transforming growth factor-β:40, 1995. e-Pub 1995.
333. Elbendary A, Havrilesky L, Bast RC, Marks J, Berchuck A. Regulation of p21 (WAF1) expression by p53 and transforming growth factor-β in ovarian cancer, 1995. e-Pub 1995.
334. Bast RC. Prevention and early detection of ovarian cancer, 1995. e-Pub 1995.
335. Woolas R, Conaway M, Xu F, Jacobs I, Yu YH, Daly L, Davies AP, O'Briant K, Berchuck A, Soper J, Clarke-Pearson DL, Rodriguez G, Oram DH, Bast RC. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses 52:110, 1994. e-Pub 1994.
336. Wu S, Xu FJ, Boyer CM, Bast RC. Proliferation and induction of NF-kappa B by tumor necrosis factor-a can be mediated through two distinct receptors in human ovarian cancer cells 35:486, 1994. e-Pub 1994.
337. Berchuck A, Kohler M, Nishii H, Risinger J, Clarke-Pearson D, Bast RC, Boyd J. Molecular genetic analysis of endometrial adenocarcinomas 52:103, 1994. e-Pub 1994.
338. Bast RC, Boyer C, Xu FJ, Wiener J, Dabel S, Wu S, Woolas R, Jacobs I, Berchuck A. Molecular approaches to the diagnosis and management of ovarian cancer:36, 1994. e-Pub 1994.
339. Kohler M, Takahashi H, Elbendery A, Bast RC, Boyd J, Berchuck A. Molecular analysis of the estrogen receptor gene in endometrial cancer 35:278, 1994. e-Pub 1994.
340. Patton SE, Jameson SB, Martin ML, Altschuler DL, Bast RC, Ostrowski MC. Activated ras signaling and uPA expression in ovarian carcinoma:34, 1994. e-Pub 1994.
341. Xu FJ, Rodriguez G, Bae DS, Whitaker R, Boyer C, Mills G, Yu YH, Bast RC. Heregulin and anti-p185c-erbB-2 antibodies inhibit proliferation, increase invasiveness and enhance tyrosine autophosphorylation of breast cancer cells that overexpress p185c-erbB-2 35:38, 1994. e-Pub 1994.
342. Hurteau J, Berchuck A, Rodriguez G, Whitaker R, Soper J, Clarke-Pearson D, Bast RC. Epidermal growth factor and tumor necrosis factor-a stimulate proliferation of some epithelial ovarian cancer cells from ascites 52:110, 1994. e-Pub 1994.
343. Wiener JR, Kassim SK, Berchuck A, Bast RC. Differential expression of protein tyrosine phosphatases in human ovarian adenocarcinomas 35:5924, 1994. e-Pub 1994.
344. Dean GS, F-J X, O'Briant KC, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC. Density of p185c-erbB-2 determines susceptibility to anti-p185c-erbB-2-RTA immunotoxin alone and in combination with anti-p170EGFR 35:504, 1994. e-Pub 1994.
345. Xu FJ, Yu YH, Anselmino L, Jacobs I, Woolas RP, Boyer CM, Bast RC. Comparison of OVX1 and carcinoembryonic antigen (CEA) in clinical and preclinical colorectal carcinoma 13:117, 1994. e-Pub 1994.
346. Greenberg CS, Hettasch JM, Hurteau J, Bast RC. The tissue transglutaminase gene is expressed in ovarian carcinoma cells in vitro and in vivo 35:34, 1994. e-Pub 1994.
347. Bast RC, Boyer C, F-J X, Wu S, Wiener J, Rodriguez G, Berchuck A. Oncogenes, tumor suppressor genes and growth factors in epithelial ovarian cancer:650, 1994. e-Pub 1994.
348. Rodriguez G, Berchuck A, Whitaker R, Young T, Stack S, Soper J, Clarke-Pearson D, Pizzo S, Bast RC. The urinary-type plasminogen activator receptor and its ligand are upregulated in epithelial ovarian cancer 52:123, 1994. e-Pub 1994.
349. Jacobs IJ, Jeyarajah AR, Xu FJ, Woolas RP, Davies AP, Oram DH, Bast RC. Combinations of markers in screening for ovarian cancer, 1994. e-Pub 1994.
350. Bast RC. PSA, CA 125 and other tumor markers in detection, diagnosis and prognosis of prostate, ovarian, and endometrial cancer:14-16, 1993. e-Pub 1993.
351. Tyer CL, Vredenburgh JJ, Peters WP, Bast RC. Two-color immunofluorescence improves the detection of tumor cells in the bone marrow:81, 1993. e-Pub 1993.
352. Woolas R, Jacobs IJ, Xu FJ, Yu Y, Daly L, Berchuck A, Oram DH, Bast RC. Serum levels of CA 125, M-CSF and OVX1 in stage I and in preclinical ovarian cancer 12:110, 1993. e-Pub 1993.
353. Tyer CL, Vredenburgh JJ, Heimer M, Bast RC, Peters WP. Breast cancer cells are effectively purged from peripheral blood progenitor cells using an immunomagnetic technique:11, 1993. e-Pub 1993.
354. Skubitz APN, Grossman PE, Wayner EA, Bast RC. Role of integrins in the interaction of ovarian carcinoma cell lines with laminin 4S:283a, 1993. e-Pub 1993.
355. Berchuck A, Kohler M, Soper J, Clarke-Pearson D, Nishii H, Sasaki H, Bast RC, Boyd J. Mutational analysis of the K-ras and p53 genes in endometrial hyperplasias:A24, 1993. e-Pub 1993.
356. Bast RC. CA 125 antigen - from the idea to the clinical application. CA 125: 10 years later 13:1636-1638, 1993. e-Pub 1993.
357. Bast RC, Wiener JR, Wu S, Hurteau JA, Rodriguez G, Kohler M, Mills GB, Boyer CM, Berchuck A. Cell growth regulation of epithelial ovarian cancer: The potential role of tyrosine phosphatases and tumor necrosis factor-a (TNF-a) 3:30, 1993. e-Pub 1993.
358. Kohler M, Jacobs I, Berchuck A, Wiseman R, Marks J, Humphrey P, Ponder B, Bast RC. Clonal origin of ovarian cancer: Analysis by loss of heterozygosity, p53 mutation and x chromosome inactivation:A6, 1993. e-Pub 1993.
359. Wiener JR, Hurteau JA, Whitaker RS, Kerns BJ, Berchuck A, Bast RC. Overexpression of the protein tyrosine phosphatase PTP1B in human ovarian carcinomas 34:527, 1993. e-Pub 1993.
360. Vredenburgh J, Bast RC, DeSombre K, Johnston W, Kamel A. Detection of tumor cells in the bone marrow or peripheral blood in breast cancer patients with 10 or more positive nodes 34:190, 1993. e-Pub 1993.
361. Stack S, Rodriguez G, Young T, Whitaker R, Moser T, Bast RC, Pizzo S. Characterization of ovarian carcinoma-associated proteinases 34:80, 1993. e-Pub 1993.
362. Xu FJ, Yu YH, Bast RC, Fujii S, Takagi M, O'Brien T, Walker R, Cornelissen G, Halberg E, Halberg F. Complementary time structures (chronomes) of OVX1 and M-CSF versus CA130 and CA125 34:39, 1993. e-Pub 1993.
363. Caminiti W, F-J X, Y-H Y, Bast RC, Anselmino L. Development of an enzyme immunoassay for the detection of the OVX1 antigen in serum, 1993. e-Pub 1993.
364. Hurteau J, Whitaker RS, Rodriguez GC, Bast RC, Berchuck A. Effect of transforming growth factor-β on proliferation of human ovarian cancer cells obtained from ascites 40:128, 1993. e-Pub 1993.
365. Boyer CM, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Super MJ, DeSombre KA, Bast RC. Cytotoxicity of immunotoxins reactive with different epitopes on the c-erbB-2 (HER-2/neu) gene product p185 34:473, 1993. e-Pub 1993.
366. Xu FJ, Boyer C, Super M, O'Briant K, Yu Y, Bast RC. The tyrosine kinase domain of the c-erbB-2 gene product (p185) is important for growth inhibition by anti p185 antibodies but not for cytotoxicity of anti p185 ricin A chain immunotoxins, 1993. e-Pub 1993.
367. Xu F, Yu Y, Daly L, Anselmino L, Berchuck A, Soper J, Clarke-Pearson D, Boyer C, Bast RC. OVX1 Radioimmunoassay: A useful marker in endometrial carcinoma 12:110, 1993. e-Pub 1993.
368. Wiener JR, Kassim S, Berchuck A, Bast RC. Role of protein tyrosine kinases and protein tyrosine phosphatases in human ovarian and mammary cancer cell growth:44-45, 1993. e-Pub 1993.
369. Vredenburgh JJ, Ross M, Meisenberg B, Hussein A, Bast RC, Shpall EJ, Tyer C, Heimer M, Tepperberg M, Affronti ML, Moore S, Peters WP. A phase II trial of high-dose chemotherapy and immuno-pharmacologically purged autologous bone marrow support for patients with metastatic breast cancer:23, 1993. e-Pub 1993.
370. Bast RC, Boyer C, Xu FJ, Wiener J, Wu S, Woolas R, Jacobs I, Hurteau J, Mills G, Kohler M, Berchuck A. Molecular approaches to the early detection and management of ovarian cancer:1-2, 1993. e-Pub 1993.
371. Rodriguez G, Young T, Stack S, Berchuck A, Whitaker R, Pizzo S, Bast RC. Urinary-type plasminogen activator receptor and its ligand are upregulated in epithelial ovarian cancer 34:82, 1993. e-Pub 1993.
372. Wu S, Meeker WA, Wiener J, Bast RC, Boyer CM. Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-α) antisense abolishes the proliferative response to interleukin-1 (IL-1) but not to TNF-α 34:439, 1993. e-Pub 1993.
373. O'Brien T, Halberg F, Bast RC, Hillman DC, Halberg E, Haus E, Fujii S, Cornelissen G. Chronobiologic comparison of the ovarian tumor marker CA 125 in blood, urine and saliva 17:47-48, 1992. e-Pub 1992.
374. Rodriguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu FJ, Bast RC. Cytotoxic effects of antibodies and immunotoxins against the extra-cellular domain of the c-erbB-2 (HER-2/neu) gene product (p185) correlate with p185 overexpression 33:A2042, 1992. e-Pub 1992.
375. Rodriguez GC, Boente MP, Berchuck A, Whitaker R, O'Briant K, Bast RC. Cytotoxic effect of antibodies and immunotoxins against the extra-cellular domain of the c-erbB-2 (HER-2/neu) gene product: Correlation with p185c-erbB-2 expression:207, 1992. e-Pub 1992.
376. Kohler MF, Berchuck A, Jacobs I, Marks J, Kerns BJ, Iglehart JD, Clarke-Pearson DL, Bast RC. Detection of p53 mutation and overexpression in paraffin-embedded ovarian cancers:112, 1992. e-Pub 1992.
377. Boente MP, Berchuck A, Davidoff A, Rodriguez GC, Xu FJ, Marks J, Whitaker R, Bast RC. The effect of interferon-gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelium:207, 1992. e-Pub 1992.
378. Berchuck A, Kohler M, Marks J, Bast RC. Expression of tumor-suppressor genes in gynecologic cancers:45, 1992. e-Pub 1992.
379. Jacobs IJ, Kohler M, Wiseman R, Futreal A, Marks J, Whitaker R, Kerns BJ, Humphrey P, Berchuck A, Smith S, Ponder BA, Bast RC. Genetic analysis of ovarian cancer by loss of heterozygosity, p53 mutation and x-chromosome inactivation:92, 1992. e-Pub 1992.
380. Handel LM, Godwin AK, Berchuck A, Bast RC, Hamaguchi K, Tracey PA, Hogan WM, Testa JR, Hamilton TC. Growth dependent spontaneous transformation of ovarian surface epithelial cells 33:A775, 1992. e-Pub 1992.
381. Franklin WA, Johnston CS, Williams S, Hami L, Jones RB, Bast RC, Shpall EJ. Immunohistochemical detection of breast cancer micrometastases in pre-transplant bone marrow 33:A1199, 1992. e-Pub 1992.
382. Vredenburgh J, Shpall EJ, Ross M, Meisenberg B, Bast RC, Tyer C, Tepperberg M, Eggleston S, Peters WP. Immunopharmacologic bone marrow purging and high-dose chemotherapy with autologous bone marrow support (ABMS) for patients with metastatic breast cancer 11:A58, 1992. e-Pub 1992.
383. Wu S, Boyer CM, Whitaker R, Berchuck A, Wiener J, Weinberg JB, Bast RC. Induction of tumor necrosis factor-a (TNF-a) in human ovarian cancer cells by treatment with TNF-a and interleukin-1-ß (IL-1-ß) 33:A1802, 1992. e-Pub 1992.
384. Jacobs IJ, Wiseman R, O'Briant K, Marks J, Kohler M, Berchuck A, Smith S, Futreal A, Ponder BA, Bast RC. Loss of heterozygosity on chromosome 17 in ovarian cancer 33:A2289, 1992. e-Pub 1992.
385. Berchuck A, Kohler M, Clarke-Pearson DL, Soper JT, Marks JR, Bast RC. Overexpression and mutation of the p53 oncogene in endometrial adenocarcinoma 39:112, 1992. e-Pub 1992.
386. Xu FJ, Yu YH, Daly L, DeSombre K, Berchuck A, Soper J, Clarke-Pearson D, Bast RC. The OVX1 radioimmunoassay (RIA) complements CA125 for predicting the presence of residual disease at second look surgical surveillance procedures 11:A201, 1992. e-Pub 1992.
387. Young TN, Moser TL, Bast RC, Pizzo SV, Stack MS. Plasminogen activators, gelatinases, and extracellular matrix proteins in ovarian cancer 6:163, 1992. e-Pub 1992.
388. Vredenburgh J, Ross M, Meisenberg B, Bast RC, Gilbert C, Lawrence J, Moore S, Affronti M, Coniglio D, Mathias B, Oette D, Peters W. Use of interleukin-3 (IL-3) and/or GM-CSF in patients with metastatic breast cancer receiving high-dose chemotherapy (HDC) and immunopharmacologically purged (IMPP) autologous bone marrow support (P-ABMS) 24:1, 1992. e-Pub 1992.
389. van den Brule FA, Berchuck A, Bast RC, Sobel ME, Castronovo V. Variable expression of two non-integrin laminin binding proteins in human ovarian carcinoma 33:A397, 1992. e-Pub 1992.
390. Berchuck A, Boente MP, Whitaker RS, Xu FJ, Kalen AE, Bell RM, Bast RC. Anti-erbB-2 (HER-2/neu) antibodies that downregulate growth of SKBr3 human breast cancer cells decrease intracellular levels of diacylglycerol (DAG) 33:A2202, 1992. e-Pub 1992.
391. Halberg F, Cornelissen G, Haus E, Halberg E, Halberg J, Halberg F, Portela A, Bast RC, F-J X, O'Brien T, Walker R, Fujii S. Chronomes of growth markers CA 130, CA 125, lUGP, M-CSF and OVX1: Circadian and circaseptan aspects, 1992. e-Pub 1992.
392. Xu FJ, Bast RC, Y-H Y, Halberg E, Cornelissen G, Haus E, Halberg F. Circadian and ultradian components of urinary OVX1 and M-CSF excretion by an ovarian cancer patient, 1992. e-Pub 1992.
393. Bast RC, Kerns BJ, MacDonald JA, Jordan PA, Boyer CM, Mendelsohn J, Berchuck A. Coexpression of the c-erbB-2 (HER-2/neu) gene product (p185) and epidermal growth factor receptor (p170) on epithelial ovarian cancers and normal tissues 33:A1906, 1992. e-Pub 1992.
394. Bast RC, Fritsche H, Malkin A, Pittaway D, Hutton J, Borden K, King C, Shaw N. CA 125 in the management of epithelial ovarian carcinoma 6:74, 1991. e-Pub 1991.
395. Hutton J, Borden K, King C, Shaw N, Bast RC, Fritsche H, Malkin A. Clinical evaluation of IMxR CA 125, an automated microparticle enzyme immunoassay for cancer antigen CA 125 37:1057, 1991. e-Pub 1991.
396. King C, Borden K, Harker K, Hutton J, Lauren L, Miceli C, Tanghal E, Walsh D, Shaw N, Bast RC, Fritsche H, Malkin A, Pittaway D. Comparative studies of Abbott IMxR and RIA CA 125 assays: Dilution linearity, precision and sensitivity 37:1051, 1991. e-Pub 1991.
397. Daly L, Ferguson J, Cram G, Haas V, Beam C, George S, McCarty K, Bast RC. Comparison of a new breast cancer serum marker, IMxBCM to CA15-3 and CEA 10:36, 1991. e-Pub 1991.
398. Bast RC, Boyer CM, Berchuck A, Xu FJ, Lidor Y, Maier LA, Crews JR, Ross M, Vredenburgh JJ, Shpall EJ, Peters WP. New strategies for management of epithelial ovarian and breast cancer based on biology and pharmacology:5, 1991. e-Pub 1991.
399. Berchuck A, Davidoff AM, Kerns BJ, Pence J, Iglehart JD, Marks JR, Bast RC. Overexpression and mutation of p53 in ovarian cancer 32:292, 1991. e-Pub 1991.
400. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC. Overexpression of Her-2/neu in endometrial carcinoma is associated with poor prognosis:A4, 1991. e-Pub 1991.
401. Bast RC, Berchuck A, Xu FJ, Daly L, Bast BS, Hass M, Anselmino L, Soper J, Clarke-Pearson D, Boyer CM. Recent advances in the biology and diagnosis of epithelial ovarian cancer 6:40, 1991. e-Pub 1991.
402. Berchuck A, Rodriguez G, Olt G, Arrick B, Clarke-Pearson DL, Bast RC. Regulation of growth of normal ovarian epithelium and ovarian cancer cell lines by transforming growth factor-ß:A34, 1991. e-Pub 1991.
403. Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast RC. Requirements for the internalization of a murine monoclonal antibody directed against the Her-2/neu (c-erbB-2) gene product p185 32:262, 1991. e-Pub 1991.
404. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker R, Bast RC. The role of peptide growth factors and oncogenes in ovarian cancer, 1991. e-Pub 1991.
405. Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC. Stimulation of ovarian tumor cell proliferation with monocyte products including IL-1-α, IL-6 and TNF-α 32:53, 1991. e-Pub 1991.
406. Xu FJ, Rodriguez GC, Whitaker R, Boente M, Berchuck A, McKenzie S, Houston L, Boyer CM, Bast RC. Antibodies against immunochemically distinct epitopes on the extracellular domain of HER-2/neu (c-erbB-2) inhibit growth of breast and ovarian cancer cell lines 32:260, 1991. e-Pub 1991.
407. Shpall E, Clarke-Pearson D, Soper J, Berchuck A, Jones R, Bast RC, Lidor Y, Peters W. High-dose alkylating agent chemotherapy with autologous bone marrow (ABM) support in patients (PTS) with Stage III/IV epithelial ovarian cancer (OCA), 1990. e-Pub 1990.
408. Shpall EJ, Bast RC, Joines W, Jones RB, Ross M, Johnston C, Eggleston S, Tepperberg M, Peters WP. Immunopharmacologic bone marrow purging in metastatic breast cancer (CA) patients (pts) receiving high-dose chemotherapy with autologous marrow support 9:A29, 1990. e-Pub 1990.
409. Shpall EJ, Jones RB, Bast RC, Ross M, Johnston CS, Anderson I, Peters WP. Immunopharmacologic purging of breast cancer from bone marrow, 1990. e-Pub 1990.
410. Bast RC, Boyer C, Xu FJ, Yu YH, Lidor Y, Crews J, Maier L, O'Briant K, DeSombre K, Whitaker R, Rodriguez G, Boente M, Berchuck A. Immunotherapy of epithelial ovarian cancer with monoclonal antibodies: Problems and opportunities. Biology and Therapy of Ovarian Cancer, 1990. e-Pub 1990.
411. Vredenburgh JJ, Ross M, Dukelow K, Johnson S, Shpall EJ, Jones RB, Bast RC, Peters WP. Intravenous gamma globulin for refractory thrombocytopenia following high-dose alkylating chemotherapy and autologous bone marrow transplantation 76:410a, 1990. e-Pub 1990.
412. Jones RB, Shpall EJ, Ross M, Bast RC, Affronti M, Peters WP. AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer. Current results 9:A30, 1990. e-Pub 1990.
413. Lidor YJ, Hamilton TC, Ozols RF, Bast RC. Alkylating agents and immunotoxins exert synergistic antitumor activity against ovarian cancer cells lines: Mechanisms of action 3:74, 1990. e-Pub 1990.
414. Lidor YJ, Xu FJ, Olt GJ, Berchuck A, Martinez O, Ramakrishnan S, Berek JS, Bast RC. Constitutive production of macrophage colony stimulating factor (M-CSF) and interleukin-6 (IL-6) by human ovarian surface epithelial cells 31:242, 1990. e-Pub 1990.
415. Deutsch M, Pence J, Kerns BJ, Plate C, Iglehart D, Bast RC. Detection of novel marker in the bronchial secretions of patients with non-small cell lung cancer (NSCLC) using the 4B5 monoclonal antibody 31:A1013, 1990. e-Pub 1990.
416. Einhorn N, Sjovall K, Schoenfeld DA, Eklund G, Knapp RC, Bast RC, Jr ZV. Early detection of ovarian cancer using the CA 125 radioimmunoassay (RIA) 9:A607, 1990. e-Pub 1990.
417. Ramakrishnan S, Xu F, Daly L, Soper J, Berchuck A, Clarke-Pearson D, Bast RC. Elevated levels of macrophage colony simulating factor (M-CSF) in serum and ascites from patients with epithelial ovarian cancer 21:40, 1990. e-Pub 1990.
418. Berchuck A, Kamel A, Soper JT, Clarke-Pearson DL, Kinney RB, Marks P, McKenzie S, Yin S, Bast RC. Epidermal growth factor receptor and neu expression in advanced epithelial ovarian cancer 31:314, 1990. e-Pub 1990.
419. Konrath JG, Przywara LW, Manderino GL, Lynch DM, Borden KK, Barghava AK, Fritsche H, Bast RC, Jr MK. Evaluation of IMx BCM automated microparticle enzyme immunoassay for breast cancer mucin 36:1097, 1990. e-Pub 1990.
420. Olt G, Berchuck A, Soisson A, Boyer C, Bast RC. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer cell lines and ascites fluid, 1990. e-Pub 1990.
421. Olt G, Berchuck A, Cram G, Boyer CM, Bast RC. Growth regulation of ovarian cancer cell lines by transforming growth factor-beta (TGF-β) 31:53, 1990. e-Pub 1990.
422. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper J, Clarke-Pearson D, Marks P, McKenzie S, Yin S, Bast RC. High Her-2/neu (c-erbB-2) oncogene expression in epithelial ovarian cancer correlates with poor survival, 1990. e-Pub 1990.
423. Shpall E, Clarke-Pearson D, Soper J, Berchuck A, Jones R, Bast RC, Lidor Y, Vanacek K, Tyler T, Peters W. High-dose alkylating agent chemotherapy with autologous bone marrow (ABM) support in patients (PTS) with stage III/IV epithelial ovarian cancer (OCA) 21:20, 1990. e-Pub 1990.
424. Bast RC, Berchuck A, Xu FJ, Olt G, Rodriguez G, Boyer C. Monoclonal antibodies, growth factors and proto-oncogenes in the diagnosis, monitoring and detection of epithelial ovarian cancer 9:30-31, 1990. e-Pub 1990.
425. Rodriguez G, Berchuck A, Whitaker R, Bast RC. Regulation of growth of normal ovarian epithelium and ovarian cancer cell lines by epidermal growth factor:42, 1990. e-Pub 1990.
426. Rodriguez G, Berchuck A, Clarke-Pearson D, Bast RC. Regulation of growth of normal ovarian epithelium and ovarian cancers by epidermal growth factor and its receptor, 1990. e-Pub 1990.
427. Berchuck A, Boente M, Rodriguez G, Bast RC. The role of peptide growth factors in proliferation of normal and malignant ovarian epithelium, 1990. e-Pub 1990.
428. Jr DW, Joines WT, Shpall EJ, Bast RC. Purging cancer cells from bone marrow using nonuniform magnetic fields:P1-17, 1989. e-Pub 1989.
429. Lidor Y, Shpall EJ, Peters WP, Bast RC. Alkylating agents and immunotoxins exert synergistic antitumor activity against ovarian cancer cell lines 30:401, 1989. e-Pub 1989.
430. Sjovall K, Bast RC, Einhorn N, Eklund G, Hall P, Knapp RC, Jr ZV. CA 125 in early detection of ovarian cancer: Further experience of the Stockholm phase I study:165, 1989. e-Pub 1989.
431. Berchuck A, Soisson AP, Soper JT, Clarke-Pearson DL, Jr MK, Bast RC. Cellular expression of CA 125 and metastatic potential of endometrial adenocarcinoma:A5, 1989. e-Pub 1989.
432. Cooper KL, Shpall EJ, Peters WP, Bast RC. Elimination of clonogenic breast cancer cells from human bone marrow: Comparison of immunotoxin treatment with chemoseparation and immunoseparation using 4-hydroperoxycyclophosphamide (4HC) and immunomagnetic separation 30:237, 1989. e-Pub 1989.
433. Berchuck A, Olt GJ, Soisson AP, Soper JT, Clarke-Pearson DL, Leslie DS, Boyer CM, Bast RC. Heterogeneity of tumor-associated antigen expression in epithelial ovarian cancer:269, 1989. e-Pub 1989.
434. Bast RC, Boyer C, Ramakrishnan S, Xu F, Yu Y, Lidor Y. Tumor associated antigens and growth factors as targets for diagnosis and treatment of epithelial ovarian cancers:11, 1989. e-Pub 1989.
435. Shpall E, Jones R, Bast RC, Shogan J, Ross M, Edwards S, Eggleston S, Johnston C, Affronti M, Coniglio D, Peters W. 4-Hydro-peroxycyclophosphamide (4HC) purging of breast cancer from the ficolled mononuclear cell fraction (FMNCF) of bone marrow 8:12, 1989. e-Pub 1989.
436. Yu YH, Ramakrishnan S, Houston L, Leslie D, Ring D, Bast RC. Synergistic antitumor activity of immunotoxins reactive with human breast carcinomas:40, 1989. e-Pub 1989.
437. Shpall EJ, Bast RC, Joines W, Jones RB, Edwards S, Eggleston S, Johnston C, Shogan J, Ross M, Affronti ML, Coniglio D, Peters WP. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation (ABMT): Pre-clinical and clinical results, 1989. e-Pub 1989.
438. Shpall EJ, Bast RC, Joines W, Jones RB, Edwards S, Eggleston S, Johnston C, Peters WP. Large-scale immunopharmacologic purging of clonogenic breast cancer cells from bone marrow for autologous bone marrow transplantation (ABMT) 30:235, 1989. e-Pub 1989.
439. Finn O, Metzgar R, Bast RC, Taylor-Papadimitriou J, Jerome K, Barnd D. Specific CTL response to human tumor associated mucins 3:A513, 1989. e-Pub 1989.
440. Bast RC, Soper J, Boyer C, Berchuck A, Olt G, Clarke-Pearson D, Xu FJ, Daly L, Ramakrishnan S. Markers for detection, growth and progression of gynecologic neoplasms, 1989. e-Pub 1989.
441. Bast RC, Boyer CM, Berchuck A, Cruse JR, Yu YH, Lidor Y. Monoclonal antibodies for the diagnosis and treatment of epithelial ovarian cancer:196, 1989. e-Pub 1989.
442. Soper JT, Berchuck A, Olt GJ, Clarke-Pearson DL, Bast RC. Preoperative evaluation of serum CA 125, CA 72, and CA 15-3 in patients with endometrial carcinoma:87, 1989. e-Pub 1989.
443. Shogan JE, Brandt SJ, Jones RB, Shpall EJ, Gilbert CJ, Atwater SK, Borowitz MJ, Bast RC, Kurtzberg J, Oette DH, Peters WP. Toxicity from recombinant human granulocyte macrophage colony stimulating factor (rHu GM CSF) after high dose chemotherapy and autologous bone marrow transplant (ABMT) 29:53, 1988. e-Pub 1988.
444. Joines WT, Shpall EJ, Dunseath WJR, Bast RC. Purging cancer cells from bone marrow using nonuniform magnetic fields:PT-29, 1988. e-Pub 1988.
445. Tyson FL, Soper JT, Daly L, Jr FW, Haskill JS, Kraus MH, Bast RC. Overexpression and amplification of the c-erbB 2 (HER 2/neu) proto oncogene in epithelial ovarian tumors and cell lines 29471, 1988. e-Pub 1988.
446. Chua C, Wood D, Brophy L, Nadler P, Bast RC. Phase I clinical trial of recombinant human tumor necrosis factor (rHuTNF) given as a daily X 5 schedule 7:171, 1988. e-Pub 1988.
447. Anderson I, Shpall EJ, Leslie D, Daly L, Nustad K, Ugelstad J, Peters W, Bast RC. Elimination of malignant clonogenic breast cancer cells from human bone marrow with immunomagnetic separation and 4 hydroperoxycyclophosphamide (4 HC) 29:A727, 1988. e-Pub 1988.
448. Peters WP, Brandt SJ, Atwater SK, Borowitz MJ, Kurtzberg J, Jones RB, Shpall EJ, Shogan J, Bast RC, Oette DH. Effect of recombinant human granulocyte macrophage colony-stimulating factor (rHu GM CSF) on hematopoietic reconstitution and granulocyte function following high dose chemotherapy (HDC) and autologous bone marrow transplantation (ABMT) 7:160, 1988. e-Pub 1988.
449. Leslie DS, Johnston WW, Daly L, Ring D, Peters W, Bast RC. Detection of breast carcinoma cells in human bone marrow: Comparison of immunodetection and conventional cytology 29:A707, 1988. e-Pub 1988.
450. Shpall EJ, Clarke-Pearson DL, Soper JT, Berchuck A, Jones RB, Bast RC, Lidor Y, Peters WP. High dose intraperitoneal and systemic chemotherapy with autologous bone marrow support for advanced ovarian cancer:107-109, 1988. e-Pub 1988.
451. Soisson A, Berchuck A, Kinney R, Flowers J, Soper J, Clarke-Pearson D, Bast RC, Jr MK. Epidermal growth factor receptor expression in adenocarcinoma of the endometrium 7:A548, 1988. e-Pub 1988.
452. Boyer C, Borowitz M, McCarty K, Kinney R, Everitt L, Dawson D, Ring D, Bast RC. Interferons produce a highly selective induction of MHC antigens in human breast and ovarian carcinoma cell lines 29:427, 1988. e-Pub 1988.
453. Anselmino L, Bast RC, Jr MK, Rivera H, Bhargava A, Brown W, Meyers M, Petrelli N, Plate C, Rittenhouse H, Manderino G. The Abbott CTA-EIA breast cancer assay and its comparison with the CA-15.3 assay, 1988. e-Pub 1988.
454. Brandt SJ, Kurtzberg J, Atwater SK, Borowitz MJ, Jones RB, Shpall EJ, Gilbert CJ, Bast RC, Oette DH, Peters WP. Effect of recombinant human granulocyte macrophage colony stimulating factor (rHuGM CSF) on hematopoietic reconstitution following high dose chemotherapy and autologous bone marrow transplantation (ABMT) 70:131a, 1987. e-Pub 1987.
455. Niloff JM, Dubeshter B, Jr ZV, Gelman R, Hunt M, Bast RC, Knapp RC. Serum Ca 125 levels correlated with survival in epithelial ovarian cancer 38:470-472, 1987. e-Pub 1987.
456. Knauf S, Bast RC. NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls:A10, 1987. e-Pub 1987.
457. Shpall E, Jones R, Egorin M, Gockerman J, Moore J, Bast RC, Olsen G, Coniglio D, Brophy L, Walsh B, Peters W. A phase I trial of high dose combination cyclophosphamide (C), cisplatinum (P) and thiotepa (T) with autologous bone marrow support (ABMS) in the treatment of resistant solid tumors 6:139, 1987. e-Pub 1987.
458. Bast RC, Knauf S, Epenetos A, Tanner M, Klug T, Soper J, Creasman W, Gall S, Knapp RC, Jr ZV, Schlom J, Kufe D, Ritts RE. Coordinate elevation of serum markers in ovarian cancer but not in benign disease 6:228, 1987. e-Pub 1987.
459. Peters WP, Jones RB, Shpall EJ, Olsen GA, Gockerman J, Bast RC, Moore JO. High dose combination alkylating agent therapy with autologous bone marrow support (ABMS) as initial chemotherapy for metastatic breast cancer (MBC) 28:227, 1987. e-Pub 1987.
460. Niloff JM, Dubeshter B, Jr ZV, Gelman R, Hunt M, Bast RC, Knapp RC. Survival following surgical reassessment in epithelial ovarian cancer:19-20, 1987. e-Pub 1987.
461. Chua C, Coleman RE, Nadler P, Bast RC. Transient hematologic abnormalities in patients receiving recombinant human tumor necrosis factor (rHuTNF) 70:86a, 1987. e-Pub 1987.
462. Einhorn N, Zurawski VR, Knapp RC, Bast RC. Preoperative elevation of CA 125, CA 72 and CA 15 3 in patients with nonmucinous epithelial ovarian cancer 28:357, 1987. e-Pub 1987.
463. Soper JT, Hunter V, Tanner M, Creasman W, Bast RC. Use of CA 125, CA 72 and CA 15 3 to discriminate malignant from benign pelvic masses 28:205, 1987. e-Pub 1987.
464. Jr ZV, Broderick S, Bast RC, Pickens P, Knapp RC. Serum CA 125 levels in a large group of nonhospitalized women: Relevance for the early detection of ovarian cancer, 1987. e-Pub 1987.
465. Einhorn N, Knapp RC, Bast RC, Jr ZV. The CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and nonmalignant diseases of the ovary:205, 1987. e-Pub 1987.
466. Einhorn, N, Bast RC, Eklund G, Hall P, Knapp RC, Sjovall K, Zurawski VR. CA 125 in early detection of ovarian cancer:19, 1987. e-Pub 1987.
467. Knapp RC, Finkler N, Benacerraf B, Malkasian GD, Mortel R, Bast RC, Jr ZV. Clinical management of ovarian cancer with CA 125: Patient classification, 1987. e-Pub 1987.
468. Bast RC, Leslie D, Everitt L, Frankel A, Peters WP, Ring D. Immunodetection of breast carcinoma cells in human bone marrow using multiple murine monoclonal antibodies and flow cytometry, 1986. e-Pub 1986.
469. Berek J, Knapp R, Malkasian G, Lavin P, Hacker N, Whitney C, Niloff J, Bast RC. CA 125 serum levels correlate with second-look operations among ovarian cancer patients: A prospective multi-institutional study:A41, 1986. e-Pub 1986.
470. Montgomery RB, Haleem A, Ramakrishnan S, Olsen GA, Peters WP, Smith CA, Kurtzburg J, Haynes BF, Houston LL, Bast RC. Elimination of malignant clonogenic T cells from bone marrow using chemoimmunoseparation with an immunotoxin and 2' deoxycoformycin/deoxyadenosine dCF/dAdo) 27:380, 1986. e-Pub 1986.
471. Introna M, Hamilton TA, Adams DO, Bast RC. Desensitization of c fos expression by different signals in murine peritoneal macrophages, 1986. e-Pub 1986.
472. Introna M, Hamilton TA, Kaufman RE, Strassman G, Adams DO, Bast RC. Functional activation of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c fos and c myc oncogenes:21, 1986. e-Pub 1986.
473. Olsen GA, Gockerman JP, Walsh B, Way T, Avery S, ReMine S, Gilbert C, Smith C, Seigler HF, Bast RC, Peters WP. High dose busulfan (BU) with autologous bone marrow support (ABMS): A phase I trial 27:236, 1986. e-Pub 1986.
474. Peters WP, Olsen GA, Gockerman JP, Walsh B, Way T, Avery S, Remine S, Gilbert C, Smith C, Moore J, Seigler HF, Bast RC. High dose combination cyclophosphamide (C), cisplatinum (P) and melphalan (M) with autologous bone marrow support (ABMS): A phase I trial 5:133, 1986. e-Pub 1986.
475. Adams DO, Weiel JE, Somers SD, Introna M, Bast RC, Hamilton TA. Induction of macrophage activation by IFN and LPS: Molecular mechanisms of signal transduction 45:485, 1986. e-Pub 1986.
476. Davis HM, Bast RC, Jr ZV, Knapp RC, Klug TL. Isolation and partial characterization of an antigen associated with human epithelial ovarian carcinomas 5:70, 1986. e-Pub 1986.
477. Antman K, Eder JP, Schryber S, Andersen J, Peters WP, Henner WD, Elias AD, Shea T, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Come S, Bast RC, Schnipper L, Frei E III. 58 solid tumor patients treated with a high dose combination alkylating agent preparative regimen with autologous bone marrow support: The DFCI/BIH experience 5:40, 1986. e-Pub 1986.
478. Peters WP, Jones RB, Shpall EJ, Gockerman J, Kurtzberg J, Moore J, Bast RC, Gilbert C, Blackburn B, Coniglio D, Brophy L, Edwards S. Strategies in the treatment of breast cancer with intensive chemotherapy and autologous bone marrow support, 1986. e-Pub 1986.
479. Peters WP, Olsen GA, Gockerman JP, Bast RC. A strategy for the development of targeted high dose combination chemotherapy programs for solid tumors and lymphoma:249, 1986. e-Pub 1986.
480. Niloff J, Welch W, Taylor S, Battaile A, Anderson D, Knapp RC, Bast RC. Antigenic heterogeneity in human ovarian cancer 23:246, 1986. e-Pub 1986.
481. Antman K, Eder JP, Schryber S, Andersen J, Peters WP, Henner WD, Finberg R, Elias AD, Shea T, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Come S, Bast RC, Schnipper L, Frei E III. A preparative regimen of combination alkylating agents with autologous bone marrow transplant (ABMT) for solid tumors: Phase II:254, 1986. e-Pub 1986.
482. Lottich SC, Boyer CM, Everitt L, Borowitz MJ, Dawson DV, Frankel AE, Ring D, Leight GS, Seigler HF, Bast RC. Antigenic heterogeneity and T-cell infiltration in human breast carcinoma 37:482-484, 1986. e-Pub 1986.
483. Peters WP, Gockerman JP, Olsen GA, Moore JO, Bast RC. High dose combination alkylating agent therapy with autologous bone marrow support as initial treatment for metastatic breast cancer 8:80, 1986. e-Pub 1986.
484. Bast RC, Montgomery B, Haleem A, Kurtzberg J, Clark AR, Ramakrishnam S, Olsen G, Smith C, Peters WP, Haynes BF, Houston L. Chemoimmunoseparation of T lymphoma cells from human bone marrow, 1986. e-Pub 1986.
485. Berek J, Knapp R, Malkasian G, Lavin P, Whitney C, Niloff J, Bast RC. Correlation of CA125 serum levels and second-look operations among ovarian cancer patients 5:112, 1986. e-Pub 1986.
486. Olsen GA, Gockerman JP, Bast RC, Peters WP. Altered immunologic reconstitution following high dose chemotherapy (HDC) and autologous bone marrow support (ABMS) 27:184, 1986. e-Pub 1986.
487. Metzgar RS, Mahvi DM, Lan MS, Finn OJ, Bast RC, Meyers WC, Borowitz MJ, Seigler HF. Clinical studies of an antigen (DU PAN 2) defined by a monoclonal antibody to pancreatic adenocarcinoma cells:36, 1985. e-Pub 1985.
488. Bast RC, Jr ZV, Knapp RC. Clinical application of monoclonal antibodies reactive with epithelial ovarian cancer:35, 1985. e-Pub 1985.
489. Eder JP, Bast RC, Peters WP, Sanchez E, Shryber S, Frei E, Schnipper LE. The Salmonella Mutagenesis Test (SMT) and CFU GM assay as a guide for bone marrow re-infusion in the autologous transplantation setting 26:331, 1985. e-Pub 1985.
490. Mahvi DM, Bast RC, Meyers WC, Seigler HF, Metzgar RS. Clinical studies of an oncofetal antigen (DU PAN 2) detected by a monoclonal antibody to pancreatic adenocarcinoma 26:291, 1985. e-Pub 1985.
491. Peters WP, Anderson K, Antman K, Eder JP, Fellows K, Finberg R, Finestone D, Gockerman J, Gorgone B, Henner W, Koepke J, Kruskall M, Leight G, Olsen G, Schnipper L, Schryber S, Seigler H, Vesilind G, Walsh B, Way T, Bast RC, Frei E. High- dose combination alkylating agent therapy and autologous bone marrow support for solid tumors: An update 3:257-258, 1985. e-Pub 1985.
492. Knapp RC, Lavin PT, Schaetzl E, Niloff JM, Bast RC. Elevation of CA 125 prior to recurrence of ovarian cancer 30:A#43, 1985. e-Pub 1985.
493. Mahvi DM, Meyers WC, Bast RC, Seigler HF, Metzgar RS. Carcinoma of the pancreas: Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody, 1985. e-Pub 1985.
494. Peters WP, Gockerman JP, Olsen GA, Moore JO, Leight G, Seigler HF, Bast RC. High dose combination alkylating agent therapy with autologous bone marrow support as initial therapy for metastatic breast cancer, 1985. e-Pub 1985.
495. Anderson KC, Sallan S, Takvorian T, Bast RC, Ritz J. Monoclonal antibody (MA) purged autologous bone marrow transplantation (ABMT) for relapsed non T acute lymphoblastic leukemia (ALL) 3:239-240, 1985. e-Pub 1985.
496. Haleem A, Olsen GA, Leslie DS, Ray L, Smith CA, Kurtzberg J, Peters WP, Haynes BF, Bast RC. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody and complement (C') 45:267a, 1985. e-Pub 1985.
497. Bast RC. Clinical application of monoclonal antibodies in the management of leukemia, lymphoma and ovarian carcinoma:24, 1985. e-Pub 1985.
498. Knapp RC, Lavin PT, Niloff JM, Schaetzl EM, Bast RC. Clinical evaluation of CA 125 immunoradiometric assay in epithelial ovarian cancer 1:6, 1985. e-Pub 1985.
499. Bast RC. Clinical application of monoclonal antibodies to autologous and allogeneic bone marrow transplantation, 1985. e-Pub 1985.
500. Bast RC, Ray L, Haleem A, LeBien T, Nadler L, Ritz J, Olsen G, Peters W, Kurtzberg J, Haynes B. Selective removal of malignant B- and T-cell neoplasms from human bone marrow 3:227, 1985. e-Pub 1985.
501. Barbieri RL, Bast RC, Niloff JM, Kistner RW, Knapp RC. Evaluation of a serologic test for the diagnosis of endometriosis using a monoclonal antibody OC 125:331, 1985. e-Pub 1985.
502. Bast RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. International Meeting on Monoclonal Antibodies in Oncology, 1984. e-Pub 1984.
503. Berek J, Knapp R, Hacker N, Lichtenstein A, Zighelboim J, Obrist R, Griffiths CT, Berkowitz R, Parker L, Lagasse L, Bast RC. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum 3:173, 1984. e-Pub 1984.
504. Bauer K, Knapp R, Bloomer W, Bast RC, Canellos G. Cis DDP, bleomycin, MTX LCV (PBM) chemotherapy in advanced, previously untreated carcinoma of the cervix (CaC) 3:169, 1984. e-Pub 1984.
505. Peters W, Eder J, Schryber S, Henner W, Bast RC, Wilmore D, Schnipper L, Frei E III. High dose combination alkylating agent therapy with autologous bone marrow support: A phase I trial 3:29, 1984. e-Pub 1984.
506. Bregni M, DeFabritiis P, Raso V, Greenberger J, Lipton J, Nadler L, Rothstein L, Ritz J, Bast RC. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using a combination of monoclonal immunotoxins reactive with different tumor cell surface determinants 25:240, 1984. e-Pub 1984.
507. Buick RN, Pullano R, Knapp RC, Urbach GI, Chang PL, Bast RC. Classification of ovarian tumor-associated antigens on the basis of distribution on cell populations undergoing differentiation 25:40, 1984. e-Pub 1984.
508. DeFabritiis P, Bregni M, Lipton J, Greenberger J, Nadler L, Korbling M, Rothstein L, Ritz J, Bast RC. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4 hydroperoxycyclophosphamide (4HC) in combination with monoclonal antibodies and complement (C') 25:324, 1984. e-Pub 1984.
509. Niloff JM, Knapp RC, Bast RC. CA 125 levels in obstetric and gynecologic patients 3:8, 1984. e-Pub 1984.
510. Niloff JM, Knapp RC, Schaetzl EM, Bast RC. Recombinant leukocyte A interferon in advanced ovarian carcinoma, 1984. e-Pub 1984.
511. Knapp RC, Niloff JM, Schaetzl E, Bast RC. Predictive value of CA 125 at second look procedures in ovarian cancer, 1984. e-Pub 1984.
512. Bast RC, Sallan S, Reynolds C, Lipton J. Treatment of bone marrow with monoclonal antibodies in vitro, 1984. e-Pub 1984.
513. Bast RC. Augmentation of antibody dependent cell mediated cytotoxicity in murine and human ovarian carcinoma, 1983. e-Pub 1983.
514. Ritz J, Sallan SE, Bast RC, Lipton JM, Nathan DG, Schlossman SF. Autologous bone marrow transplantation following in vitro treatment with J5 monoclonal antibody and complement, 1983. e-Pub 1983.
515. Bast RC, Klug T, Jenison E, Niloff J, Lazarus H, Berkowitz R, Leavitt T, Griffiths CT, Parker L, Zurawski V, Knapp RC. Monitoring growth of human ovarian carcinoma with a radioimmunoassay for antigens defined by a murine monoclonal antibody (OC 125) 14:13, 1983. e-Pub 1983.
516. Obrist R, Valone F, Knapp RC, Bast RC. Inhibitors of arachidonic acid oxygenation enhance lymphokine-mediated activation of human monocytes 24:215, 1983. e-Pub 1983.
517. Bast RC, DeFabritiis P, Maver C, Lipton J, Ritz J, Nadler L, Sallan S, Nathan DG, Schlossman SF. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement (C') 24:223, 1983. e-Pub 1983.
518. Knapp RC, StJohn E, Niloff JM, Griffiths CT, Leavitt T, Berkowitz RS, Bast RC. Clinical application of a monoclonal antibody against human ovarian cancer, 1983. e-Pub 1983.
519. Bast RC, DeFabritiis P, Maver C, Lipton J, Nadler L, Sallan S, Schlossman SF, Ritz J. Application of monoclonal antibodies to autologous bone marrow transplantation, 1983. e-Pub 1983.
520. Sallan SE, Bast RC, Lipton JM, Ritz J. Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia, 1983. e-Pub 1983.
521. Nadler L, Takvorian T, Finberg R, Bast RC, Botnick L, Hellman S, Canellos GP, Schlossman S. Autologous marrow transplantation for relapsed non Hodgkins lymphoma: Anti B1 monoclonal antibody treated autologous bone marrow 62:226a, 1983. e-Pub 1983.
522. Obrist R, Sandberg AL, Bast RC, Obrecht JP. In vitro and in vivo effects of chemotactic antitumor antibody conjugates, 1983. e-Pub 1983.
523. Bast RC, Klug TL, Schaetzl E, Lavin P, Niloff JM, Zurawski VR, Knapp RC. Monitoring human ovarian carcinoma with a combination of CA 125, CA19 9 and carcinoembryonic antigen (CEA) 6:619, 1983. e-Pub 1983.
524. Bast RC, Klug T, StJohn E, Jenison E, Niloff J, Lazarus H, Berkowitz R, Leavitt T, Griffiths CT, Parker L, Zurawski V, Knapp RC. A radioimmunoassay for monitoring patients with epithelial ovarian carcinoma: Comparison of CA125 and CEA 2:11, 1983. e-Pub 1983.
525. Bast RC, Klein S, Inbar M, Karnovsky M, Knapp RC, Greene MI. Tumor cell membrane vesicles block T cell mediated cytotoxicity and induce TS1 suppressor cells 42:1081, 1983. e-Pub 1983.
526. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC 125 48:42A, 1983. e-Pub 1983.
527. Parker LM, Griffiths CT, Janis D, Welch WR, Gelman RS, Bast RC, Knapp RC, Canellos GP. Advanced ovarian carcinoma: Integration of surgical treatment and chemotherapy with cyclophosphamide (C), adriamycin (A), and cis-diamminedichloroplatinum (P) 2:153, 1983. e-Pub 1983.
528. Sang DN, Anderson DJ, Bast RC, Schepens CL. Class I MHC antigens (HLA-A,-B,-C) in the human fetal and adult eye 22:134, 1982. e-Pub 1982.
529. Bast RC. Application of monoclonal antibodies to autologous bone marrow transplantation, 1982. e-Pub 1982.
530. Bast RC, Ritz J, Feeney M, Lipton J, Sallan S, Nathan D, Schlossman SF. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement (C') 23:264, 1982. e-Pub 1982.
531. Valone FH, Obrist R, Tarlin N, Bast RC. Increased arachidonic acid lipooxygenation by phorbol myristate acetate (PMA) stimulated K562 cells 30:424A, 1982. e-Pub 1982.
532. Bast RC, Ritz J, Sallan S, Lipton J, Nathan DG, Schlossman SF. Hematopoietic and lymphoreticular reconstitution following autologous bone marrow transplantation in childhood acute lymphoblastic leukemia (ALL):88, 1982. e-Pub 1982.
533. Bast RC. Intraperitoneal immunotherapy with Corynebacterium parvum, 1982. e-Pub 1982.
534. Obrist R, Reilly R, Leavitt T, Lazarus H, Knapp RC, Bast RC. Monocyte chemotaxis mediated by f Met Leu Phe (fMLP) conjugated with monoclonal antibodies against human ovarian carcinoma 4:285, 1982. e-Pub 1982.
535. Berek JS, Zighelboim J, Hacker NF, Bast RC, Chamorro T, Lagasse LD. Natural killer (NK) lymphocytes and antibody dependent cell mediated cytotoxicity in the peritoneal effluents of advanced cancer patients treated with intraperitoneal Corynebacterium parvum, 1982. e-Pub 1982.
536. Ritz J, Sallan SE, Bast RC, Lipton JM, Nathan DG, Schlossman SF. Utilization of monoclonal antibodies in the diagnosis and treatment of acute lymphoblastic leukemia 9, 1982. e-Pub 1982.
537. Sang DN, Bast RC, Rodrick M, Jr SG, Schepens CL. Peripheral uveitis: Circulating immune complex (CIC) levels correlate with disease activity 89:105, 1982. e-Pub 1982.
538. Bast RC. Monoclonal antibodies in autologous marrow transplantation, 1982. e-Pub 1982.
539. Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz R, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum 1:38, 1982. e-Pub 1982.
540. Bast RC. Immunomodulation with cytotoxic drugs, 1982. e-Pub 1982.
541. Bast RC, Maver C, Lipton J, DeFabritiis P, Ritz J, Nadler L, Sallan S, Nathan DG, Schlossman SF. Development of a clonogenic assay to measure elimination of malignant cells from human bone marrow using monoclonal antibody and complement (C'):78, 1982. e-Pub 1982.
542. Sallan S, Bast RC, Lipton J, Schlossman S, Nathan D, Ritz J. Autologous bone marrow transplantation in childhood acute lymphoblastic leukemia (ALL) 60:172a, 1982. e-Pub 1982.
543. Clavell L, Bast RC, Lipton J, Sallan S, Pesando J, Ritz J. Absence of common ALL antigen on normal pluripotential myeloid, erythroid and granulocyte progenitors 15:576, 1981. e-Pub 1981.
544. Bast RC. Monoclonal antibodies their use in clinical practice, 1981. e-Pub 1981.
545. Ritz J, Sallan SE, Bast RC, Lipton JM, Nathan DG, Schlossman SF. Autologous bone marrow transplantation in CALLA positive ALL following in vitro treatment with J5 monoclonal antibody and complement 58:175, 1981. e-Pub 1981.
546. Berkowitz RC, DeWolfe WC, Goldstein DP, Hornig-Rohan J, Bast RC, Klein S, Knapp RC. HLA (A,B,C and DR) antigen frequency distribution in patients with choriocarcinoma and their husbands 8:15, 1980. e-Pub 1980.
547. Bast RC, Lazarus HJ, Feeney M, Knapp RC. Corynebacterium parvum activates human and murine peritoneal cells to mediate antibody dependent tumor cell killing 28:650A, 1980. e-Pub 1980.
548. Bast RC, Lazarus H, Feeney M, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma 21:207, 1980. e-Pub 1980.
549. Bast RC, Lazarus H, Knapp RC. New approach to serotherapy of human ovarian carcinoma 10:370, 1980. e-Pub 1980.
550. Ozer H, McCusker LE, Breard J, Bast RC, Schlossman SF. Target specificity of antibody-dependent cellular cytotoxicity (ADCC): Isolation of effector cells mediating independent cytotoxic functions 38:925, 1979. e-Pub 1979.
551. Bast RC, Feeney M, Greenberger JS, Knapp RC. Elimination of leukemic cells from rat bone marrow using antibody and complement (C') 20:239, 1979. e-Pub 1979.
552. Bast RC, Thurston J, Mitchell K, Tucker R, Knapp RC. Combination immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific xenoantiserum 19:158, 1978. e-Pub 1978.
553. Bast RC, Thurston J, Knapp RC. Combination immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and xenoantiserum, 1978. e-Pub 1978.
554. Altman A, Bast B, Bast RC, Rapp HJ. The relationship between tumor immunogenicity and the appearance of splenic immunosuppressor cells in tumor bearing mice 36:1274, 1977. e-Pub 1977.
555. Bast RC, Okuda T, Plotkin E, Rapp HJ, Tarone RE, Gelboin HV. Aryl hydrocarbon hydroxylase in human monocytes 17:186, 1976. e-Pub 1976.
556. Bast RC, Zbar B, Rapp HJ. Local antitumor activity of a primary and an anamnestic response to a syngeneic guinea pig hepatoma 16:33, 1975. e-Pub 1975.
557. Smith HG, Bast RC, Zbar B, Rapp HJ. Immunotherapy of experimental cancer with BCG and surgery, 1974. e-Pub 1974.
558. Bast RC, Zbar B, Smith H, Miller TE, Mackaness GB, Rapp HJ. BCG immunotherapy of guinea pig tumors. U.S. Japan Cooperative Medical Science Program, 1974. e-Pub 1974.
559. Bast RC. Discussion: BCG therapy of malignancies. National Cancer Institute Conference on the Interaction of Radiation and Host Immune Defense Mechanisms in Malignancy:318-319, 1974. e-Pub 1974.
560. Bast RC, Zbar B, Miller TE, Mackaness GB, Rapp HJ. Suppression of tumor growth at the site of infection with Listeria Monocytogenes (LM) 15:88, 1974. e-Pub 1974.
561. Bast RC, Dvorak HF. Lymphocyte stimulation in cutaneous basophil (Jones-Mote) hypersensitivity 29:501, 1970. e-Pub 1970.
562. Libre EP, Bast RC, Shulman NR. Blood cell antigens and the mixed leukocyte reaction, 1966. e-Pub 1966.
563. Skubitz APN, Boylan KLM, Starr TK, Pu X, Cao Q, Geschwind K, Bast RC, Lu KH, Celestino J, Petersen AJ. A serum protein biomarker signature for the detection of early stages of ovarian cancer.
564. Gray JP, Bildik-Elcik G, Sutton MN, Zhou Y, Millward S, Hancock JF, Lu Z, Bast RC. Helical stapled peptides derived from DIRAS3 block KRAS dimerization and downstream MEK/ERK signaling in pancreatic and ovarian cancers.
565. Santiago-O’Farrill JM, Blessing A, Becker SE, Lu Z, Bast RC. Crizotinib improves the therapeutic efficacy in ovarian cancer. Proc Amer Ass Cancer Research.
566. Fan D, Yang H, Mao W, Pan L, Ahmed AA, Vankayalapati H, Lu Z, Bast RC. A novel compound ARN-3261 inhibits salt induced kinase 2 and sensitizes ovarian cancer cell lines to carboplatin. Proc Amer Ass Cancer Research.
567. Bildik G, Ozyurt R, Mao W, De Wever O, Wong KK, Carey MS, Lu Z, Bast RC. Targeting PARP to Enhance Sensitivity to MEK Inhibitors in Low-Grade Serous Ovarian Cancer. AACR.
568. Lu Z, Mao W, Santiago-O’Farrill J, Yang H, Pang L, Ahmed AA, Vankayalapati H, Bast RC. Novel SIK2 inhibitors sensitize ovarian and breast cancers to PARP inhibitors. Proc Amer Assoc Cancer Res.
569. Fu S, Jazaeri AA, Lu Z, Peter M, Morris SW, Bast RC. GRN300–001: Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination with Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

Book Chapters

1. Holland JF, Bast RC, Byrd JC, Croce C, Hawk ET, Khuri FR, Pollock RE, Tsimberidou AM, Willett CG, Wilman CL. Cardinal Manifestations of Cancer. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 3-6, 2023.
2. Berek J, Renz M, Friedlander ML, Bast RC. Epithelial Ovarian, Fallopian Tube and Peritoneal Cancer. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 1311-1328, 2023.
3. Berek J, Renz M, Bast RC. Nonepithelial Ovarian Malignancies. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 1329-1342, 2023.
4. Coyne ZL, Kalakand RD, Hennessey BD, Bast RC, Mills GB. Molecular Diagnostics in Cancer. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 505-518, 2023.
5. Tsimberidou AM, Bast RC, Khuri F, Byrd JC. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 10th. John Wiley & Sons, Inc, 553-566, 2023.
6. Bast RC, Zalutsky MR. Monoclonal Antibody and Targeted Toxin Therapy. In: Holland-Frei Cancer Medicine. 10th, 755-780, 2023.
7. Holland JF, Hong, WK, Kufe DW, Bast RC, Hait WN, Pollock RE, Weichselbaum RR. Cardinal Manifestations of Cancer. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 3-6, 2017.
8. Berek JS, Friedlander ML, Bast RC. Nonepithelial Ovarian Cancers. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 1339-52, 2017.
9. Kalachand RD, Hennessy BD, Bast RC, Mills, GC. Molecular Diagnostics in Cancer. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 469-80, 2017.
10. Bast RC, Zalutsky MR, Frankel AE. Monoclonal Serotherapy. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 757-776, 2017.
11. Patriotis C, Simmons AR, Lu KH, Bast RC, Skates SJ. State-of the-Science in Biomarker Research–Ovarian Cancer. In: Biomarkers in Cancer Screening and Early Detection. John Wiley & Sons, Inc, 93-103, 2017.
12. Hait WN, Holland JF, Kufe DW, Bast RC, Hong WK, Piccart M. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 511-20, 2017.
13. Berek JS, Friedlander ML, Bast RC. Epithelial Ovarian, Fallopian Tube and Peritoneal Cancer. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 1317-38, 2017.
14. Bast RC, Markman M, Hawk, E. Preface. In: Targeted Therapy in Translational Cancer Research. John Wiley & Sons, Inc, xiii, 2016.
15. Bast RC, Romero I, Mills GB. Molecular pathogenesis of ovarian cancer. In: The Molecular Basis of Cancer. 4th. Elsevier Health, 531-47, 2015.
16. Sutton MN, Lu Z, Bast RC. The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy. In: Tumor Dormancy, Quiescence, and Senescence. Springer Science, 99-109, 2014.
17. Suh G, Hennessy B, Verhaak R, Yang JY, Mills GB, Bast RC. Molecular Targets for Ovarian Cancer. In: Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press, 600-18, 2014.
18. Bast RC, Markman M, Hawk E. Preface. In: Cancer Gene Therapy with Viral and Non-Viral Vectors. 1st. John Wiley & Sons, Inc, 2014.
19. Roux R, Romero I, Zweifel M, Rustin GM, Bast RC. Recurrent ovarian cancer: When to treat and how to assess. In: Controversies in the Management of Gynecological Cancers. Springer, 2014.
20. Le XF, Bast RC. Molecular and cellular alterations modified by HER2 inhibition and overexpression. In: Horizons in Cancer Research. Nova Science Publishers, 159-184, 2011.
21. Ahmed AA, Knapp S, Sood AK, Bast RC. Targeting therapy in ovarian cancer. In: Gynaecological Cancers - Biology and Therapeutics. 60th RCOG Study Group, Royal College of Obstetricians and Gynecologists, RCOG Press, 167-181, 2011.
22. Berek JS, Friedlander ML, Bast RC. Ovarian Cancer. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 1344-1375, 2010.
23. Hait WN, Holland JF, Kufe DW, Bast RC, Hong WK, Piccart M. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 541-9, 2010.
24. Holland JF, Frei E III, Hong WK, Kufe DW, Bast RC, Hait WN, Pollock RE, Weichselbaum RR. Cardinal manifestations of cancer. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 1-3, 2010.
25. Keeler ER, Das P, Bast RC, Lu KH. Ovarian Cancer Screening. In: Early Diagnosis of Ovarian Cancer. Elsevier, 87-107, 2010.
26. Hennessy B, Bast RC, Mills GB. Molecular diagnostics in cancer. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 335-346, 2010.
27. Bast RC, Zalutsky M, Kreitman RM, Frankel AE. Monoclonal Serotherapy. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 710-724, 2010.
28. Le XF, Bast RC. p27Kip1 as a biomarker and target for treatment of cancer. In: Checkpoint Response in Cancer Therapy. Springer/Humana Press, 215-233, 2010.
29. Holland JF, Frei E III, Kufe DW, Bast RC, Pollock RE, Weichselbaum RR, Hong WK, Hait WN. Multidisciplinary management. In: Holland-Frei Cancer Medicine. 8th. PMPH-USA, 823-829, 2010.
30. Moore RG, Bast RC. Biomarkers and ovarian cancer. In: Ovarian Cancer: State of the Art. Remedica, 35-58, 2009.
31. Lu Z, Bast RC. Tumor suppressor genes. In: Cancer Treat Res. 2nd. Springer, 109-29, 2009.
32. Hennessy B, Bast RC, Gonzalez-Angulo AM, Mills GB. Early detection of cancer: Molecular Screening. In: The Molecular Basis of Cancer. 3rd. Saunders-Elsevier, 335-350, 2008.
33. Bast RC, Mills GB. Molecular pathogenesis of epithelial ovarian cancer. In: The Molecular Basis of Cancer. 3rd. Saunders-Elsevier, 441-454, 2008.
34. Lu Z, Feng W, Luo RZ, Liao WSL, Bast RC, Yu Y. E2F-HDAC complexes regulate tumor suppressor genes in cancer. In: Control of Cellular Physiology by E2F Transcription Factors. Research Signpost, 303-307, 2008.
35. Yu Y, Luo R, Lu Z, Wei Feng W, Badgwell D, Issa JP, Rosen DG, Liu J, Bast RC. Biochemistry and Biology of ARHI (DIRAS3), an Imprinted Tumor Suppressor Gene Whose Expression is Lost in Ovarian and Breast Cancers. In: Methods Enzymol, 455-68, 2006.
36. Holland JF, EIII F, Kufe DW, Bast RC, Pollack RW, Weichselbaum RR, Hong WK, Hait W. Principles of multidisciplinary management. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 935-940, 2006.
37. Holland JF, Frei E III, Kufe DW, Bast RC, Pollock R, Weichselbaum RR, Hong WK, Hait WN. Cardinal manifestations of cancer. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 3-8, 2006.
38. Hait WN, Holland JF, Frei E III, Kufe DW, Bast RC, Hong WK. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 562-569, 2006.
39. Bast RC, Zalutsky M, Kreitman R, Frankel A. Monoclonal Serotherapy. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 770-785, 2006.
40. Berek JS, Bast RC. Ovarian Cancer. In: Holland-Frei Cancer Medicine. 7th. B C Decker, Inc, 1543-1568, 2006.
41. Rosen DG, Yang G, Bast RC, Liu J. Use of ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. In: Methods Enzymol, 660-76, 2006.
42. Bast RC, Mills GB. Molecular mechanisms of pathogenesis and progression of epithelial ovarian cancer. In: The Ovary. 2nd. Elsevier Science, 425-445, 2004.
43. Berek J, Bast RC. Ovarian Cancer. In: Holland-Frei Cancer Medicine. 6th. B C Decker, Inc, 1831-1862, 2003.
44. Bast RC, Kousparou CA, Epenetos AA, Kreitman RJ, Sausville EA, Frankel AE. Monoclonal Serotherapy. In: Holland-Frei Cancer Medicine. 6th. B C Decker, Inc, 881-898, 2003.
45. Holland JF, Frei E III, Kufe DW, Bast RC, Pollock RE, Weichselbaum RR. Multidisciplinary management. In: Holland-Frei Cancer Medicine. 6th. B C Decker, Inc, 1079-1084, 2003.
46. Holland JF, Frei E III, Kufe DW, Bast RC. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 6th. B C Decker, Inc, 637-644, 2003.
47. Bast RC, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. In: Cancer Treat Res. Kluwer Publishers, (Cancer Treat Res 107:61-97), 2002.
48. Lu Y, Shayestri L, Lapushin R, Yu S, Cuevas B, Fang X, Eder A, Furui T, Plikoff D, Kuo WL, Baldocchi R, Vanhaesebroeck B, Bast RC, Pinkel D, Siminovitch K, Jaffe R, Gray J, Mills GB. Phosphatidylinositol 3' kinase in ovarian cancer: From genomics to therapeutics. In: Textbook of Ovarian Cancer. Oxford University Press, 565-578, 2001.
49. Bast RC, Mills GB. The molecular pathogenesis of ovarian cancer. In: The Molecular Basis of Cancer. 2nd. W.B. Saunders Co, 361-384, 2001.
50. Yu Y, Xu FJ, Peng H, Fang X, Zhao S, Xia W, Kuo WL, Gray JW, Siciliano M, Hogg D, Berchuck A, Hunt K, Mills GB, Bast RC. ARHI (NOEY2) an imprinted tumor suppressor gene in epithelial ovarian cancer. In: Textbook of Ovarian Cancer, 125-129, 2001.
51. Bast RC, Mills GB. Alterations in oncogenes, tumor suppressor genes and growth factors associated with epithelial ovarian cancers. In: Methods Mol Med. Humana Press, 37-48, 2001.
52. Bast RC. Comment: Clinical Practice Guidelines for the use of tumor markers in breast and colorectal cancer. In: Classic Papers and Current Comments: Evidence-Based Medicine and the Contribution of Guidelines. 4. Lippincott, Williams and Wilkins, 974-1009, 2000.
53. Bast RC, Zalutsky MR, Kreitman RR, Sausville EA, Frankel AE. Monoclonal Serotherapy. In: Holland Frei Cancer Medicine. 5th. B C Decker, Inc, 860-875, 2000.
54. Bookman MA, Boente MP, Bast RC. Immunology and Immunotherapy of Gynecologic cancers. In: Principles and Practice of Gynecologic-Oncology. 3rd. Lippincott-Raven Publishers, 129-164, 2000.
55. Holland JF, Frei E III, Kufe DW, Bast RC. Principles of Medical Oncology. In: Holland Frei Cancer Medicine. 5th. B C Decker, Inc, 503-510, 2000.
56. Bast RC, Morton DL. Immunostimulants. In: Holland Frei Cancer Medicine. 5th. B C Decker, Inc, 790-799, 2000.
57. Holland JF, Frei E III, Kufe DW, Bast RC, Pollock R, Weichselbaum RR. Principles of Multi-disciplinary Management. In: Holland Frei Cancer Medicine. 5th. B C Decker, Inc, 986-991, 2000.
58. Bast RC, F-J X, Yu Y, Fang X, Wiener J, Mills GB. Overview - The molecular biology of ovarian cancer. In: Ovarian Cancer 5. Isis Medical Media, 87-98, 1998.
59. Gallion HH, Kohn E, Mills GB, Bast RC. Clinical application of basic science investigation. In: Controversies in the Management of Ovarian Cancer. Churchill Livingston Publishing Co, 357-397, 1998.
60. Wolf JK, Mills GB, Bast RC, Roth JA, Gershenson DA. p53-mediated gene therapy. In: Ovarian Cancer 5. Isis Medical Media, 259-271, 1998.
61. Xu Y, Fang XJ, Furui T, Sasagawa T, Pustilnik T, Lu Y, Shen Z, Wiener JR, Shayesteh L, Gray JW, Bast RC, Mills GB. Regulation of growth of ovarian cancer cells by phospholipid growth factors. In: Ovarian Cancer. 5th. Isis Medical Media, 109-120, 1998.
62. Boente MP, Bookman M, Bast RC. Immunology and immunotherapy of gynecologic cancers. In: Gynecologic Oncology: Principles and Practice. 2nd. Lippincott-Raven, 149-176, 1997.
63. Bast RC. Foreword. In: What You Really Need to Know About Cancer, xiii-xiv, 1997.
64. Bast RC. An oncologist's perspective: Utility of tumor markers and the effectiveness of therapy. In: Tumor Markers: Reclassification, Reimbursement and Recent Advances, 23-37, 1997.
65. Bast RC, Frankel A, Zalutsky MR. Monoclonal Serotherapy. In: Cancer Medicine. 4th. Williams & Wilkins, 1245-1262, 1996.
66. Holland JF, Frei E III, Kufe DW, Bast RC, Morton DL, Weichselbaum RR. Principles of multidisciplinary management. In: Cancer Medicine. 4th. Williams & Wilkins, 1395-1401, 1996.
67. Berchuck A, Kohler MF, Bast RC. Molecular genetic features of ovarian cancer. In: Prog Clin Biol Res. John Wiley & Sons, Publishers, 269-284, 1996.
68. Holland JF, Frei E III, Kufe DW, Bast RC. Principles of Medical Oncology. In: Cancer Medicine. 4th. Williams & Wilkins, 755-765, 1996.
69. Soto-Wright V, Skates S, Berkowitz RS, Bast RC, Knapp RC. Natural history and detection of epithelial ovarian cancer. In: Gynecology and Obstetrics. Lippincott-Raven Publishers, 1-11, 1996.
70. Bast RC, Mills G, Gibson S, Boyer CM. Tumor Immunology. In: Cancer Medicine. 4th. Williams & Wilkins, 207-242, 1996.
71. Bast RC, Boyer CM, Dable RM, F-J X, Y-H Y, Berchuck A. New strategies for prevention and treatment. In: Ovarian Cancer. 4th. Chapman & Hall Medical, 199-204, 1996.
72. Bast RC, Morton DL. Immunostimulants. In: Cancer Medicine. 4th. Williams & Wilkins, 1169-1178, 1996.
73. Bast RC, Boyer CM, Xu FJ, Wiener J, Dabal R, Havrilesky L, Hurteau J, Elbendary A, Berchuck A. Cell growth regulation in human epithelial ovarian cancer. In: The Biology of Gynaecological Cancer. Royal College of Obstetricians and Gynaecologists Press, 119-127, 1995.
74. Berchuck A, Hurteau J, Bast RC. Oncogenes and tumor suppressor genes in ovarian cancer. In: Diagnosis and Management of Ovarian Disorders. Igaku-Shoin Medical Publishers, 208-227, 1995.
75. Elbendary AA, Berchuck A, Bast RC. Biology of epithelial ovarian cancer. In: Epithelial Cancer of the Ovary. British Medical Journal Publishing Group, 20-35, 1995.
76. Bast RC, Xu F, Yu Y, Crews J, Argon Y, Maier L, Lidor Y, Berchuck A, Boyer CM. Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. In: Immunol Ser. Marcel Dekker Inc, 23-30, 1994.
77. Berchuck A, Bast RC. Molecular genetic features of ovarian cancers: Potential for development of early detection strategies. In: Early Detection of Cancer: Molecular Markers. Futura Publishing Co., Inc, 279-288, 1994.
78. Bast RC, Wiener JR, Kassim S, Wu S, Boyer C, DeSombre K, Hurteau J, Rodriguez G, Mills G, Berchuck A. Cell growth regulation in ovarian cancer: Tyrosine kinases, tyrosine phosphatases and tumor necrosis factor-α. In: Ovarian Cancer. 3rd. Chapman & Hall, 109-113, 1994.
79. Boyer CM, Knapp RC, Bast RC. Biology of gynecologic cancers. In: Practical Gynecologic Oncology. 2nd. Williams & Wilkins, 75-116, 1994.
80. Bast RC, F-J X, Woolas RP, Y-H Y, Conaway M, O'Briant K, Daly L, Oram D, Berchuck A, Clarke-Pearson DL, Soper JT, Rodriguez G, Jacobs I. Complementary and coordinate markers for detection of epithelial ovarian cancers. In: Ovarian Cancer. 3rd. Chapman & Hall, 189-192, 1994.
81. Bast RC, Berchuck A. Ovarian Cancer. In: Harrison's Principles of Internal Medicine. 13th. McGraw-Hill Publishing, 1853-1858, 1994.
82. Holland JF, Frei EI, Bast RC, Kufe DW. Principles of medical oncology. In: Cancer Medicine. 3rd. Lea and Febiger, 588-597, 1993.
83. Bast RC, Morton DL. Immunostimulants. In: Cancer Medicine. 3rd. Lea and Febiger, 905-912, 1993.
84. Holland JF, Frei E III, Bast RC, Kufe DW, Morton D, Weichselbaum RR. Principles of multidisciplinary management. In: Cancer Medicine. 3rd. Lea and Febiger, 1073-1079, 1993.
85. Bast RC, Zalutsky MR, Frankel AE. Monoclonal Serotherapy. In: Cancer Medicine. 3rd. Lea and Febiger, 968-982, 1993.
86. Berchuck A, Bast RC. Oncogenes and tumor-suppressor genes. In: Ovarian Cancer. McGraw-Hill, 21-37, 1993.
87. Bast RC, Bookman MA, Knapp RC. Gynecologic tumor immunology. In: Gynecologic Oncology. 2nd. McGraw-Hill, 56-82, 1993.
88. Shpall EJ, Stemmer SM, Bearman SI, Bast RC, Peters WP, Ross M, Jones RB. High-dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer. In: Cancer of the Ovary. Raven Press, Ltd, 327-338, 1993.
89. Berchuck A, Bast RC. Use of CA 125 and other tumor markers for early diagnosis of epithelial ovarian cancer. In: Surgical Gynecologic Oncology. George Thieme Verlag Stuttgart, 440-442, 1993.
90. Berchuck A, Bast RC. Use of CA 125 and other markers for monitoring of epithelial ovarian cancer. In: Surgical Gynecologic Oncology. George Thieme Verlag Stuttgart, 449-450, 1993.
91. Berchuck A, Bast RC. Growth factors, oncogenes and tumor-suppressor genes. In: Cancer of the Ovary. Raven Press, 61-78, 1993.
92. Bast RC, Boyer CM. Tumor Immunology. In: Cancer Medicine. 3rd. Lea and Febiger, 171-197, 1993.
93. Bast RC, Xu FJ, Rodriguez GC, Whitaker R, Boente M, Berchuck A, McKenzie S, Houston LL, Boyer CM. Inhibition of breast and ovarian tumor cell growth by antibodies and immunotoxins reactive with distinct epitopes on the extracellular domain of HER-2/neu (c-erbB- 2). In: Ovarian Cancer 2: Biology, Diagnosis and Management. Chapman & Hall Medical, 67-72, 1992.
94. Bast RC, Boyer CM, Berchuck A, Xu FJ, Wu S, Lidor Y, Maier LA, Crews JR, Rosse M, Vredenburgh JJ, Shpall EJ, Peters WP. New strategies for the management of ovarian and breast cancer based on biology and pharmacology. In: Cancer Chemotherapy: Challenges for the Future, Volume 7. Excerpta Medica, 3-20, 1992.
95. Jacobs I, Bast RC. Tumor markers for ovarian cancer. In: Manual of Clinical Laboratory Immunology. 4th. American Society for Microbiology, 811-816, 1992.
96. Boente MP, Berchuck A, Bast RC. Immunology of gynecologic cancers. In: Principles and Practice of Gynecologic Oncology. JB Lippincott, 117-135, 1992.
97. Berchuck A, Marks JR, Bast RC. Expression of the epidermal growth factor receptor, HER-2/neu and p53 in ovarian cancer. In: Ovarian Cancer 2: Biology, Diagnosis and Management. Chapman & Hall Medical, 53-60, 1992.
98. Bast RC, Rodriguez GC, Wu S, Boyer CM, Berchuck A. Factors regulating the growth of normal and malignant ovarian epithelium. In: Ovarian Cancer 2: Biology, Diagnosis and Management. Chapman & Hall Medical, 61-66, 1992.
99. Sjövall K, Bast RC, Eklund G, Hall P, Knapp RC, Schoenfeld DA, Jr ZV, Einhorn N. Phase I investigation for early diagnosis of ovarian carcinoma: What problems are to be expected in a larger screening programme?. In: Cancer Screening. Cambridge University Press, 221-239, 1991.
100. Berchuck A, Rodriguez G, Bast RC. Recent advances in immunodiagnosis and immunotherapy. In: Gynecologic Oncology: Treatment Rationale and Techniques. Elsevier Science Publishing Co. Inc, 33-55, 1991.
101. Shpall EJ, Bast RC, Johnston CS, Peters WP, Jones RB. Combined purging approaches an autologous transplantation. In: Bone Marrow Processing and Purging: A Practical Guide. CRC Press, Inc, 307-328, 1991.
102. Rodriguez GC, Berchuck A, Bast RC. Monoclonal antibodies for immunodiagnosis and immunotherapy of epithelial ovarian cancer. In: Biologic Therapy of Cancer. JB Lippincott, 550-563, 1991.
103. Berek JS, Gritz ER, Bast RC, Kurman R, Rimer BK. Women's cancer screening: Guidelines and effect on mortality. In: Syntex Annual Women's Healthcare Roundtable Monograph 1991. Syntex Laboratories, 57-127, 1991.
104. Jerome KR, Barnd DL, Boyer CM, Taylor-Papadimitriou J, McKenzie IFC, Bast RC, Finn OJ. Adenocarcinoma reactive cytotoxic T lymphocytes recognize an epitope present on the protein core of epithelial mucin molecules. In: Cellular Immunity and the Immunotherapy of Cancer. UCLA Symposia on Molecular and Cellular Biology. New Series. Wiley-Liss Inc, 321-328, 1990.
105. Jacobs I, Bast RC. Immunodiagnosis of ovarian tumors. In: Immunol Ser. Marcel Dekker Inc, 323-38, 1990.
106. Bast RC, Boyer CM, Olt GJ, Berchuck A, Soper JT, Clarke-Pearson D, Xu FJ, Ramakrishnan S. Identification of markers for early detection of epithelial ovarian cancer. In: Ovarian Cancer. Biological and Therapeutic Challenges. Chapman & Hall Medical, 265-275, 1990.
107. Boyer CM, Knapp RC, Bast RC. Immunology and immunotherapy. In: Practical Gynecologic Oncology. Williams & Wilkins, 73-108, 1989.
108. Bast RC. Antigens associated with epithelial ovarian carcinomas. In: Prog Clin Biol Res. Alan R. Liss, 73-83, 1989.
109. Peters WP, Atwater S, Kurtzberg J, Borowitz M, Brandt SJ, Coleman RE, Kim CS, Gilbert C, Shpall EJ, Jones RB, Shogan J, Bast RC, Oette D, Stuart A, Coniglio D, Affronti ML, Evans S. The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. In: Autologous Bone Marrow Transplantation. Proc 4th Int Symp. The University of Texas M.D. Anderson Hospital and Tumor Institute, 657-667, 1989.
110. Jr MK, Kinney RB, Bast RC. Epithelial "tumor" markers in lesions of the breast. In: Hormones and Cancer. 3rd. Raven Press Ltd, 282-289, 1988.
111. Finkler NJ, Knapp RC, Bast RC. Monoclonal Antibodies in Ovarian Cancer. In: Cancer Diagnosis in vitro Using Monoclonal Antibodies. Marcel Dekker Inc, 141-167, 1988.
112. Knapp RC, Berkowitz RS, Jr LT, Bast RC. Natural history and detection of ovarian cancer. In: Gynecology and Obstetrics. Harper & Row Publishers, 1-16, 1988.
113. Peters WP, Jones RB, Shpall EJ, Gockerman J, Kurtzberg J, Moore J, Bast RC, Gilbert C, Blackburn B, Coniglio D, Brophy L, Edwards S. Strategies in the treatment of breast cancer with intensive chemotherapy and autologous bone marrow support. In: Autologous Bone Marrow Transplantation. Proc 3rd Int Symp. The University of Texas MD Anderson Hospital and Tumor Institute, 465-474, 1987.
114. Kaizer H, Bast RC. Workshop summary: Autologous bone marrow transplantation in leukemia. In: UCLA Symposia on Molecular and Cellular Biology: Progress in Bone Marrow Transplantation. Alan R. Liss Inc, 779-785, 1987.
115. Frankel AE, Boyer CM, Bast RC. Immunobiology of Human Breast Cancer. In: Immunology of Malignant Disease. MTP Press, 167-224, 1987.
116. Bast RC, Knapp RC. The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma. In: Important Adv Oncol. JB Lippincott, 39-53, 1987.
117. Bast RC, Knapp RC. Humoral markers for epithelial ovarian carcinoma. In: Ovarian Malignancies: Diagnostic and Therapeutic Advances. Churchill Livingstone Publishing Co, 11-25, 1987.
118. Bast RC, Leslie D, Everitt L, Boyer C, Frankel A, Peters W, Ring D. Immunodetection of breast carcinoma cells in human bone marrow using multiple murine monoclonal antibodies and flow cytometry. In: Autologous Bone Marrow Transplantation. Proc 3rd Int Symp. The University of Texas MD Anderson Hospital and Tumor Institute, 485-487, 1987.
119. Antman K, Eder JP, Elias A, Shea T, Schryber S, Andersen J, Peters WP, Henner WD, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Bast RC, Schnipper L, Frei E III. A preparative regimen of combination alkylating agent with autologous bone marrow transplant (ABMT) for solid tumors phase II. In: UCLA Symposia on Molecular and Cellular Biology: Progress in Bone Marrow Transplantation. Alan R. Liss Inc, 855-864, 1987.
120. Bast RC, Montgomery B, Haleem A, Kurtzberg J, Rhinehardt Clark A, Ramakrishnan S, Olsen G, Smith C, Leslie D, Peters W, Houston L. Chemoimmunoseparation of T lymphoma cells from human bone marrow. In: Autologous Bone Marrow Transplantation. Proc 3rd Int Symp. The University of Texas M.D. Anderson Hospital and Tumor Institute, 347-350, 1987.
121. Antman K, Peters WP, Eder JP, Schryber S, Andersen J, Henner WD, Elias A, Shea T, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Come S, Gorgone B, Bast RC, Schnipper L, Frei E III. Treatment of 58 patients on a phase I and II protocol using a high-dose combination alkylating agent preparative regimen with autologous bone marrow support. In: Accomplishments in Cancer Research. JB Lippincott Co, 152-165, 1986.
122. Bast RC, Knapp RC. Monoclonal reagents in immunodiagnosis and immunotherapy of human epithelial ovarian carcinoma. In: Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment. Futura Publishing Co, 61-86, 1986.
123. Peters WP, Shpall EJ, Jones RB, Olsen G, Gockerman J, Eder JP, Antman K, Kurtzberg J, Bast RC, Moore JO, Egorin MJ. Critical factors in the design of high dose combination chemotherapy regimens. In: Adv Cancer Chemother: High-Dose Thiotepa and Autologous Marrow Transplantation. Symposium Proceedings, 43-52, 1986.
124. Bast RC, Knapp RC. Concepts of gynecologic tumor immunology. In: Gynecologic Oncology. MacMillan Publishing Co, 97-118, 1986.
125. Bast RC, Knapp RC. Antigenic markers for ovarian carcinoma. In: Manual of Clinical Laboratory Immunology. 3rd. American Society for Micro-biology, 817-821, 1986.
126. Ritz J, Sallan SE, Bast RC, Takvorian T, Schlossman SF. Serotherapy and bone marrow transplantation. In: Hybridoma Technology in the Biosciences and Medicine. Plenum Publishing Co, 493-504, 1985.
127. Bast RC, DeFabritiis P, Bregni M, Raso V, Reynolds C, Lipton JM, Greenberger JS, Nadler LM, Sallan SE, Ritz J. Removal of malignant cells from human bone marrow using monoclonal antibodies and complement. In: Autologous Bone Marrow Transplantation. Proc 1st Int Symp. The University of Texas MD Anderson Hospital and Tumor Institute, 373-376, 1985.
128. Bast RC. Principles of cancer biology: Tumor immunology. In: Cancer: Principles and Practice of Oncology. 2nd. JB Lippincott, 125-150, 1985.
129. Bast RC, Sallan SE, Reynolds C, Lipton J, Ritz J. Autologous bone marrow transplantation for CALLA positive acute lymphoblastic leukemia: An Update. In: Autologous Bone Marrow Transplantation. Proc 1st Int Symp. The University of Texas MD Anderson Hospital and Tumor Institute, 3-6, 1985.
130. Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossman SF. In vitro treatment with B1 monoclonal antibody prior to autologous bone marrow transplantation for relapsed B cell non Hodgkin's lymphoma. In: Immunopharmacology. Serono Symposia Publications. Raven Press, 129-139, 1985.
131. Bast RC, Knapp RC. Recent advances in the immunodiagnosis of epithelial ovarian carcinoma. In: Ovarian Cancer. Martinus Nijoff Publishers, 23-25, 1985.
132. Peters WP, Eder JP, Henner WD, Bast RC, Schnipper L, Frei E III. Novel toxicities associated with high-dose combination alkylating agents and autologous bone marrow support. In: Autologous Bone Marrow Transplantation. Proc 1st Int Symp. The University of Texas MD Anderson Hospital and Tumor Institute, 231-235, 1985.
133. Bast RC, Sallan SE, Nadler L, DeFabritiis P, Bregni M, Raso V, Reynolds C, Lipton J, Ritz J. Treatment of bone marrow with monoclonal antibodies in vitro prior to autologous bone marrow transplantation. In: Monoclonal Antibodies '84: Biological and Clinical Applications. Editrice Kurtis, 449-463, 1985.
134. Introna M, Bast RC. Epithelial ovarian carcinoma: Cell lines and antigenic tumor markers. In: Cancer of the Female Reproductive System. John Wiley and Sons, 153-180, 1985.
135. Bast RC, Zurawski VR, Knapp RC. Clinical application of monoclonal antibodies reactive with epithelial ovarian cancer. In: Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, 37-51, 1985.
136. Bast RC, Knapp RC. Immunologic monitoring techniques and immunotherapy. In: Ovarian Cancer: New Approaches with Curative Intent. Sieber and McIntyre, 73-86, 1984.
137. Bast RC, Knapp RC. Monoclonal antibodies reactive with human ovarian carcinoma. In: Monoclonal Antibodies and Cancer. Marcel Dekker Inc, 241-252, 1984.
138. Bast RC, Knapp RC. CA 125 antigen for diagnosis and monitoring of epithelial ovarian carcinoma. In: Monoclonal Antibodies in Oncology: Clinical Applications. Proc Int Meeting. Conseil Regional Des Pays De Loire, 35-38, 1984.
139. Ritz J, Sallan SE, Bast RC, Lipton J, Hercend T, Nathan D, Schlossman SF. In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. In: Quo Vadis. Flow Cytometry and Monoclonal Antibodies for Therapy Monitoring. Sanofi Recherche, 163-172, 1984.
140. Sallan SE, Bast RC, Lipton JM, Ritz J. Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia. In: Minimal Residual Disease in Acute Leukemia. Martinus Nijhoff Publishers, 255-264, 1984.
141. Bast RC, Ritz J. Application of monoclonal antibodies to autologous bone marrow transplantation. In: Biological Responses in Cancer: Progress Toward Potential Application, Volume 2. Plenum Press, 185-206, 1984.
142. Drebin JA, Schatten S, Tominaga A, Lefort S, Letvin NL, Bast RC, Mizel SB, Greene MI. Characterization of ultraviolet radiation- induced impairment of antigen presenting cell function at the cellular and molecular levels. In: Effects of Ultraviolet Radiation on the Immune System. Academic Press, 123-127, 1983.
143. Bast RC, Knapp RC. The immunobiology of ovarian carcinoma. In: Gynecologic Oncology. Martinus Nijhoff Publishers, 187-226, 1983.
144. Ritz J, Sallan SE, Bast RC, Lipton JM, Nathan DG, Schlossman SF. In vivo and in vitro use of monoclonal antibodies for treatment of acute lymphoblastic leukemia. In: Leukemia Research: Advances in Cell Biology and Treatment. Elsevier Science Publishing Co. Inc, 281-294, 1983.
145. Bast RC. Effects of cancers and their treatment on host immunity. In: Cancer Medicine. 2nd. Lea and Febiger, 1134-1173, 1982.
146. Bast RC. Tumor immunology: An overview of future prospects. In: Cancer: A Manual for Practitioners. American Cancer Society, Massachusetts Division, 72-82, 1982.
147. Obrist R, Bast RC, Berkowitz R, Knapp RC. The immunology of gynecological malignancies. In: Current Problems in Obstetrics and Gynecology, Volume 5. Year Book Medical Publishers, Inc, 1-58, 1982.
148. Bast RC, Bast BS, Gelboin HV. Metabolism of polycyclic aromatic hydrocarbons by lymphoreticular cells. In: Extrahepatic Metabolism of Drugs and Other Foreign Compounds. MTP Press, 277-294, 1980.
149. Bast RC, Rapp HJ. The immunology of animal tumors. In: Immunological Diseases. 3rd. Little, Brown and Co, 359-388, 1978.
150. Gelboin HV, Selkirk J, Okuda T, Nemoto N, Yang SK, Wiebel FJ, Jr WJ, Rapp HJ, Bast RC. Benzo[a]pyrene metabolism: Enzymatic and liquid chromatographic analysis and application to human liver, lymphocytes and monocytes. In: Biological Reactive Intermediates. Plenum Press, 98-123, 1977.
151. Gelboin HV, Okuda T, Selkirk JK, Nemoto N, Yang SK, Rapp HJ, Bast RC. Benzo(a)pyrene metabolism: Enzymatic and liquid chromatographic analysis and application to human tissues. In: Fundamentals in Cancer Prevention. University Park Press, 167-190, 1976.
152. Gelboin HV, Okuda T, Selkirk J, Nemoto N, Yang SK, Wiebel FJ, Jr WJ, Rapp HJ, Bast RC. Benzo[a]pyrene metabolism: Enzymatic and liquid chromatographic analysis and application to human liver, lymphocytes and monocytes. In: Screening Tests in Chemical Carcinogenesis. IARC Scientific Publications, 225-247, 1976.
153. Zbar B, Smith HG, Bast RC, Rapp HJ. Immunologic eradication of lymph node metastases. In: BCG in Cancer Immunotherapy. Grune and Stratton, 361-366, 1976.

Books (edited and written)

1. Bast RC, Byrd JC, Croce C, Hawk ET, Khuri FR, Pollock RE, Tsimberidou AM, Willett CG, Wilman CL. Holland-Frei Cancer Medicine. Ed(s) 10th. John Wiley & Sons, 2023.
2. Bast RC, Hait WN, Hong WK, Kufe DW, Piccart-Gebart M, Pollock RE, Wang H, Weichselbaum RR, Holland JF. Holland-Frei Cancer Medicine. Ed(s) 9th. John Wiley & Sons, Inc, 2017.
3. Srivastava S, Bast RC, Markman M, Hawk E. Biomarkers Cancer Screening and Early Detection. Wiley Blackwell, 2017.
4. Tsimberidou AM, Kurzrock R, Anderson K, Bast RC, Markman M, Hawk E. Targeted Therapy in Translational Cancer Research. Wiley-Blackwell, 2016.
5. Brenner M, Hung MC, Bast RC, Markman M, Hawk E. Cancer Gene Therapy by Viral and Non-Viral Vectors. Wiley-Blackwell, 2014.
6. Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III. Holland-Frei Cancer Medicine. Ed(s) 8th. PMPH-USA, 2010.
7. Bast RC, Markman M. Ovarian Cancer: State of the Art. Remedica, 2009.
8. Kufe DW, Bast RC, Hong WK, Hait W, Pollack RW, Weichselbaum RR, Holland JF, Frei E III. Holland-Frei Cancer Medicine. Ed(s) 7th. B.C. Decker, Inc, 2006.
9. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E III. Holland-Frei Cancer Medicine. Ed(s) 6th. B.C. Decker, Inc, 2003.
10. Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III. Holland-Frei Cancer Medicine. Ed(s) 5th. B.C. Decker, Inc, 2000.
11. Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III. Cancer Medicine. Ed(s) 5 Review. B.C. Decker, Inc, 2000.
12. Sharp F, Blackett T, Berek J, Bast RC. Ovarian Cancer. Ed(s) 5th. Isis Medical Media, 1998.
13. Holland JF, Frei E III, Bast RC, Kufe DW, Morton DL, Weichselbaum RR. Cancer Medicine. Ed(s) 4th. Williams & Wilkins, 1996.
14. Holland JF, Frei E III, Bast RC, Kufe DW, Morton DL, Weichselbaum RR. Cancer Medicine. Ed(s) 3rd. Lea and Febiger, 1993.
15. Kimura K, Saito H, Carter SK, Bast RC. Cancer Chemotherapy: Challenges for the Future. Excerpta Medica, 1992.

Letters to the Editor

1. Harris L, Hayes D, Bast RC. 2007 ASCO Tumor Marker Guidelines, Reply to Letters from Cardoso et al and Bernards et al. J Clin Oncol 26: 2060-2061, 2008.
2. Kemeny N, Locker GY, Bast RC, Hayes DF. Carcinoembryonic Antigen Monitoring for Early Detection of Asymptomatic Incurable Metastatic Colorectal Cancer - Reply to the Letter-to-the-Editor. J Clin Oncol 25: 1294, 2007.
3. Bast RC. Tumor marker guidelines - Reply to the Letter-to-the-Editor. J Clin Oncol 15: 2175-2176, 1997.
4. Bast RC. Guidelines for the use of carcinoembryonic antigen in colorectal cancer - Reply to the Letter-to-the-Editor. J Clin Oncol 15: 864, 1997.
5. Bast RC, Woolas R. Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. BMJ 306: 1684-5, 1993.